

# STN SEARCH TRANSCRIPT → 10/771,725

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:asptal623zct

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR 7):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page URL's for STN Seminar Schedule - N. America  
 NEWS 2 \*ATOSCH for self-help around the clock  
 NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within STN Express with Discover!  
 NEWS 4 OCT 28 KOREAPAT now available on STN  
 NEWS 5 NOV 30 PHAR reloaded with additional data  
 NEWS 6 DEC 01 LISA now available on STN  
 NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004  
 NEWS 8 DEC 15 MEDLINE update schedule for December 2004  
 NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness alerts (SDIs) affected  
 NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness alerts (SDIs) affected  
 NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness alerts (SDIs) affected  
 NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness alerts (SDIs) affected  
 NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IPAT/IFIUDB/IFICDB  
 NEWS 14 DEC 30 EPPULL: New patent full text database to be available on STN  
 NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED  
 NEWS 16 JAN 03 No connect-hour charges in EPPULL during January and February 2005

NEWS EXPRESS OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT

MACINTOSH VERSION IS V6.0e (EKG) AND V6.0e (JPF),

AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS INTER General Internet Information

NEWS LOGIN Welcome Banner and News Items

NEWS PHONE Direct Dial and Telecommunication Network Access to STN

NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 13:04:14 ON 06 JAN 2005

>> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL


FULL ESTIMATED COST

ENTRY

SESSION

0.21

0.21



Structure attributes must be viewed using STN Express query preparation.

>> # 11

SAMPLE SEARCH INITIATED 13:04:54 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 59 TO ITERATE

100.0% PROCESSED 59 ITERATIONS

14 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 720 TO 1640

PROJECTED ANSWERS: 56 TO 504

L2 14 SEA SSS SAM L1

>> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY

SESSION

0.43

0.64

FILE 'CAPLUS' ENTERED AT 13:05:04 ON 06 JAN 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA LEXICON is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jan 2005 VOL 142 ISS 2

FILE LAST UPDATED: 5 Jan 2005 (20050105/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

>> # 12

L3 2 L2

>> d 1-2

FILE 'REGISTRY' ENTERED AT 13:04:34 ON 06 JAN 2005  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JAN 2005 HIGHEST RN 808732-83-4  
 DICTIONARY FILE UPDATES: 5 JAN 2005 HIGHEST RN 808732-83-4


TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

>> Uploading C:\Program Files\Stnexp\Queries\HONG'S DIV IMIDAZOLE.str



chain nodes :

12 13 14 15 16

ring nodes :

1 2 3 4 5 6 7 8 9 10 11

chain bonds :

1-11 7-12 8-13 9-14 14-15 14-16

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11

exact/norm bonds :

7-8 7-11 8-9 9-10 10-11 14-16

exact bonds :

1-11 7-12 8-13 9-14 14-15

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom

11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

>> d 11

L1 HAS NO ANSWERS

L1 STR

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS ON STN

2002:107321 CAPLUS

DN 136:167373

TI Preparation of imidazolyl derivatives as agonists or antagonists of somatostatin receptors

IN Thureau, Christophe Alain; Poitout, Lydie Francine; Galcera, Marie-Odile; Gordon, Thomas D.; Morgan, Barry A.; Moinet, Christophe Philippe; Bigg, Dennis

PA Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.

SO PCT Int. Appl., 369 pp.

CODEN: PIXX2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002010140	A2	20020207	WO 2001-US23959	20010731
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GR, GM, HU, ID, IL, IN, IS, JP, KR, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, BD, BE, BG, BR, BS, BU, CA, CH, CL, CN, CO, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, ML, MR, NE, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	A3	20020808		
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, ML, MR, NE, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	AA	20020207	CA 2001-2417204	20010731
CA 2417204	AA	20020207	CA 2001-2417204	20010731
EP 1305294	A2	20030502	EP 2001-957342	20010731
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, ML, MR, NE, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW	T2	20040624	JP 2002-516272	20010731
JP 2004518613	T2	20040624	JP 2002-516272	20010731
NZ 523774	A	20040924	NZ 2001-523774	20010731
NO 2003000473	A	20030130	NO 2003-473	20030130
PRAI US 2000-2225849	P	20000801		
WO 2001-US23959	W	20010731		
OS MARPAT 136:167373				

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS ON STN

1999:795794 CAPLUS

DN 132:35701

TI Preparation of imidazolyl derivatives as agonists or antagonists of somatostatin receptors

IN Thureau, Christophe Alain; Poitout, Lydie Francine; Galcera, Marie-Odile; Gordon, Thomas D.; Morgan, Barry; Moinet, Christophe Philippe

PA Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.,

SO PCT Int. Appl., 342 pp.

CODEN: PIXX2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9964401	A2	19991216	WO 1999-US12760	19990608
W: AS, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GR, GM, HU, ID, IL, IN, IS, JP, KR, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW	A3	20030417		
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZM, AM, AZ, BY, BD, BE, BG, BR, BS, BU, CA, CH, CL, CN, CO, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, ML, MR, NE, NI, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				

LA, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GM, ML, MR, NS, SN, TD, TG

CA 2334945 AA 19991216 CA 1999-2334945 19990608  
AU 9944257 A1 19991230 AU 1999-44257 19990608  
AU 746963 B2 20020509  
EP 1086086 A1 20010328 EP 1999-927323 19990608  
EP 1086086 B1 20041013

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI  
JP 2003523921 T2 20030812 JP 2000-533440 19990608  
AT 279396 E 20041015 AT 1999-927323 19990608  
NO 200006367 A 20010207 NO 2000-6267 20001211  
US 2004176379 A1 20040909 US 2004-771725 20040204

PRAI US 1998-89087P P 19980612  
US 1998-96431 A1 19980612  
WO 1999-US12760 W 19990608  
US 2001-719457 A3 20010613  
OS MARPAT 132:35701

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jan 2005 VOL 142 ISS 2  
FILE LAST UPDATED: 5 Jan 2005 (20050105/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

--> file reg  
COST IN U.S. DOLLARS

SINCE FILE ENTRY TOTAL  
SESSION 2.65 3.29

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:05:55 ON 06 JAN 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JAN 2005 HIGHEST RN 808732-83-4  
DICTIONARY FILE UPDATES: 5 JAN 2005 HIGHEST RN 808732-83-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryas.html>

--> s 11 sss full  
FULL SEARCH INITIATED 13:06:07 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1175 TO ITERATE

100.0% PROCESSED 1175 ITERATIONS  
SEARCH TIME: 00.00.01

344 ANSWERS

L4 344 SEA SSS FUL L1

--> file caplus  
COST IN U.S. DOLLARS

SINCE FILE ENTRY TOTAL  
SESSION 161.33 164.62

FULL ESTIMATED COST


FILE 'CAPLUS' ENTERED AT 13:06:11 ON 06 JAN 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.:

FR 1999-12643 A 19991011  
FR 2000-10151 A 20000801  
FR 2000-11169 A 20000901  
WO 2000-FR2805 W 20001010  
JP 1989-4943 A 20010410  
JP 1990-1811 A 20020214  
US 2002-89993 A2 20020404  
EP 2000-967988 A3 20001010

OTHER SOURCE(S): MARPAT 141:106475  
GI



AB The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivs. of general formula (I) (wherein Het = thiazole, oxazole, imidazole, isoxazole or isoxazoline; n = an integer from 0 to 6; A = optionally substituted aromatic radical; B = H, alkyl, Ph, R1, R2 = H, alkyl, cycloalkyl; D = NR46R47 or OR48; R46, R47 = H, alkyl, cycloalkyl, (CH2)k-CO2R51; R51 = alkyl, haloalkyl; R48 = H, alkyl). These compds. have advantageous pharmacol. properties which allow their use in a medicament intended to inhibit monoamine oxidases (MAO) and/or lipidic peroxidation, and/or to act as modulators of the sodium channels and notably their use in therapeutics for treating (1) central or peripheral nervous system, (2) neurodegenerative disorders selected from Parkinson's disease, Alzheimer's disease, Huntington's chorea and amyotrophic lateral sclerosis or (3) pain selected from the group consisting of postoperative pain, migraine, neuropathic pain, central pain, chronic inflammatory pain and pain linked to a cancer. Thus, 2-[[[(1,1-dimethylethoxy)carbonyl]methyl]amino]ethanethioamide (4.3 g, 2.11 mmol) and 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (6.9 g, 2.11 mmol) were dissolved in 75 mL benzene under argon atmosphere and stirred at ambient temperature for 12 h to give,

after workup and silica gel chromatog., 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-2-thiazolemethanamine which was treated with CF3CO2H and triethylamine in 50 mL CH2Cl2 to give, after workup, 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-2-thiazolemethanamine (II). II showed IC50 of lower than 10 µM for inhibiting lipid peroxidation of the cerebral cortex of rats.

IT 252314-87-7P, N-[(1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenylurea  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Uses)

(preparation of 5-membered heterocycle derivs. for treating diseases of central or peripheral nervous system, neurodegenerative disorders, or pain)

RN 252314-87-7 CAPLUS  
CN Urea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenyl- (9C1) (CA INDEX NAME)

Absolute stereochemistry.

--> s 14  
L5 5 L4

--> s 15 not 13  
L6 3 L5 NOT L3

--> d 1-3 ibib abs hitstr

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:550745 CAPLUS  
DOCUMENT NUMBER: 141:106475

TITLE: Preparation of 5-membered heterocycle derivatives for treating neurodegenerative disorders or pain  
INVENTOR(S): Chabrier De Lasseunier, Pierre-Etienne; Harnett, Jeremiah; Biggs, Dennis; Liberatore, Anne-Marie; Pomier, Jacques; Lannoy, Jacques; Thureau, Christophe

PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 150 pp., Cont.-in-part of U.S. Ser. No. 89,993.  
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004132788	A1	20040708	US 2003-681002	20031008
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NS, TD, TG				
EP 1228760	A2	20020807	EP 2002-76763	20001010
EP 1228760	A3	20040128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:283789 CAPLUS  
DOCUMENT NUMBER: 134:311210

TITLE: 5-Membered heterocycle derivatives useful as monoamine oxidase inhibitors, lipid peroxidation inhibitors, and sodium channel modulators, and the production thereof, and use thereof as medicaments  
INVENTOR(S): Chabrier de Lasseunier, Pierre-Etienne; Harnett, Jeremiah; Biggs, Dennis; Pomier, Jacques; Lannoy, Jacques; Liberatore, Anne-Marie; Thureau, Christophe

PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S., Fr.

SOURCE: PCT Int. Appl., 261 pp.  
CODEN: PIXX22

DOCUMENT TYPE: Patent

LANGUAGE: French


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NS, TD, TG				
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801
CA 3388505	AA	20010419	CA 2000-2388505	20001010
BR 2000014649	A	20020618	BR 2000-14649	20001010
EP 1223933	A2	20020724	EP 2000-967988	20001010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1228760	A2	20020807	EP 2002-76763	20001010
EP 1228760	A3	20040128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511416	T2	20030325	JP 2001-529718	20001010
NZ 518304	A	20040730	NZ 2000-518304	20001010
NO 2002001689	A	20020530	NO 2002-1689	20020410
US 2004132788	A1	20040708	US 2003-681002	20031008
PRIORITY APPLN. INFO.:				
				FR 1999-12643 A 19991011
				FR 2000-10151 A 20000801
				FR 2000-11169 A 20000901
				EP 2000-967988 A3 20001010


EP 2002-76763 A3 20001010  
WO 2000-FR2805 W 20001010  
JP 1989-4943 A 20010410  
JP 1990-1811 A 20020214  
US 2002-89993 A2 20020404

OTHER SOURCE(S): MARPAT 134:311210  
GI




AB The invention relates to pharmaceutical use of heterocyclic compds. of general formula Het(A)(B)-(CH<sub>2</sub>)<sub>n</sub>-CR<sub>1</sub>R<sub>2</sub>-Q [I]; wherein the substituted heterocyclic ring Het(A)(B) = Q1-Q4; A = various aryl or heteroaryl systems, especially a substituted Ph or biphenyl radical, or also alkyl, cycloalkyl, or cycloalkylalkyl; B = especially H or alkyl, or also aryl or substituted alkyl; X = especially NH or S, or also substituted NH; Y = O or S; n = 0-6; R<sub>1</sub>, R<sub>2</sub> = especially H, alkyl, or cycloalkyl; Q = NR<sub>3</sub>R<sub>4</sub> or OR<sub>5</sub>; R<sub>3</sub> and R<sub>4</sub> = especially H, alkyl, cycloalkyl, alkynyl, cyanoalkyl, alkoxyalkyl, aralkoxyalkyl, or (cycloalkyl)oxyalkyl; R<sub>5</sub> = H, alkyl, alkynyl, or cyanoalkyl. I and their racemates, enantiomers, and/or salts can be used for producing medicaments for inhibiting monoamine oxidases (MAO), inhibiting lipid peroxidation, and/or for acting as modulators of sodium channels. The resulting medicaments are particularly for use in treating Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, schizophrenia, depression, psychosis, pain and epilepsy. Approx. 350 synthetic examples of I and their salts are given, and numerous free bases of I are claimed. For instance, protection of sarcosinamide-HCl with BOC anhydride gave 72% BOC-N(Me)CH<sub>2</sub>CONH<sub>2</sub>, which was converted to the thioamide with (P2S<sub>5</sub>)<sub>2</sub> in 65% yield. Cyclocondensation of the thioamide with 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (28%), followed by deprotection (73%) and saponification (92%), gave thiazole derivative II as the HCl salt. II inhibited binding of the MAO-B specific ligand [3H]-Ro-19-6327 to rat mitochondrial preps. with IC<sub>50</sub> < 10 μM. Selected I also inhibited formation of malondialdehyde by lipid peroxidation in rat cerebral cortex preps., and inhibited specific binding of [3H]-betrachotoxin to voltage-dependent

sodium channels in rat cerebral cortex homogenates.  
IT 252314-87-7, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenylurea  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USSS (Uses)  
(drug candidate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidation inhibitors, and sodium channel modulators)  
RN 252314-87-7 CAPLUS  
CN Urea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)  
Absolute stereochemistry.




L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2001:279029 CAPLUS  
DOCUMENT NUMBER: 135:107278  
TITLE: Novel non-peptide ligands for the somatostatin sst3 receptor  
AUTHOR(S): Moinet, C.; Contour-Galera, M.-O.; Poitout, L.; Morgan, B.; Gordon, T.; Roubert, P.; Thureau, C.  
CORPORATE SOURCE: ZA de Courtaubouef, Institut Henri Beaufour, Les Ulis, F-91966, Fr.  
SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(8), 991-995  
CODEN: BMCLES; ISSN: 0960-894X  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB A series of imidazole derivs. has been prepared using high throughput parallel synthesis. Several compds. showed high affinity (K<sub>i</sub> in 10<sup>-6</sup>-10<sup>-8</sup> M range) and selectivity at recombinant human somatostatin receptor subtype 3 (hst3).  
IT 252292-71-0P 252311-56-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of phenylimidazolyl(indolyl)ethylamines as somatostatin receptor antagonists)  
RN 252292-71-0 CAPLUS  
CN Urea, N-(2,4-difluorophenyl)-N'-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)  
Absolute stereochemistry.



RN 252311-56-1 CAPLUS  
CN Urea, N-(1,1-dimethylethyl)-N'-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RS FORMAT

FILE REG	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	17.52	182.14
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-2.19	-2.19

FILE 'REGISTRY' ENTERED AT 13:09:42 ON 06 JAN 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JAN 2005 HIGHEST RN 808732-83-4  
DICTIONARY FILE UPDATES: 5 JAN 2005 HIGHEST RN 808732-83-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more

information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

Uploading C:\Program Files\Stnexp\Queries\HONG'S DIV IMIDAZOLS.str




chain nodes :  
12 13 14 15 16  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11  
chain bonds :  
1-11 7-12 8-13 9-14 14-15 14-16  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11  
exact/norm bonds :  
7-8 7-11 8-9 9-10 10-11 14-16  
exact bonds :  
1-11 7-12 8-13 9-14 14-15  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS

L7 STRUCTURE UPLOADED

=> d 17  
L7 HAS NO ANSWERS  
L7 STR



Structure attributes must be viewed using STN Express query preparation.

=> s k7  
L8 252 K7  
=> s 17  
SAMPLE SEARCH INITIATED 13:10:01 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 606 TO ITERATE

100.0% PROCESSED 606 ITERATIONS 50 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 10644 TO 13596  
PROJECTED ANSWERS: 1114 TO 2206

L9 50 SEA SSS SAM L7

=> # 17 sss full  
FULL SEARCH INITIATED 13:10:10 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 11875 TO ITERATE

100.0% PROCESSED 11875 ITERATIONS 1671 ANSWERS  
SEARCH TIME: 00.00.01

L10 1671 SEA SSS FUL L7

=> d his

(FILE 'HOMES' ENTERED AT 13:04:14 ON 06 JAN 2005)

L1 FILE 'REGISTRY' ENTERED AT 13:04:34 ON 06 JAN 2005  
L2 STRUCTURE UPLOADED  
14 S L1

L3 FILE 'CAPLUS' ENTERED AT 13:05:04 ON 06 JAN 2005  
2 S L2

L4 FILE 'REGISTRY' ENTERED AT 13:05:55 ON 06 JAN 2005  
344 S L1 SSS FULL

L5 FILE 'CAPLUS' ENTERED AT 13:06:11 ON 06 JAN 2005  
5 S L4  
L6 3 S L5 NOT L3

L7 FILE 'REGISTRY' ENTERED AT 13:09:42 ON 06 JAN 2005  
STRUCTURE UPLOADED  
L8 252 S K7  
L9 50 S L7  
L10 1671 S L7 SSS FULL

=> # 110 not 14  
L11 1327 L10 NOT L4

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 166.36 348.50  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL  
ENTRY SESSION  
CA SUBSCRIBER PRICE 0.00 -2.19

FILE 'CAPLUS' ENTERED AT 13:11:11 ON 06 JAN 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.



FILE COVERS 1907 - 6 Jan 2005 VOL 142 ISS 2  
FILE LAST UPDATED: 5 Jan 2005 (20050105/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> # 111  
L12 36 L11  
=> d 1-36 ibib abs hitatr

L12 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2004:701970 CAPLUS  
DOCUMENT NUMBER: 141:225511  
TITLE: Preparation of substituted azoles as protein tyrosine phosphatase inhibitors for treatment of diabetes and other PTPase mediated conditions  
INVENTOR(S): Mjalli, Adnan M. M.; Andrews, Robert C.; Yarragunta, Ravindra R.; Xie, Rongyuan; Ren, Tan; Subramanian, Govindan; Quada, James C., Jr.  
PATENT ASSIGNEE(S): Transtech Pharma Inc., USA  
SOURCE: PCT Int. Appl., 224 pp.  
CODEN: PIXX02  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004071448	A2	20040826	WO 2004-US4076	20040212
WO 2004071448	A3	20041014		
M: AB, AS, AG, AL, AM, AM, AM, AT, AT, AU, AZ, BA, BB, BG, BO, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DS, DS, DK, DK, DM, DZ, EC, EC, ES, ES, ES, ES, FI, FI, GB, GB, GE, GE, GH, GH, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LJ, LV, NA, MD, MD, MG, MK, MN, MX, MX, MZ, MZ, NA, NI				
RW: BW, CH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZM, AT, BE, BG, CH, CY, CZ, DS, DK, ES, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CH, GA, GN, CO, GW, ML, MR, NS, SN, TD, TG, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NS, SN, TD, TG				
US 2004186151	A1	20040923	US 2004-777471	20040212
PRIORITY APPLN. INFO.:			US 2003-446924P	P 20030212
OTHER SOURCE(S):			MARPAT 141:225511	
GI				




AB Title imidazoles and analogs I [wherein m, n = independently 0, 1; A = H, alkyl, alkenyl, alkynyl; L1 = a bond, O, alkylene, CO, NHCO, NH, NHCO2, etc.; T = H, (un)substituted (cyclo)alkyl, heterocyclyl, (hetero)aryl, etc.; W = O, S, NR4; X = a bond, CO, CH2, SO2; R1 = H, halo, CN, alkyl, (hetero)aryl, heterocyclyl, etc.; R2 = H, perfluoroalkyl, alkylene optionally interrupted by one or more heteroatoms, (hetero)aryl, heterocyclyl, etc.; R3 = H, alkyl, (cyclo)alkylalkylene, (hetero)arylalkylene; R4 = H, alkyl, (hetero)arylalkylene, heterocyclylalkylene, etc.; Ar1 = (un)substituted optionally fused (hetero)aryl; Ar2 = (un)substituted optionally fused (hetero)arylene; and pharmaceutically acceptable salts, solvates, and prodrugs thereof] were prepared as inhibitors of protein tyrosine phosphatases (PTPases). For example, 3-[(tert-butoxycarbonyl)amino]-2-(4-butoxy-3-butoxycarbonylphenyl)-2-ethyl-4-(4-nitrophenyl)imidazole was coupled with 4-nitrophenacyl bromide to give the keto ester, which was treated with ammonium acetate in glacial acetic acid/anhydrous DMF to afford the imidazole II (40%). Comps. of the invention inhibited PTP 18 activity with IC50 values ranging from about 0.01  $\mu$ M to about 20  $\mu$ M. Thus, I and pharmaceutical comps. comprising them may be useful for the management, treatment, control, and adjunct treatment of diseases mediated by PTPase activity, such as Type I diabetes, Type II diabetes, immune dysfunction, AIDS, autoimmune diseases, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis and/or production of growth hormone or cytokines, of Alzheimer's disease (no data).

IT 746657-71-6P 746657-73-8P 746657-81-8P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(PTPase inhibitor; preparation of substituted imidazoles as PTPase inhibitors for treatment of diabetes and other PTPase mediated conditions)  
RN 746657-71-6 CAPLUS  
CN Cyclohexanecarboxamide, N-[(1S)-2-(4-butoxyphenyl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 746657-73-8 CAPLUS  
CN Cyclohexanecarboxamide, N-[(1S)-2-(4-butoxyphenyl)-1-[4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]ethyl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746657-81-8 CAPLUS  
CN Cyclohexanecarboxamide, N-[(1S)-2-(4-butoxyphenyl)-1-[4-(pentafluorophenyl)-1H-imidazol-2-yl]ethyl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 746658-03-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(PTPase inhibitor; preparation of substituted imidazoles as PTPase inhibitors for treatment of diabetes and other PTPase mediated conditions)  
RN 746658-03-7 CAPLUS


CN Benzoic acid, 4-[[4-[(2S)-2-[4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[4-(1,1-dimethylethyl)cyclohexyl]carbonyl]amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 745832-99-9P 745833-00-5P 745833-02-7P  
745833-75-4P, (2S)-2-Amino-4-[2-nitro-2-[4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]ethyl]phenol hydrochloride 745833-76-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of substituted imidazoles as PTPase inhibitors for treatment of diabetes and other PTPase mediated conditions)  
RN 745832-99-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -[[4-(4-butoxyphenyl)methyl]-4-(4-nitrophenyl)-, monohydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 745833-00-5 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -[[4-(4-butoxyphenyl)methyl]-4-(2,4-dichlorophenyl)-, monohydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 745833-70-9 745833-94-7, [(1S)-1-[4-(2,4-Dichlorophenyl)-1H-imidazol-2-yl]-2-[4-(4-hydroxyphenyl)ethyl]carbamic acid tert-butyl ester 746658-05-9  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of substituted imidazoles as PTPase inhibitors for treatment of diabetes and other PTPase mediated conditions)  
RN 745833-70-9 CAPLUS  
CN Cyclohexanecarboxamide, N-[(1S)-1-[4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[4-(4-hydroxyphenyl)ethyl]-4-ethyl-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 745833-94-7 CAPLUS  
CN Carbamic acid, [(1S)-1-[4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[4-(4-hydroxyphenyl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746658-05-9 CAPLUS  
CN Benzoic acid, 4-[[4-[(2S)-2-[4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[[4-(1,1-dimethylethyl)cyclohexyl]carbonyl]amino]ethyl]phenoxy]methyl]- methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 745833-02-7 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -[[4-(4-butoxyphenyl)methyl]-4-(pentafluorophenyl)-, monohydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 745833-75-4 CAPLUS  
CN Phenol, 2-amino-4-[(2S)-2-[4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-nitroethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 745833-76-5 CAPLUS  
CN Cyclohexanecarboxamide, N-[(1S)-1-[4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]-2-[4-(4-hydroxy-3-nitrophenyl)ethyl]-4-ethyl-, trans- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 2 OF 36 CAPLUS COPYRIGHT 2005 ACS on STM  
ACCESSION NUMBER: 2004:550745 CAPLUS  
DOCUMENT NUMBER: 141:106475  
TITLE: Preparation of 5-membered heterocycle derivatives for treating neurodegenerative disorders or pain  
INVENTOR(S): Chabrier De Lasseunier, Pierre-Stienne; Harnett, Jeremiah; Biggs, Dennis; Liberatore, Anna-Marie; Pommer, Jacques; Lannoy, Jacques; Thureau, Christophe  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 150 pp., Cont.-in-part of U.S. Ser. No. 89,993.  
CODEN: USMXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004132788	A1	20040708	US 2003-681002	20031008
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GR, GU, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, NG, SN, TD, TG				
EP 1228760	A2	20020807	EP 2002-76763	20001010
EP 1228760	A3	20040128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL				
PRIORITY APPLN. INFO.: FR 1999-12643 A 19991011				
FR 2000-10151 A 20000801				
FR 2000-11169 A 20000901				
WO 2000-FR2805 W 20001010				
JP 1989-4943 A 20010410				
JP 1990-1811 A 20020214				
US 2002-89993 A2 20020404				



AB The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivs. of general formula (I) [wherein Het = thiazole, oxazole, imidazole, isoxazole or isoxazoline; n = an integer from 0 to 6; A = optionally substituted aromatic radical; B = H, alkyl, Ph; R1, R2 = H, alkyl, cycloalkyl; Q = NR46R47 or OR48; R46, R47 = H, alkyl, cycloalkyl, (CH2)k-CO2R51; R51 = alkyl, haloalkyl; R48 = H, alkyl]. These compds. have advantageous pharmacol. properties which allow their use in a medicament intended to inhibit monoamine oxidases (MAO) and/or lipidic peroxid. and/or to act as modulators of the sodium channels and notably their use in therapeutics for treating (1) central or peripheral nervous system, (2) neurodegenerative disorders selected from Parkinson's disease, Alzheimer's disease, Huntington's chorea and amyotrophic lateral sclerosis or (3) pain selected from the group consisting of postoperative pain, migraine, neuropathic pain, central pain, chronic inflammatory pain and pain linked to a cancer. Thus, 2-[[[(1,1-dimethylethoxy)carbonyl]methyl]amino]ethanethioamide (4.3 g, 2.11 mmol) and 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (6.9 g, 2.11 mmol) were dissolved in 75 mL benzene under argon atmospheric and stirred at ambient temperature for 12 h to give,

after workup and silica gel chromatog., 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-[[[(1,1-dimethylethoxy)carbonyl]methyl]-2-thiazole]methanamine which was treated with CF3CO2H and triethylsilane in 50 mL CH2Cl2 to give, after workup, 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-2-thiazolemethanamine (II). II showed IC50 of lower than 10 µM for inhibiting lipid peroxid. of the cerebral cortex of rats.

IT 252279-09-7P, (1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 252302-96-8P, (1R)-N-Benzyl-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335244-94-5P 335246-59-8P 335246-68-9P, N-Benzyl[4-(1,1'-biphenyl-4-yl)-1H-imidazol-2-yl]methanamine 335246-82-7P 335247-34-2P, 1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-5-methyl-1-hexanamine


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (intermediate; preparation of 5-membered heterocycle deriva. for treating diseases of central or peripheral nervous system, neurodegenerative disorders, or pain)

RN 252279-09-7 CAPLUS

CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)



RN 335247-34-2 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-(4-methylpentyl)- (9CI) (CA INDEX NAME)



IT 335247-29-5P, tert-Butyl [(S)-cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]carbamate 335247-30-8P,

(S)-Cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine


335247-35-3P, tert-Butyl [1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]heptyl]carbamate 473541-90-1P 473541-95-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of 5-membered heterocycle deriva. for treating diseases of central or peripheral nervous system, neurodegenerative disorders, or pain)

RN 335247-29-5 CAPLUS

CN Carbamic acid, [(S)-cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335247-30-8 CAPLUS

CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-(4-fluorophenyl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252302-96-8 CAPLUS


CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-94-5 CAPLUS

CN Carbamic acid, [1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-5-methylhexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335246-59-8 CAPLUS

CN 1H-Imidazole-2-methanamine, α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335246-68-9 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-82-7 CAPLUS




RN 335247-35-3 CAPLUS

CN Carbamic acid, [1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 473541-90-1 CAPLUS

CN Carbamic acid, methyl[[4-(10H-phenothiazin-2-yl)-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473541-95-6 CAPLUS

CN Carbamic acid, [[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



IT 167983-80-4P 175531-38-1P, (4-Phenyl-1H-imidazol-2-yl)methanamine 218944-40-2P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-nitrobenzoyl)-1H-imidazole-2-methanamine

218944-41-3P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-aminobenzoyl)-1H-imidazole-2-methanamine 218944-66-2P

, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-nitrophenyl)-1H-imidazole-2-methanamine 218944-68-4P,

4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-aminophenyl)-1H-imidazole-2-methanamine 252279-15-5P, (1R)-2-(1H-indol-3-yl)-

1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethanamine 252302-55-9P,


N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-1-hexanamine

252303-16-5P, (1R)-N-(Cyclohexylmethyl)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 252306-13-1P


352309-65-2P, (1S)-N-Benzyl-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 280775-44-2P, N-Benzyl-4-phenyl-1H-imidazol-2-yl)methanamine 335242-80-3P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-1H-imidazole-2-methanamine 335242-92-7P, N-[(S)-Cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl)methyl]cyclobutanamine 335242-94-9P, N-[(1,1'-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-5-methylthyl)-N-cyclohexylamine 335242-95-0P, N-[(1,1'-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]heptyl)cyclohexanamine 335242-98-3P, N-Benzyl-N-[(1,1'-biphenyl-4-yl)-1H-imidazol-2-yl)methyl]-1-hexanamine 335242-99-4P, N-Benzyl[4-(1,1'-biphenyl-4-yl)-1H-imidazol-2-yl]-N-methylmethanamine 335243-00-0P  
335243-01-1P, 335243-04-4P, 335243-04-4P  
335243-05-5P, 335243-07-7P, (4-Phenyl-1H-imidazol-2-yl)methanamine hydrochloride 335243-10-2P, 335243-14-6P  
335243-15-7P, 335243-16-8P, 335243-19-1P  
335243-20-4P, 335243-23-7P, 335243-24-8P  
335243-26-0P, 335243-27-1P, 335243-28-2P  
335243-29-3P, 335243-30-6P, 335243-31-7P  
335243-32-8P, 335243-33-9P, 335243-34-0P, Butyl [(4-(1,1'-biphenyl-4-yl)-1H-imidazol-2-yl)methyl]carbamate 335243-35-1P, 335243-36-2P, (S)-Cyclohexyl[4-phenyl-1H-imidazol-2-yl)methyl]amine hydrochloride 335243-41-9P, N-[(S)-Cyclohexyl[4-(3-fluoro-4-methoxyphenyl)-1H-imidazol-2-yl)methyl]cyclobutanamine 335243-42-0P, N-[(S)-Cyclohexyl[4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)methyl]cyclobutanamine 335243-43-1P, N-[(S)-Cyclohexyl[4-(3-fluorophenyl)-1H-imidazol-2-yl)methyl]cyclobutanamine 335243-50-0P, tert-Butyl [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]carbamate 335243-51-1P, (1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-52-2P, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]benzamide 335243-53-3P, Benzyl [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]carbamate 335243-56-6P, tert-Butyl [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]carbamate 335243-57-7P, tert-Butyl [(4-phenyl-1H-imidazol-2-yl)methyl]carbamate 335243-59-9P, 335243-60-2P, (1R)-2-(1H-indol-3-yl)-1-(4-(4-nitrophenyl)-1H-imidazol-2-yl)ethanamine hydrochloride 335243-62-4P, (1R)-2-(1H-indol-3-yl)-N-(2-phenoxyethyl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335243-65-7P, 335243-68-0P, 335243-70-4P, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]benzamide 335243-71-5P, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxybenzamide 335243-74-8P, tert-Butyl [(1R)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]carbamate 335243-75-9P, 335243-79-3P, tert-Butyl [(1R)-3-phenyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]carbamate 335243-80-6P, 335243-80-6P, (1R)-2-cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]carbamate 335243-83-9P, 335243-84-0P, 335243-85-1P, 335243-86-2P, 335243-87-3P, 4-[2-[(tert-Butoxycarbonyl)amino]methyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335243-88-4P, N-[(S)-Cyclohexyl[4-(4-methylsulfonylphenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine 335243-91-9P, 335243-91-9P, 4-[2-[(S)-Amino(cyclohexyl)methyl]-1H-imidazol-2-yl)methanamine hydrochloride 335243-94-2P, N,N-Dibenzyl[4-(1,1'-biphenyl-4-yl)-1H-imidazol-2-yl)methanamine 335243-95-3P, 335244-02-5P, 4-[2-[(tert-Butoxycarbonyl)amino]methyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-04-7P, 4-[2-[(1R)-1-[(tert-Butoxycarbonyl)amino]-2-cyclohexylmethyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-11-6P, (1R)-1-(4-(1,1'-Biphenyl-4-yl)-1H-imidazol-2-yl)-2-cyclohexylethanamine hydrochloride 335244-12-7P, 4-[2-[(1,1'-Biphenyl-4-yl)-1H-imidazol-2-yl]-N-methylmethanamine hydrochloride 335244-26-3P, 4-[2-[(Benzyl(tert-butoxycarbonyl)amino)methyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-28-5P, 335244-29-6P, N-Benzyl[4-(1,1'-biphenyl-4-yl)-1H-imidazol-2-yl)methanamine hydrochloride 335244-30-9P, 335244-31-0P, 335244-35-4P

(S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(3-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)methanamine hydrochloride 335245-73-3P, 335245-74-4P, 4-[2-[(S)-Amino(cyclohexyl)methyl]-1H-imidazol-4-yl]-N,N-diethylaniline hydrochloride 335245-75-5P, (S)-1-Cyclohexyl-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl)methanamine hydrochloride 335245-76-6P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl)methanamine hydrochloride 335245-78-8P, N-[(S)-Cyclohexyl[4-(3-fluorophenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine hydrochloride 335245-80-2P, 4-[2-[(S)-Amino(cyclohexyl)methyl]-1H-imidazol-4-yl]-2,6-di-tert-butylphenol hydrochloride 335245-82-4P, (R)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl)methanamine hydrochloride 335246-23-6P, 335246-24-7P, 4-[2-[(S)-Amino(cyclohexyl)methyl]-1H-imidazol-4-yl]-2,6-di-tert-butylphenol 335246-41-8P, 335246-42-9P, 335246-43-0P, (S)-Cyclohexyl[4-phenyl-1H-imidazol-2-yl)methyl]amine 335246-44-1P, 335246-46-3P, N-[(S)-Cyclohexyl[4-phenyl-1H-imidazol-2-yl)methyl]cyclobutanamine 335246-47-4P, 335246-50-9P, 335246-51-0P, 335246-54-3P, 335246-56-5P, 335246-57-6P, 335246-58-7P, 4-(1,1'-Biphenyl-4-yl)-1H-imidazol-2-yl)methanamine 335246-67-8P, 335246-69-0P, 335246-70-3P, 335246-71-4P, 335246-72-5P, 335246-73-6P, 335246-74-7P, 335246-76-9P, 335246-77-0P, 335246-78-1P, 335246-79-2P, 335246-80-5P, 335246-81-6P, 335246-83-0P, 335246-84-9P, 335246-85-0P, 335246-86-1P, 335246-87-2P, 335246-89-4P, 335246-90-7P, 335246-91-8P, 335246-92-9P, 335246-93-0P, 335246-94-1P, (S)-Cyclohexyl[4-(3,4-difluorophenyl)-1H-imidazol-2-yl)methanamine 335246-95-2P, (S)-Cyclohexyl[4-(3-fluoro-4-methoxyphenyl)-1H-imidazol-2-yl)methanamine 335246-96-3P, 335246-97-4P, 335246-98-5P, (S)-Cyclohexyl-N-(cyclohexylmethyl)[4-phenyl-1H-imidazol-2-yl)methanamine 335246-99-6P, 335247-00-2P, (S)-Cyclohexyl-N-(cyclopropylmethyl)[4-phenyl-1H-imidazol-2-yl)methanamine 335247-01-3P, (S)-Cyclohexyl-N-(cyclopropylmethyl)[4-(4-fluorophenyl)-1H-imidazol-2-yl)methanamine 335247-02-4P, N-[(S)-Cyclohexyl[4-(4-cyclohexylphenyl)-1H-imidazol-2-yl)methyl]cyclobutanamine 335247-04-6P, 4-[2-[(S)-Cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]-N,N-diethylaniline 335247-05-7P, 2,6-Di-tert-butyl-4-[2-[(S)-cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]phenol 335247-06-8P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1H-imidazol-4-yl]-N,N-diethylaniline 335247-07-9P, N-[(S)-[4-(3-Bromophenyl)-1H-imidazol-2-yl]cyclohexylmethyl]cyclohexanamine 335247-08-0P, (1R)-2-Cyclohexyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl)methanamine 335247-09-1P, 4-[2-[(S)-Amino(cyclohexyl)methyl]-1H-imidazol-4-yl]-N,N-diethylaniline 335247-10-6P, (S)-1-Cyclohexyl-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl)methanamine 335247-11-5P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl)methanamine 335247-12-6P, N-[(S)-Cyclohexyl[4-(3-fluorophenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine 335247-13-7P, (R)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl)methanamine 335247-14-8P, (1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine 335247-16-0P, N-[(1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethyl]cyclohexanamine 335247-17-1P, (1R)-N-(cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine 335247-20-6P, (1R)-1-[4-(1,1'-Biphenyl-4-yl)-1H-imidazol-2-yl]-2-cyclohexylethanamine 335247-37-5P, 4-[1,1'-Biphenyl-4-yl)-1H-imidazol-2-yl]-N-methylmethanamine 335247-38-6P, 335247-39-7P, 335247-40-8P, 335247-41-9P, 335247-42-0P, 335247-43-1P, 335247-44-2P, 335247-45-3P, 335247-46-4P, 335247-47-5P, 335247-48-6P, 335247-49-7P, 335247-50-8P, 335247-51-9P, 335247-52-0P, 335247-53-1P, 335247-54-2P, 335247-55-3P, 335247-56-4P, 335247-57-5P, 335247-58-6P, 335247-59-7P, 335247-60-8P, 335247-61-9P, 335247-62-0P, 335247-63-1P, 335247-64-2P, 335247-65-3P, 335247-66-4P, 335247-67-5P, 335247-68-6P, 335247-69-7P, 335247-70-8P, 335247-71-9P, 335247-72-0P, 335247-73-1P, 335247-74-2P, 335247-75-3P, 335247-76-4P, 335247-77-5P, 335247-78-6P, 335247-79-7P, 335247-80-8P, 335247-81-9P, 335247-82-0P, 335247-83-1P, 335247-84-2P, 335247-85-3P, 335247-86-4P, 335247-87-5P, 335247-88-6P, 335247-89-7P, 335247-90-8P, 335247-91-9P, 335247-92-0P, 335247-93-1P, 335247-94-2P, 335247-95-3P, 335247-96-4P, 335247-97-5P, 335247-98-6P, 335247-99-7P, 335248-00-8P, 335248-01-9P, 335248-02-0P, 335248-03-1P, 335248-04-2P, 335248-05-3P, 335248-06-4P, 335248-07-5P, 335248-08-6P, 335248-09-7P, 335248-10-8P, 335248-11-9P, 335248-12-0P, 335248-13-1P, 335248-14-2P, 335248-15-3P, 335248-16-4P, 335248-17-5P, 335248-18-6P, 335248-19-7P, 335248-20-8P, 335248-21-9P, 335248-22-0P, 335248-23-1P, 335248-24-2P, 335248-25-3P, 335248-26-4P, 335248-27-5P, 335248-28-6P, 335248-29-7P, 335248-30-8P, 335248-31-9P, 335248-32-0P, 335248-33-1P, 335248-34-2P, 335248-35-3P, 335248-36-4P, 335248-37-5P, 335248-38-6P, 335248-39-7P, 335248-40-8P, 335248-41-9P, 335248-42-0P, 335248-43-1P, 335248-44-2P, 335248-45-3P, 335248-46-4P, 335248-47-5P, 335248-48-6P, 335248-49-7P, 335248-50-8P, 335248-51-9P, 335248-52-0P, 335248-53-1P, 335248-54-2P, 335248-55-3P, 335248-56-4P, 335248-57-5P, 335248-58-6P, 335248-59-7P, 335248-60-8P, 335248-61-9P, 335248-62-0P, 335248-63-1P, 335248-64-2P, 335248-65-3P, 335248-66-4P, 335248-67-5P, 335248-68-6P, 335248-69-7P, 335248-70-8P, 335248-71-9P, 335248-72-0P, 335248-73-1P, 335248-74-2P, 335248-75-3P, 335248-76-4P, 335248-77-5P, 335248-78-6P, 335248-79-7P, 335248-80-8P, 335248-81-9P, 335248-82-0P, 335248-83-1P, 335248-84-2P, 335248-85-3P, 335248-86-4P, 335248-87-5P, 335248-88-6P, 335248-89-7P, 335248-90-8P, 335248-91-9P, 335248-92-0P, 335248-93-1P, 335248-94-2P, 335248-95-3P, 335248-96-4P, 335248-97-5P, 335248-98-6P, 335248-99-7P, 335249-00-8P, 335249-01-9P, 335249-02-0P, 335249-03-1P, 335249-04-2P, 335249-05-3P, 335249-06-4P, 335249-07-5P, 335249-08-6P, 335249-09-7P, 335249-10-8P, 335249-11-9P, 335249-12-0P, 335249-13-1P, 335249-14-2P, 335249-15-3P, 335249-16-4P, 335249-17-5P, 335249-18-6P, 335249-19-7P, 335249-20-8P, 335249-21-9P, 335249-22-0P, 335249-23-1P, 335249-24-2P, 335249-25-3P, 335249-26-4P, 335249-27-5P, 335249-28-6P, 335249-29-7P, 335249-30-8P, 335249-31-9P, 335249-32-0P, 335249-33-1P, 335249-34-2P, 335249-35-3P, 335249-36-4P, 335249-37-5P, 335249-38-6P, 335249-39-7P, 335249-40-8P, 335249-41-9P, 335249-42-0P, 335249-43-1P, 335249-44-2P, 335249-45-3P, 335249-46-4P, 335249-47-5P, 335249-48-6P, 335249-49-7P, 335249-50-8P, 335249-51-9P, 335249-52-0P, 335249-53-1P, 335249-54-2P, 335249-55-3P, 335249-56-4P, 335249-57-5P, 335249-58-6P, 335249-59-7P, 335249-60-8P, 335249-61-9P, 335249-62-0P, 335249-63-1P, 335249-64-2P, 335249-65-3P, 335249-66-4P, 335249-67-5P, 335249-68-6P, 335249-69-7P, 335249-70-8P, 335249-71-9P, 335249-72-0P, 335249-73-1P, 335249-74-2P, 335249-75-3P, 335249-76-4P, 335249-77-5P, 335249-78-6P, 335249-79-7P, 335249-80-8P, 335249-81-9P, 335249-82-0P, 335249-83-1P, 335249-84-2P, 335249-85-3P, 335249-86-4P, 335249-87-5P, 335249-88-6P, 335249-89-7P, 335249-90-8P, 335249-91-9P, 335249-92-0P, 335249-93-1P, 335249-94-2P, 335249-95-3P, 335249-96-4P, 335249-97-5P, 335249-98-6P, 335249-99-7P, 335250-00-8P, 335250-01-9P, 335250-02-0P, 335250-03-1P, 335250-04-2P, 335250-05-3P, 335250-06-4P, 335250-07-5P, 335250-08-6P, 335250-09-7P, 335250-10-8P, 335250-11-9P, 335250-12-0P, 335250-13-1P, 335250-14-2P, 335250-15-3P, 335250-16-4P, 335250-17-5P, 335250-18-6P, 335250-19-7P, 335250-20-8P, 335250-21-9P, 335250-22-0P, 335250-23-1P, 335250-24-2P, 335250-25-3P, 335250-26-4P, 335250-27-5P, 335250-28-6P, 335250-29-7P, 335250-30-8P, 335250-31-9P, 335250-32-0P, 335250-33-1P, 335250-34-2P, 335250-35-3P, 335250-36-4P, 335250-37-5P, 335250-38-6P, 335250-39-7P, 335250-40-8P, 335250-41-9P, 335250-42-0P, 335250-43-1P, 335250-44-2P, 335250-45-3P, 335250-46-4P, 335250-47-5P, 335250-48-6P, 335250-49-7P, 335250-50-8P, 335250-51-9P, 335250-52-0P, 335250-53-1P, 335250-54-2P, 335250-55-3P, 335250-56-4P, 335250-57-5P, 335250-58-6P, 335250-59-7P, 335250-60-8P, 335250-61-9P, 335250-62-0P, 335250-63-1P, 335250-64-2P, 335250-65-3P, 335250-66-4P, 335250-67-5P, 335250-68-6P, 335250-69-7P, 335250-70-8P, 335250-71-9P, 335250-72-0P, 335250-73-1P, 335250-74-2P, 335250-75-3P, 335250-76-4P, 335250-77-5P, 335250-78-6P, 335250-79-7P, 335250-80-8P, 335250-81-9P, 335250-82-0P, 335250-83-1P, 335250-84-2P, 335250-85-3P, 335250-86-4P, 335250-87-5P, 335250-88-6P, 335250-89-7P, 335250-90-8P, 335250-91-9P, 335250-92-0P, 335250-93-1P, 335250-94-2P, 335250-95-3P, 335250-96-4P, 335250-97-5P, 335250-98-6P, 335250-99-7P, 335251-00-8P, 335251-01-9P, 335251-02-0P, 335251-03-1P, 335251-04-2P, 335251-05-3P, 335251-06-4P, 335251-07-5P, 335251-08-6P, 335251-09-7P, 335251-10-8P, 335251-11-9P, 335251-12-0P, 335251-13-1P, 335251-14-2P, 335251-15-3P, 335251-16-4P, 335251-17-5P, 335251-18-6P, 335251-19-7P, 335251-20-8P, 335251-21-9P, 335251-22-0P, 335251-23-1P, 335251-24-2P, 335251-25-3P, 335251-26-4P, 335251-27-5P, 335251-28-6P, 335251-29-7P, 335251-30-8P, 335251-31-9P, 335251-32-0P, 335251-33-1P, 335251-34-2P, 335251-35-3P, 335251-36-4P, 335251-37-5P, 335251-38-6P, 335251-39-7P, 335251-40-8P, 335251-41-9P, 335251-42-0P, 335251-43-1P, 335251-44-2P, 335251-45-3P, 335251-46-4P, 335251-47-5P, 335251-48-6P, 335251-49-7P, 335251-50-8P, 335251-51-9P, 335251-52-0P, 335251-53-1P, 335251-54-2P, 335251-55-3P, 335251-56-4P, 335251-57-5P, 335251-58-6P, 335251-59-7P, 335251-60-8P, 335251-61-9P, 335251-62-0P, 335251-63-1P, 335251-64-2P, 335251-65-3P, 335251-66-4P, 335251-67-5P, 335251-68-6P, 335251-69-7P, 335251-70-8P, 335251-71-9P, 335251-72-0P, 335251-73-1P, 335251-74-2P, 335251-75-3P, 335251-76-4P, 335251-77-5P, 335251-78-6P, 335251-79-7P, 335251-80-8P, 335251-81-9P, 335251-82-0P, 335251-83-1P, 335251-84-2P, 335251-85-3P, 335251-86-4P, 335251-87-5P, 335251-88-6P, 335251-89-7P, 335251-90-8P, 335251-91-9P, 335251-92-0P, 335251-93-1P, 335251-94-2P, 335251-95-3P, 335251-96-4P, 335251-97-5P, 335251-98-6P, 335251-99-7P, 335252-00-8P, 335252-01-9P, 335252-02-0P, 335252-03-1P, 335252-04-2P, 335252-05-3P, 335252-06-4P, 335252-07-5P, 335252-08-6P, 335252-09-7P, 335252-10-8P, 335252-11-9P, 335252-12-0P, 335252-13-1P, 335252-14-2P, 335252-15-3P, 335252-16-4P, 335252-17-5P, 335252-18-6P, 335252-19-7P, 335252-20-8P, 335252-21-9P, 335252-22-0P, 335252-23-1P, 335252-24-2P, 335252-25-3P, 335252-26-4P, 335252-27-5P, 335252-28-6P, 335252-29-7P, 335252-30-8P, 335252-31-9P, 335252-32-0P, 335252-33-1P, 335252-34-2P, 335252-35-3P, 335252-36-4P, 335252-37-5P, 335252-38-6P, 335252-39-7P, 335252-40-8P, 335252-41-9P, 335252-42-0P, 335252-43-1P, 335252-44-2P, 335252-45-3P, 335252-46-4P, 335252-47-5P, 335252-48-6P, 335252-49-7P, 335252-50-8P, 335252-51-9P, 335252-52-0P, 335252-53-1P, 335252-54-2P, 335252-55-3P, 335252-56-4P, 335252-57-5P, 335252-58-6P, 335252-59-7P, 335252-60-8P, 335252-61-9P, 335252-62-0P, 335252-63-1P, 335252-64-2P, 335252-65-3P, 335252-66-4P, 335252-67-5P, 335252-68-6P, 335252-69-7P, 335252-70-8P, 335252-71-9P, 335252-72-0P, 335252-73-1P, 335252-74-2P, 335252-75-3P, 335252-76-4P, 335252-77-5P, 335252-78-6P, 335252-79-7P, 335252-80-8P, 335252-81-9P, 335252-82-0P, 335252-83-1P, 335252-84-2P, 335252-85-3P, 335252-86-4P, 335252-87-5P, 335252-88

nitrophenyl)amino)methyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 218944-68-4 CAPLUS  
CN Phenol, 4-[2-[[[4-(4-nitrophenyl)methylamino)methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)]- (9CI) (CA INDEX NAME)




RN 252279-15-5 CAPLUS  
CN 1H-Indole-3-ethanamine, alpha-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-55-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-hexyl-alpha-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-16-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)-alpha-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335242-92-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-alpha-cyclohexyl-4-(4-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 335242-94-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl-alpha-(4-methylpentyl)- (9CI) (CA INDEX NAME)




RN 335242-95-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-alpha-hexyl- (9CI) (CA INDEX NAME)



RN 335242-98-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-13-1 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252309-65-2 CAPLUS  
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 280775-44-2 CAPLUS  
CN 1H-Indole-3-ethanamine, 4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335242-80-3 CAPLUS  
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[2-[[[methylamino)methyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

RN 335242-99-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-00-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,N,alpha-trihexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-01-1 CAPLUS  
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-2-pyrimidinyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-03-3 CAPLUS  
CN 1H-Indole-3-ethanamine, N-methyl-alpha-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-04-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(2-phenylethyl)-alpha-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 335243-05-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-N,α-bis(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-07-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 335243-10-2 CAPLUS  
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-14-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-butyl-1-methyl-α-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335243-24-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-[(4-chlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-26-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-[(2-chlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-27-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-[(2-fluorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-28-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-butyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-29-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-N-(3-methylbutyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-15-7 CAPLUS  
CN Carbamic acid, [1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-16-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-butyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-19-1 CAPLUS  
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-20-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,α-dihexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-23-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-[(2,6-dichlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-30-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N,α-dihexyl- (9CI) (CA INDEX NAME)




RN 335243-31-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-N-pentyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-32-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-33-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-34-0 CAPLUS  
CN Carbamic acid, [1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]-, butyl ester (9CI) (CA INDEX NAME)




RN 335243-35-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclopentyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-36-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-phenyl-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



•x HCl


RN 335243-41-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(3-fluoro-4-methoxyphenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-42-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(4-(trifluoromethyl)phenyl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



•x HCl


RN 335243-52-2 CAPLUS  
CN Benzamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 335243-53-3 CAPLUS  
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-56-6 CAPLUS  
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-(4-nitrophenyl)-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-43-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(3-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-50-0 CAPLUS  
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335243-51-1 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 335243-57-7 CAPLUS  
CN Carbamic acid, [(4-phenyl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-59-9 CAPLUS  
CN 1H-Indole-3-ethanamine, 6-fluoro-α-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-60-2 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



•x HCl


RN 335243-62-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(2-phenoxyethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-65-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-(benzo[b]thien-3-ylmethyl)-4-phenyl-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-68-0 CAPLUS  
CN Carbanic acid, [2-(6-chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-70-4 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-71-5 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-74-8 CAPLUS  
CN Carbanic acid, [(1R)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

(CA INDEX NAME)




RN 335243-84-0 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -(cyclohexylmethyl)-4-phenyl-N-(phenylmethyl)-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-85-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl- $\alpha$ -(2-phenylethyl)-N-(phenylmethyl)-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-86-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- $\alpha$ -(4,4,4-trifluorobutyl)- (9CI) (CA INDEX NAME)




RN 335243-87-3 CAPLUS  
CN Carbanic acid, [(4-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-88-4 CAPLUS

Absolute stereochemistry.




RN 335243-75-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -(2-methylpropyl)-4-phenyl-N-(phenylmethyl)-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-79-3 CAPLUS  
CN Carbanic acid, [(1R)-3-phenyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-80-6 CAPLUS  
CN Carbanic acid, [(1R)-2-cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335243-83-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ ,4-diphenyl-N-(phenylmethyl)- (9CI)

CN 1H-Imidazole-2-methanamine, N, $\alpha$ -dicyclohexyl-4-[4-(methylsulfonyl)phenyl]-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-91-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-, hydrochloride (9CI) (CA INDEX NAME)




•x HCl


RN 335243-94-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-95-3 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-02-5 CAPLUS  
CN Carbanic acid, [(4-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-04-7 CAPLUS  
CN Carbamic acid, [(1R)-1-(4-{[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl}-2-cyclohexylethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-11-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-{[1,1'-biphenyl]-4-yl- $\alpha$ -(cyclohexylmethyl)-, hydrochloride, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 335244-12-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-{[1,1'-biphenyl]-4-yl-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 335244-26-3 CAPLUS  
CN Carbamic acid, [(4-{[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl}(phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-35-4 CAPLUS  
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-43-4 CAPLUS  
CN Carbamic acid, [1-(4-(4-methylphenyl)-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-44-5 CAPLUS  
CN Carbamic acid, [1-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-47-8 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -butyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-48-9 CAPLUS




RN 335244-28-5 CAPLUS  
CN Carbamic acid, [(1R)-1-(4-{[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl}-3-phenylpropyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-29-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-{[1,1'-biphenyl]-4-yl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 335244-30-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-{[1,1'-biphenyl]-4-yl-N-(cyclohexylmethyl)-N-(phenylmethyl)-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335244-31-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-{[1,1'-biphenyl]-4-yl-N-(2-phenylethyl)-N-(phenylmethyl)-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


CN Carbamic acid, [1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-50-3 CAPLUS  
CN Carbamic acid, [1-(4-(3-bromophenyl)-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-53-6 CAPLUS  
CN Carbamic acid, [1-(4-{[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl}heptyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-54-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- $\alpha$ -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-56-9 CAPLUS  
CN Carbamic acid, [(1S)-1-(4-{[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl}propyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-57-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-60-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-ethyl-N-(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335244-63-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(2-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-64-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-pentyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-68-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-bromophenyl)-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-76-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)-α-propyl-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335244-77-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-[(3-chlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335244-78-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(3-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-79-6 CAPLUS  
CN Benzonitrile, 4-[2-[1-[(phenylmethyl)amino]heptyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 335244-84-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-butyl-α-ethyl-, (aS)- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 335244-69-4 CAPLUS  
CN Carbamic acid, [(1R)-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-70-7 CAPLUS  
CN Carbamic acid, [(1R)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-74-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-bromophenyl)-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-75-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)-α-propyl-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 335244-85-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-methyl-4-phenyl-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335244-86-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-phenyl-N-propyl- (9CI) (CA INDEX NAME)




RN 335244-89-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-N-[(4-methoxyphenyl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 335244-96-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-N-(2-methylpropyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 335244-98-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-(4-methylpentyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-99-0 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335245-03-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- $\alpha$ -hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335245-04-0 CAPLUS  
CN Carbamic acid, [(1S)-1-(4-{[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl}ethyl)-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-05-1 CAPLUS  
CN Carbamic acid, [(1R)-1-(4-{[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl}ethyl)-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-23-3 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-4-(3-fluoro-4-methoxyphenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-25-5 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-4-(4-fluorophenyl)-N-(1-methylethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-26-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- $\alpha$ -cyclohexyl-4-(3,4-difluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-06-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, N, $\alpha$ -dicyclohexyl-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335245-11-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-N-(1-methylethyl)-4-phenyl-, (9CI) (CA INDEX NAME)




RN 335245-18-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl-, (9CI) (CA INDEX NAME)




RN 335245-22-2 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-4-(3,4-difluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-28-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, N, $\alpha$ -dicyclohexyl-4-(4-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl.

RN 335245-29-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-N-(cyclohexylmethyl)-4-phenyl-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-31-3 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-N-(cyclopropylmethyl)-4-phenyl-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-34-6 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-[4-(trifluoromethoxy)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-37-9 CAPLUS  
CN 1H-imidazole-2-methanamine, α-cyclohexyl-N-(cyclopropylmethyl)-4-(4-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-38-0 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclobutyl-α-cyclopentyl-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 335245-39-1 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(4-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-40-4 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclobutyl-4-(4-fluorophenyl)-α-(1-methylethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-41-5 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(4-(trifluoromethyl)phenyl)-, (aS)-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 335243-42-0  
CMF C21 H26 F3 N3

Absolute stereochemistry.




CM 2

CRN 64-19-7  
CMF C2 H4 O2




RN 335245-46-0 CAPLUS  
CN 1H-imidazole-2-methanamine, N,α-dicyclohexyl-4-[4-(methylthio)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-47-1 CAPLUS  
CN 1H-imidazole-2-methanamine, N,α-dicyclohexyl-4-(4-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-48-2 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[3,5-bis(trifluoromethyl)phenyl]-N,α-dicyclohexyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-51-7 CAPLUS  
CN 1H-imidazole-2-methanamine, N,α-dicyclohexyl-4-(3,4-difluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-53-9 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)-α-cyclohexyl-N-(cyclohexylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-54-0 CAPLUS  
CN 1H-imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-[4-(diethylamino)phenyl]-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-55-1 CAPLUS  
CN Phenol, 4-[[5-(cyclohexyl[(cyclohexylmethyl)amino]methyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-56-2 CAPLUS  
CN 1H-imidazole-2-methanamine, N,α-dicyclohexyl-4-[(4-(diethylamino)phenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-57-3 CAPLUS  
CN 1H-imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-(4-


Absolute stereochemistry.



●x HCl


RN 335245-62-0 CAPLUS  
CN 1H-imidazole-2-methanamine, N,α-dicyclohexyl-4-[(4-(trifluoromethyl)phenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-65-3 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cycloheptyl-α-cyclohexyl-4-(4-(trifluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-68-6 CAPLUS  
CN 1H-imidazole-2-methanamine, N,α-dicyclohexyl-4-[(4-(trifluoromethyl)phenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-59-5 CAPLUS  
CN 1H-imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-(4-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-60-8 CAPLUS  
CN 1H-imidazole-2-methanamine, N,α-dicyclohexyl-4-[(4-(trifluoromethyl)phenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-61-9 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)-N,α-dicyclohexyl-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


RN 335245-69-7 CAPLUS  
CN 1H-imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-[3-(trifluoromethyl)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-70-0 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)-α-cyclohexyl-N-(cyclohexylmethyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-71-1 CAPLUS  
CN 1H-imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-[3-(trifluoromethyl)phenyl]-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






●x HCl


RN 335245-73-3 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclohexyl-N-(cyclohexylmethyl)-4-(4-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-74-4 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclohexyl-4-{4-[(diethylamino)phenyl]}-hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-75-5 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclohexyl-4-(3-fluorophenyl)-hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-82-4 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclohexyl-N-(cyclohexylmethyl)-4-(4-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335246-23-6 CAPLUS  
CN Phenol, 4-[2-[(S)-aminocyclohexylmethyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 335246-24-7 CAPLUS  
CN Phenol, 4-[2-[(S)-aminocyclohexylmethyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-76-6 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclohexyl-N-(cyclohexylmethyl)-4-(3-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-78-8 CAPLUS  
CN 1H-imidazole-2-methanamine, N,N-dicyclohexyl-4-(3-fluorophenyl)-hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




●x HCl

RN 335245-80-2 CAPLUS  
CN Phenol, 4-[2-[(S)-aminocyclohexylmethyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335246-41-8 CAPLUS  
CN 1H-imidazole-2-methanamine, N-pentyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335246-42-9 CAPLUS  
CN 1H-imidazole-2-methanamine, N-hexyl-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-43-0 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclohexyl-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-44-1 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(2-chlorophenyl)-N-cyclohexyl-N-hexyl- (9CI) (CA INDEX NAME)




RN 335246-46-3 CAPLUS

CN 1H-Imidazole-2-methanamine, N-cyclobutyl- $\alpha$ -cyclohexyl-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-47-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-4-(4-fluorophenyl)- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)



RN 335246-50-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl- $\alpha$ -(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-51-0 CAPLUS  
CN 1H-Indole-3-ethanamine, 1-methyl- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335246-54-3 CAPLUS  
CN 1H-Indole-3-ethanamine, 6-chloro- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 335246-70-3 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-71-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)



RN 335246-72-5 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-73-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)




RN 335246-74-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -ethyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-56-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl- $\alpha$ -(2-phenylethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-57-6 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -(cyclohexylmethyl)-4-phenyl-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-58-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)




RN 335246-67-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -(2-phenylethyl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-69-0 CAPLUS



RN 335246-76-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-77-0 CAPLUS  
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 335246-78-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -propyl-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-79-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl- $\alpha$ -propyl-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-80-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)




RN 335246-81-6 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -methyl-4-phenyl-, (aR)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.




RN 335246-83-8 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(2-chlorophenyl)- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)




RN 335246-84-9 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(4-fluorophenyl)- $\alpha$ -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-85-0 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(2-chlorophenyl)- $\alpha$ -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335246-86-1 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(4-(diethylamino)phenyl)- $\alpha$ -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-93-0 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- $\alpha$ -(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 335246-94-1 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -cyclohexyl-4-(3,4-difluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-95-2 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -cyclohexyl-4-(3-fluoro-4-methoxyphenyl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-96-3 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -cyclopropyl-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 335246-87-2 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(3,4-dichlorophenyl)- $\alpha$ -hexyl- (9CI)  
(CA INDEX NAME)




RN 335246-89-4 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclohexyl-4-(3,4-dichlorophenyl)- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)




RN 335246-90-7 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-cyclohexyl- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)




RN 335246-91-8 CAPLUS  
CN 1H-indole-3-ethanamine, 5-fluoro- $\alpha$ -[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 335246-92-9 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclobutyl-5-fluoro- $\alpha$ -[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 335246-97-4 CAPLUS  
CN 1H-imidazole-2-methanamine, N-(cyclohexylmethyl)- $\alpha$ -hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335246-98-5 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -cyclohexyl-N-(cyclohexylmethyl)-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-99-6 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclohexyl- $\alpha$ -cyclopropyl-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 335247-00-2 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -cyclohexyl-N-(cyclopropylmethyl)-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-01-3 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -cyclohexyl-N-(cyclopropylmethyl)-4-(4-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335247-02-4 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclobutyl- $\alpha$ -cyclohexyl-4-(4-cyclohexylphenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-04-6 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -cyclohexyl-N-(cyclohexylmethyl)-4-[4-(diethylamino)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-06-8 CAPLUS  
CN 1H-imidazole-2-methanamine, N, $\alpha$ -dicyclohexyl-4-[4-(diethylamino)phenyl]-, (aS)- (9CI) (CA INDEX NAME)




RN 335247-05-7 CAPLUS  
CN Phenol, 4-[2-[(S)-cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-06-8 CAPLUS  
CN 1H-imidazole-2-methanamine, N, $\alpha$ -dicyclohexyl-4-[4-(diethylamino)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-07-9 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)-N, $\alpha$ -dicyclohexyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-08-0 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -(cyclohexylmethyl)-4-(4-fluorophenyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-09-1 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -cyclohexyl-4-[4-(diethylamino)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-10-4 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -cyclohexyl-4-(3-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-11-5 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -cyclohexyl-N-(cyclohexylmethyl)-4-(3-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-12-6 CAPLUS  
CN 1H-imidazole-2-methanamine, N, $\alpha$ -dicyclohexyl-4-(3-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-13-7 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -cyclohexyl-N-(cyclohexylmethyl)-4-(4-fluorophenyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335247-14-8 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(4-fluorophenyl)- $\alpha$ -(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335247-16-0 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- $\alpha$ -


(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-17-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)-4-(4-fluorophenyl)-α-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-20-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(cyclohexylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335247-37-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl- (9CI) (CA INDEX NAME)




RN 396135-27-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-butyl- (9CI) (CA INDEX NAME)



RN 396135-28-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-butyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 473540-88-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-methyl-4-(10H-phenothiazin-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 473541-06-9 CAPLUS  
CN Phenol, 4-[2-(aminomethyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 473541-81-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-methyl-4-(10H-phenothiazin-2-yl)- (9CI) (CA INDEX NAME)




RN 473541-84-3 CAPLUS  
CN Phenol, 4-[2-(aminomethyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 717914-12-0 CAPLUS  
CN 1H-Indole-3-ethanamine, N-hexyl-α-(4-phenyl-1H-imidazol-2-yl)-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 717914-13-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-(2-methylpropyl)-4-phenyl-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 717914-14-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-pentyl-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-15-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methoxyphenyl)-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-16-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(3-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-17-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-N-cyclohexyl-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-20-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-4-(4-fluorophenyl)-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-22-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-α-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-23-3 CAPLUS  
CN 1H-Indole-3-ethanamine, 1-methyl-α-(4-phenyl-1H-imidazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-25-5 CAPLUS  
CN 1H-Indole-3-ethanamine, 6-chloro-α-(4-phenyl-1H-imidazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

IT 717914-30-2P 717914-32-4P 717914-33-5P  
717914-34-6P 717914-35-7P 717914-36-8P  
717914-37-9P 717914-38-0P 717914-39-1P  
717914-40-4P 717914-42-6P 717914-44-8P  
717914-45-9P 717914-46-0P 717914-47-1P  
717914-48-2P 717914-50-6P 717914-51-7P  
717914-52-8P 717914-53-9P 717914-54-0P  
717914-55-1P 717914-56-2P 717914-57-3P  
717914-58-4P 717914-59-5P 717914-60-8P  
717914-61-9P 717914-62-0P 717914-63-1P  
717914-64-2P 717914-65-3P 717914-66-4P  
717914-67-5P 717914-68-6P 717914-69-7P  
717914-70-0P 717914-71-1P 717914-72-2P  
717914-74-4P 717914-75-5P 717914-76-6P  
717915-64-5P 717915-66-7P

RU: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 5-membered heterocycle derivs. for treating diseases of central or peripheral nervous system, neurodegenerative disorders, or pain)


RN 717914-30-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-32-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(2-phenylethyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 717914-33-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-butyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 717914-26-6 CAPLUS  
CN Carbamic acid, phenyl[(4-phenyl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 717914-27-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,4-diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-28-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-α-(2-phenylethyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 717914-29-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-(cyclohexylmethyl)-4-phenyl-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl




● HCl

RN 717914-34-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-butyl-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-35-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-36-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(2-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-37-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-39-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-39-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-40-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-hexyl-N-(phenylmethyl)-, monoacetate (9CI) (CA INDEX NAME)


CM 1

CRN 335244-54-7  
CMP C23 H28 Br N3




CM 2

CRN 64-19-7  
CMP C2 H4 O2



● HCl


RN 717914-47-1 CAPLUS  
CN Phenol, 4-[2-((1-aminohexyl)-2,6-bis(1,1-dimethylethyl))phenyl]-2,6-bis(1,1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-48-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-α-propyl-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 717914-50-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl




RN 717914-42-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-ethyl-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 717914-44-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methylphenyl)-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-45-9 CAPLUS  
CN Benzonitrile, 4-[2-((1-aminohexyl)-1H-imidazol-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-46-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-propyl-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 717914-51-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-methyl-4-phenyl-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 717914-52-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-53-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-54-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-[3-methoxyphenyl]-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-55-1 CAPLUS  
CN Benzonitrile, 4-[2-[(phenylmethyl)amino]heptyl]-1H-imidazol-4-yl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-56-2 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(4-fluorophenyl)-α-hexyl-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-57-3 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(2-chlorophenyl)-α-hexyl-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-58-4 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(4-(diethylamino)phenyl)-α-hexyl-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

CRN 64-19-7  
CMF C2 H4 O2




RN 717914-62-0 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclohexyl-4-(3,4-dichlorophenyl)-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-63-1 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-cyclohexyl-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-64-2 CAPLUS  
CN 1H-indole-3-ethanamine, 5-fluoro-α-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-65-3 CAPLUS  
CN 1H-indole-3-ethanamine, N-cyclobutyl-5-fluoro-α-(4-(4-fluorophenyl)-1H-imidazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-59-5 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-60-8 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)-α-(4-methylpentyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-61-9 CAPLUS  
CN 1H-imidazole-2-methanamine, α-hexyl-N-(2-methylpropyl)-4-phenyl-, monoacetate (9CI) (CA INDEX NAME)

CM 1  
CRN 335244-96-7  
CMF C20 H31 N3




CM 2




● HCl

RN 717914-66-4 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-α-(3-methylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-67-5 CAPLUS  
CN 1H-imidazole-2-methanamine, α-cyclopropyl-4-(4-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-68-6 CAPLUS  
CN 1H-imidazole-2-methanamine, N-(cyclohexylmethyl)-α-hexyl-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-69-7 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclohexyl-α-cyclopropyl-4-(4-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-70-0 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-(2-bromophenyl)-N-cyclohexyl-α-(4-methylpentyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-71-1 CAPLUS

CN 1H-Imidazole-2-methanamine, α-(cyclohexylmethyl)-4-(4-fluorophenyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 717914-72-2 CAPLUS

CN 1H-Imidazole-2-methanamine, N-cyclohexyl-α-(cyclohexylmethyl)-4-(4-fluorophenyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 717915-64-5 CAPLUS

CN 1,1-Hexanediamine, N-[(4-{[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl}-(phenylmethyl)]-, (9CI) (CA INDEX NAME)



RN 717915-66-7 CAPLUS

CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N5-(phenylmethyl)- (9CI) (CA INDEX NAME)



L13 ANSWER 3 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STM

ACCESSION NUMBER: 2004:142985 CAPLUS

DOCUMENT NUMBER: 140:199746

TITLE: Preparation of growth hormone-releasing peptides

INVENTOR(S): Zheng, Xin Dong

PATENT ASSIGNEE(S): Societe de Conseil de Recherches et d'Applications

Scientifiques, S.A.S., Fr.

SOURCES: PCT Int. Appl., 77 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014415	A1	20040219	WO 2003-US24834	20030808
M:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KZ, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,			




● HCl

RN 717914-74-4 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-(phenylmethyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 717914-75-5 CAPLUS

CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-α-(phenylmethyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 717914-76-6 CAPLUS

CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)-4-(4-fluorophenyl)-α-(phenylmethyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, SP, BJ, CF, CO, CI, CM, GA, GN, GO, GW, ML, MR, NS, SN, TD, TG

PRIORITY APPLN. INFO.: MARPAT 140:199746

OTHER SOURCE(S):  
AB Disclosed are peptide and peptidomimetic compds. R1-A1-A2-A3-A4-A5-R2 [A1 is Aib (α-aminoisobutyric acid), Apc (4-amino-4-piperidinecarboxylic acid), or Inp (isonipecotic acid); A2, A3 are D-Bal (3-benzothienylalanine), D-Bip (4,4'-biphenylalanine), D-Bpa (4-benzophenylalanine), D-Dip (β,β-diphenylalanine), D-1Nal (β-1-naphthylalanine), D-2Nal, D-Ser (Ser), or D-Trp; A4 is 2Pua (β-2-furylalanine), Orn, 2Pal (β-2-pyridylalanine), 3Pal, 4Pal, Pff (pentafluorophenylalanine), Phe, Pim (4-phenyl-2-imidazolyl), Taz (β-4-thiazolylalanine), 2Thi (β-2-thienylalanine), 3Thi, or Thr (Ser); A5 is Apc, Dab (2,4-diaminobutyric acid), Dap (2,3-diaminopropionic acid), Lys, Orn, or deleted; R1 is H, alkyl, aryl, alkylaryl, cycloalkyl, or acyl; R2 is OH or NH2; (with provisos)] and their pharmaceutically-acceptable salts which are useful as GHRP analogs. Thus, claimed peptide H-Inp-D-Bal-D-Trp-Phe-Apc-NH2 was prepared by the solid-phase method using a Rink Amide MBHA resin.


IT  
661472-77-1P 661472-78-2P 661472-79-3P  
661472-80-6P 661472-81-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRSP (Preparation); USES (Uses)

(preparation of growth hormone-releasing peptides)

RN 661472-77-1 CAPLUS

CN 4-Piperidinecarboxamide, N-[(1R)-2-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-1-(2-naphthalenylmethyl)-2-oxoethyl]]-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 661472-78-2 CAPLUS


CN 4-Piperidinecarboxamide, N-[(1R)-2-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-1-(2-naphthalenylmethyl)-2-oxoethyl]]-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 661472-79-3 CAPIUS  
CN 4-Piperidinecarboxamide, N-((1R)-1-(benzo[b]thien-3-ylmethyl)-2-((1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl)amino)-2-oxoethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 661472-80-6 CAPIUS  
CN D-Serinamide, 2-methylalanyl-N-((1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl)-O-(phenylmethyl)-(9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 661472-81-7 CAPIUS  
CN 1H-Indole-3-propanamide, N-((1R)-2-(2-naphthalenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl)-O-((4-piperidinylcarbonyl)amino)-, (aR)-(9CI) (CA INDEX NAME)

OTHER SOURCES(S): MARPAT 140:146136  
GI





AB Title compds. I [wherein R1 = H, cyclo/cycloalkyl/alkyl, (un)substituted aryl, aralkyl; R2 = H, alkyl; R3 = H, alkyl, aralkyl; X = a bond or alkylene; Y = H, cycloalkyl, NH2 and deriva., (un)substituted aryl, etc.; A = a bond or phenylene; B = independently cyclo/alkyl, NH2 and deriva., SR4, (un)substituted aryl carbocyclyl or aryl heterocyclyl R4 = (un)substituted alkyl; their racemates, stereoisomers, and their salts] were prepared as inhibitors of nitric oxide (NO) synthases and as modulators of the sodium channels for treatment of pain, multiple sclerosis, as well as of the central and peripheral nervous system. For example, 2-isomer of II was prepared by reacting N-Boc-β-alanine with 4-azidophenacyl bromide to form the 4-aminophenylimidazole intermediate, and its condensation with 2-thiophenecarboximidamide (preparation given). Selected I exhibited IC50 values < 10 μM towards binding to sodium channels of the cerebral cortex of rats. Selected I gave IC50 values < 10 μM for inhibiting rat neuronal NO synthase in vitro.


IT 651354-13-1P, N-[4-[2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide hydrochloride 651354-20-0P, N'-[3-[2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide hydrochloride 651354-21-1P, N-[4-[2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide hydrochloride 651354-22-2P, N-[4-[2-[(dibenzylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide hydrochloride 651354-23-3P, N'-[4-[2-[(benzylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide hydrochloride 651354-24-4P, N'-[3-[2-[(aminomethyl)-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide hydrochloride 651354-38-0P, N'-[3-[2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide 651354-39-1P, N'-[4-[2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide 651354-40-4P, N'-[4-[2-[(dibenzylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide 651354-41-5P, N'-[4-[2-[(benzylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide 651354-42-6P, N'-[3-[2-[(aminomethyl)-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide 652965-45-2P, 652965-46-3P 652965-98-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Uses)

(inhibitor of nitric oxide synthase; preparation of arylimidazoles as inhibitors of nitric oxide (NO) synthase and as modulators of sodium channels)


RN 651354-13-1 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[4-[2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 651354-23-3 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[4-[2-[(phenylmethyl)amino)methyl]-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 651354-24-4 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[3-[2-[(aminomethyl)-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 651354-38-0 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[3-[2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 651354-39-1 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[4-[2-[(cyclohexylmethylamino)methyl]-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 651354-40-4 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[4-[2-[(bis(phenylmethyl)amino)methyl]-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)




● HCl

RN 651354-20-0 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[3-[2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 651354-21-1 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[4-[2-[(cyclohexylmethylamino)methyl]-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 651354-22-2 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[4-[2-[(bis(phenylmethyl)amino)methyl]-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl




RN 651354-41-5 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[4-[2-[(phenylmethyl)amino)methyl]-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 651354-42-6 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[3-[2-[(aminomethyl)-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 652965-45-2 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[3-[2-[(8)-(amino-2-thienylmethylene)amino)methyl]-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 652965-46-3 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[4-[2-[(8)-(amino-2-thienylmethylene)amino)methyl]-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 652965-98-5 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[4-{2-[(6S)-(amino-2-thienylmethylene)amino]methyl}-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)




IT 651354-18-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(inhibitor of nitric oxide synthase; preparation of arylimidazoles as inhibitors of nitric oxide (NO) synthase and s modulators of sodium channels)

RN 651354-18-6 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[4-{2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)




IT 651354-15-3P, tert-Butyl [[4-{(4-azidophenyl)-1H-imidazol-2-yl]methyl]carbamate 651354-16-4P, tert-Butyl [[4-{(4-aminophenyl)-1H-imidazol-2-yl]methyl]carbamate 651354-17-5P, N'-[4-{2-(Aminomethyl)-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide hydrochloride 651354-25-5P, tert-Butyl [[4-{(3-nitrophenyl)-1H-imidazol-2-yl]methyl]carbamate 652965-43-0P, tert-Butyl [[4-{[(1S)amino(thien-2-yl)methylene]amino]phenyl]-1H-imidazol-2-yl]methyl]carbamate 652965-44-1P, tert-Butyl [[4-{[(1S)amino(thien-2-yl)methylene]amino]phenyl]-1H-imidazol-2-yl]methyl]carbamate 652965-97-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of arylimidazoles as inhibitors of nitric oxide (NO) synthase and s modulators of sodium channels)

RN 652965-44-1 CAPLUS  
CN Carbamic acid, [[4-{3-[(6S)-(amino-2-thienylmethylene)amino]phenyl]-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 652965-97-4 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[3-{2-[(6S)-(amino-2-thienylmethylene)amino]methyl}-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 6 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN  
ACCESSION NUMBER: 2003:591202 CAPLUS  
DOCUMENT NUMBER: 139:145836  
TITLE: Synthetic peptide substrates of human aggrecanase-1 and -2 for drug screening applications  
INVENTOR(S): Fourie, Anne; Karlsson, Lars; Coles, Fawn  
PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA  
SOURCE: PCT Int. Appl., 63 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062263	A2	20030731	WO 2003-US1327	20030115
WO 2003062263	A3	20040115		
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IS, IT, LJ, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GU, GW, ML, MR, NE, SN, TD, TO				
US 2003166037	A1	20030904	US 2002-50200	20020116
EP 1474509	A2	20041110	US 2003-702145	20030115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, SE, HU, SK				
PRIORITY APPL. INFO.:			US 2002-50200	A 20020116


RN 651354-15-3 CAPLUS  
CN Carbamic acid, [[4-{(4-azidophenyl)-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 651354-16-4 CAPLUS  
CN Carbamic acid, [[4-{(4-aminophenyl)-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 651354-17-5 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[4-{2-(aminomethyl)-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 651354-25-5 CAPLUS  
CN Carbamic acid, [[4-{(3-nitrophenyl)-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 652965-43-0 CAPLUS  
CN Carbamic acid, [[4-{4-[(6S)-(amino-2-thienylmethylene)amino]phenyl]-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



WO 2003-US1327 W 20030115  
AB The present invention describes synthetic peptide substrates of the metalloproteases, aggrecanase-1 and/or -2 suitable for assays of enzyme activity. The substrates are peptides less than 40 amino acids in length having a cleavage site between Glu on the N-terminal side of the cleavage site and a non-polar or uncharged residue on the C-terminal side of the cleavage site. The invention also describes methods using these peptides to discover pharmaceutical agents that modulate these proteases.  
IT 659652-30-8  
RL: BSU (Biological study, unclassified); BIOL (Biological study) (aggrecanase inhibition by; synthetic peptide substrates of human aggrecanase-1 and -2 for drug screening applications)  
RN 569652-30-8 CAPLUS  
CN Butanediamide, N4-hydroxy-N1-[(1S)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-2-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN  
ACCESSION NUMBER: 2003:532661 CAPLUS  
DOCUMENT NUMBER: 139:101128  
TITLE: Preparation of chemokine receptor binding (benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amines and related heterocyclic compounds with enhanced efficacy against AIDS and other disorders  
INVENTOR(S): Bridger, Gary J.; Skerlj, Renato T.; Kaller, Al; Harwig, Curtis; Bogucki, David; Wilson, Trevor; Crawford, Jason; McEachern, Ernest J.; Atama, Bem; Nan, Sigiso; Zhou, Yuanxi; Schols, Dominique; Smith, Christopher Dennis; Di Fluri, Rosaria Maria  
PATENT ASSIGNEE(S): Anormed Inc., Can.; et al.  
SOURCE: PCT Int. Appl., 360 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003058876	A1	20030710	WO 2002-US41407	20021223
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IS, IT, LJ, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GU, GW, ML, MR, NE, SN, TD, TO				
BR 2002015050	A	20041013	BR 2002-15050	20021223
EP 1465889	A1	20041013	EP 2002-805977	20021223

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK  
PRIORITY APPLN. INFO.: US 2001-342716P P 20011221  
US 2002-350822P P 20020117  
WO 2002-US41407 W 20021223

OTHER SOURCE(S): MARPAT 139:101128  
GI



AB The invention relates to heterocyclic compds. (shown as I; e.g. (1H-benzimidazol-2-ylmethyl)(piperidin-3-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amine trihydrobromide) consisting of a core N atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolylmethyl and tetrahydroquinolyl, and the 3rd pendant group contains N and optionally contains addnl. rings. The compds. bind to chemokine receptors, including CXCR4 and CXCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV). Many I exhibit IC50 values of 5-5.5 nM for inhibition of HIV-1 (NL4.3) replication in peripheral blood mononuclear cells and 5 nM-5 µM for inhibition of SDF-1α induced Ca flux in CCRP-CD4 cells, a T-lymphoblastoid cell line that expresses CXCR4. Although the methods of preparation are not claimed, >170 example preps. are included. For I: X and Y = N or CR1; Z is S, O, NRI or CR12; each R1-R6 = H or a noninterfering substituent; n1 is 0-4; n2 is 0-1, wherein the a signifies C.tpbond.C may be substituted for CR5:CR5; n3 is 0-4; wherein n1 + n2 + n3 = ≥ 2; b is 0-2; wherein the following combinations of R groups may be coupled to generate a ring, which ring may be (un)saturated: R2 + R2, one R2 + R3, R3 + one R4, R4 + R4, one R5 + another R5, one R5 + one R6, and R6 + R6; wherein the ring may not be aromatic when the participants in ring formation are two R5; and wherein when n2 is 1, neither n1 nor n3 can be 0.

IT 558441-83-1P, N1-[[5-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of chemokine receptor binding benzimidazolylmethyl tetrahydroquinolyl amines and related heterocyclic compds. with enhanced efficacy against AIDS and other disorders)

RN 558441-83-1 CAPLUS


CN 1,4-Butanediamine, N-[[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyl)- (9CI) (CA INDEX NAME)

UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, CA, GN, ML, MR, NE, SN, TD, TG  
US 6335445 B1 20020101 US 1999-456205 19991207  
US 2002007062 A1 20020117 US 2001-882264 20010615  
US 6630461 B2 20031007

PRIORITY APPLN. INFO.:

FR 1997-3528 A 19970324  
FR 1997-7701 A 19970620  
WO 1998-FR288 W 19980216  
WO 1998-FR1250 W 19980615  
US 1999-456205 A3 19991207  
US 2001-882264 A2 20010615  
US 1999-381749 A2 19990922

OTHER SOURCE(S): MARPAT 138:337988  
GI



AB Title compds., e.g., N-[4-[[[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl]methyl]amino]methyl]phenyl]thiophene-2-carboximidamide (I) are prepared. The compds. are inhibitors of NO synthases, and are also antioxidants which inhibit lipid peroxidn. Approx. 70 examples are prepared. I had IC50 for inhibiting rat neuronal NO synthase in vitro < 3.5 µM, and the IC50 for inhibiting rat cerebral lipid peroxidn. in vitro is < 30 µM.


IT 218944-42-4P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-[[4-[[imino(2-thienyl)methyl]amino]benzoyl]-N-methyl-1H-imidazole-2-methanamine hydrochloride 218944-69-5P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-[[4-[[imino(2-thienyl)methyl]amino]phenyl]-N-methyl-1H-imidazole-2-methanamine hydrochloride

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and testing of 2-[[[iminomethyl]amino]phenyl] deriva. as inhibitors of NO synthase and lipid peroxidn.)

RN 218944-42-4 CAPLUS

CN Benzamide, N-[[5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-4-[[imino(2-thienyl)methyl]amino]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2003:319488 CAPLUS  
DOCUMENT NUMBER: 138:337988  
TITLE: Novel 2-[[[iminomethyl]amino]phenyl] derivatives useful as inhibitors of NO synthase and lipid peroxidation, their preparation, their application as medicines, and pharmaceutical compositions containing them

INVENTOR(S): Chabrier De Lassauniere, Pierre Stienne; Auvin, Serge; Bigg, Dennis; Auguet, Michel; Harnett, Jeremiah  
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et D'Applications scientifiques (S.C.R.A.S.), Fr.  
SOURCE: U.S. Pat. Appl. Publ., 78 pp., Cont.-in-part of U.S. Ser. No. 882,264.  
CODEN: USXXCO

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003078420	A1	20030424	US 2002-191950	20020709
US 6809088	B2	20041026		
FR 2761066	A1	19980925	FR 1997-3528	19970324
FR 2761066	B1	20001124		
FR 2764889	A1	19981224	FR 1997-7701	19970620
FR 2764889	B1	20000901		
WO 9842696	A1	19981001	WO 1998-FR288	19980216
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, ER, ES, FI, GB, GR, GH, GM, GU, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
WO 9858934	A1	19981230	WO 1998-FR1250	19980615
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, ER, ES, FI, GB, GR, GH, GM, GU, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,				



● HCl

RN 218944-69-5 CAPLUS

CN 2-Thiophenecarboximidamide, N-[4-[[[4-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-1H-imidazol-2-yl]methyl]methylamino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 218944-36-6P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-[[phenylmethoxycarbonyl]-1H-imidazole-2-methanamine 218944-40-2P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-[[4-nitrobenzoyl]-1H-imidazole-2-methanamine 218944-41-3P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-[[4-aminobenzoyl]-1H-imidazole-2-methanamine 218944-66-2P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-[[4-nitrophenyl]-1H-imidazole-2-methanamine 218944-68-4P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-[[4-aminophenyl]-1H-imidazole-2-methanamine

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and testing of 2-[[[iminomethyl]amino]phenyl] deriva. as inhibitors of NO synthase and lipid peroxidn.)

RN 218944-36-6 CAPLUS


CN Carbamic acid, [[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 218944-40-2 CAPLUS

CN Benzamide, N-[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-


2-ylmethyl]-N-methyl-4-nitro- (9CI) (CA INDEX NAME)




RN 218944-41-3 CAPLUS  
CN Benzamide, 4-amino-N-[[4-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-1H-imidazol-2-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 218944-66-2 CAPLUS  
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[2-[[methyl(4-nitrophenyl)amino]methyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 218944-68-4 CAPLUS  
CN Phenol, 4-[2-[[[4-aminophenyl]methylamino]methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 9 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2003:58808 CAPLUS  
DOCUMENT NUMBER: 138:106702  
TITLE: Preparation of 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype

RN 179333-51-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-methyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 10 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2002:814116 CAPLUS  
DOCUMENT NUMBER: 137:325417  
TITLE: Preparation and application of 5-membered heterocycles as medicaments  
INVENTOR(S): Hammett, Jeremiah; Bigg, Dennis; Liberatore, Anne-Marie; Rolland, Alain  
PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques (SCRAS), Fr.  
SOURCES: PCT Int. Appl., 132 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083656	A2	20021024	WO 2002-FR1218	20020409
WO 2002083656	A3	20030103		
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
FR 2823208	A1	20021011	FR 2001-4943	20010410
FR 2823208	B1	20040319		
CA 2443403	AA	20021024	CA 2002-2443403	20020409
EP 1379514	A2	20040114	EP 2002-761921	20020409
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004531526	T2	20041014	JP 2002-581412	20020409
NZ 528645	A	20041126	NZ 2002-528645	20020409
NO 2003004524	A	20031029	NO 2003-4524	20031009
PRIORITY APPL. INFO.:			FR 2001-4943	A 20010410
			FR 2002-1811	A 20020214
			WO 2002-FR1218	W 20020409

GI

specific ligands  
INVENTOR(S): Thurkauf, Andrew; Horvath, Raymond F.; Yuan, Jun; Peterson, John M.  
PATENT ASSIGNEE(S): Neurogen Corporation, USA  
SOURCES: U.S. Pat. Appl. Publ., 37 pp., Cont. of U.S. Ser. No. 281,169.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003018025	A1	20030123	US 2002-156262	20020528
PRIORITY APPL. INFO.:			US 1995-478291	B1 19950607
			US 1999-281169	A1 19990330

OTHER SOURCE(S): MARPAT 138:106702




AB The imidazoles I (R1 = optionally substituted aryl, heteroaryl, arylalkyl, or cycloalkyl, naphthyl; X, Z, and Y = optionally substituted nitrogen or carbon atoms; R2 = H, alkyl; m = 0, 1 or 2; and R3 and R4 = H, alkyl, R3R4N may form a ring) and the pharmaceutically acceptable addition salts thereof, which compds. are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrgs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Thus, 2-phenyl-4-(hydroxymethyl)imidazole was treated with SOCI2 followed by 1-(2-methoxyphenyl)piperazine to give 2-phenyl-4(5)-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]imidazole. 2-Phenyl-4(5)-[[4-(2-pyrimidinyl)piperazin-1-yl]methyl]imidazole dihydrochloride was shown to bind to the dopamine D4 receptor site (Ki = 1033, 8200, 2.7 for D2, D3, D4 binding sites, resp.).  
IT 179332-49-1P 179333-51-8P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazole deriva. as dopamine receptor partial agonists or antagonists for memory enhancement and treatment of schizophrenia and depression and Parkinsonism)  
RN 179332-49-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-methyl-4-phenyl-N-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl




II


AB The invention relates to thiazole, oxazole or imidazole derive. having at least one of the following pharmacol. activities: inhibition of monoamine oxidases (MAO); inhibition of lipid peroxid.; modulation of sodium channels. The inventive compds. comprise, for example, 2,6-di-(tert-butyl)-4-[[2-[[2-(methylamino)ethyl]-1,3-thiazol-4-yl]phenol (I); and 4-methylpentyl-2-[[4-(1,1'-biphenyl-4-yl)-1H-imidazol-2-yl]ethyl]carbamate (II). Thus, I-HCl was prepared from N-methyl-β-alaninonitrile via N-protection with (Boc)2O in CH2Cl2 containing Et3N(CH2)2, sulfuration with H2S in EtOH containing Et3N, cyclocondensation with α-bromo-1-(3,5-di(tert-butyl)-4-hydroxyphenyl)ethanone and acid-catalyzed deprotection with HCl in EtOAc. By virtue of their pharmacol. properties, said compds. can be used to treat one of the following disorders or diseases: Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, schizophrenia, depression, psychoses, migraine or pain, especially neuropathic pain. The pharmacol. activity of I was determined [C150 ≤ 10 μM vs. monoamine oxidase B; C150 ≤ 10 μM vs. lipid peroxid.; C150 ≤ 1.0 μM on sodium channels from the cerebral cortex of rats].  
IT 473541-90-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and N-deprotection in; preparation of 5-membered heterocycles

with one of the following pharmacol. activities: monoamine oxidase inhibition, lipid peroxidation or sodium channel modulation)


RN 473541-90-1 CAPLUS  
CN Carbanic acid, methyl[[4-(10H-phenothiazin-2-yl)-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 473541-95-6P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and hydrogenolysis of, in; preparation of 5-membered heterocycles  
 with one of the following pharmacol. activities: monoamine oxydase inhibition, lipid peroxidation or sodium channel modulation)  
 RN 473541-95-6 CAPLUS  
 CN Carbanic acid, {4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl}-, phenylmethyl ester (9CI) (CA INDEX NAME)




IT 473540-88-4P 473541-06-9P 473541-81-0P  
 473541-84-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 5-membered heterocycles with one of the following pharmacol. activities: monoamine oxydase inhibition, lipid peroxidation or sodium channel modulation)  
 RN 473540-88-4 CAPLUS  
 CN 1H-imidazole-2-methanamine, N-methyl-4-(10H-phenothiazin-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 473541-06-9 CAPLUS  
 CN Phenol, 4-[2-(aminomethyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 473541-81-0 CAPLUS  
 CN 1H-imidazole-2-methanamine, N-methyl-4-(10H-phenothiazin-2-yl)- (9CI) (CA INDEX NAME)



RN 473541-84-3 CAPLUS  
 CN Phenol, 4-[2-(aminomethyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




L12 ANSWER 11 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN  
 ACCESSION NUMBER: 2002:532824 CAPLUS  
 DOCUMENT NUMBER: 138:250527  
 TITLES: Fluorescence polarization assay and SDS-PAGE confirms matrilysin degrades fibronectin and collagen IV whereas gelatinase A degrades collagen IV but not fibronectin  
 AUTHOR(S): Kraft, Patricia J.; Haynes-Johnson, Donna E.; Patel, Lekha; Lenhart, Judy A.; Zivin, Robert A.; Palmer, Stephen S.  
 CORPORATE SOURCE: The R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ, USA  
 SOURCE: Connective Tissue Research (2001), 42(2), 149-163  
 CODEN: CVTRBC; ISSN: 0300-8207  
 PUBLISHER: Gordon & Breach Science Publishers  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Matrilysin and gelatinase A are hypothesized to have significant roles in uterine and ovarian function. However, proteolytic activity assays for these enzymes are limited. We describe the development of simple and rapid assays for the proteolysis of fluorescein-labeled full-length substrates, collagen IV (Col-IV) and fibronectin (FN), and demonstrate the selectivity of matrilysin (MMP-7) compared to gelatinase A (MMP-2) for fibronectin. Changes in fluorescence intensity (FIU) and fluorescence

polarization (mP) resulting from the protease activity of matrilysin and gelatinase A were measured. These studies show that the fluorescently labeled substrates, Col-IV and FN, are as reliable and amenable to rapid in vitro assay as peptide substrates. In addition, they are easier to use than previously described, non-fluorescent methods. The results demonstrate that assays using full-length, biol. matrix proteins are more sensitive indicators of MMP-specific substrate activity than peptide based assays.

IT 181361-72-8, RWJ 68257  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (metalloproteinase inhibitor; fluorescently labeled fibronectin and collagen IV substrates for assay of matrilysin and gelatinase A)  
 RN 181361-72-8 CAPLUS  
 CN Butanediamide, N-(4-hydroxy-N1-((1S)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl)-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN  
 ACCESSION NUMBER: 2002:220576 CAPLUS  
 DOCUMENT NUMBER: 136:263160  
 TITLES: Preparation of azolymethylaminotetrahydroquinolines and related compounds as chemokine receptor binding agents.  
 INVENTOR(S): Bridger, Gary; Skerlj, Renato; Kaller, Al; Harwig, Curtis; Bogucki, David; Wilson, Trevor R.; Crawford, Jason; McSachern, Ernest J.; Atama, Ben; Nan, Siquiao; Zhou, Yuanxi; Scholz, Dominique; Smith, Christopher Dennis; Di, Fluri Rosaria Maria  
 PATENT ASSIGNEE(S): Anormed Inc., Can.  
 SOURCE: PCT Int. Appl., 254 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022600	A2	20020321	WO 2001-CA1326	20010917
WO 2002022600	A3	20020510		
W: AR, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, NZ, PA, PE, PG, PH, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BS, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GD, GU, GW, ML, MR, NE, NI, SN, TD, TO				
CA 2419224	AA	20020321	CA 2001-2419224	20010917


AU 2001091569	A5	20020326	AU 2001-91569	20010917
US 2003018046	A1	20030123	US 2001-957682	20010917
EP 1317445	A2	20030611	EP 2001-971574	20010917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013930	A	20030624	BR 2001-13930	20010917
TR 200300322	T2	20030922	TR 2003-200300322	20010917
JP 2004508422	T2	20040318	JP 2002-526853	20010917
ZA 2003001398	A	20040521	ZA 2003-1398	20030220
NO 2003001179	A	20030314	NO 2003-1179	20030314
US 2004171638	A1	20040902	US 2004-799386	20040311
US 2004220207	A1	20041104	US 2004-858910	20040601
PRIORITY APPLN. INFO.:				
			US 2000-232891P	P 20000915
			US 2000-234510P	P 20000922
			US 2001-957682	AJ 20010917
			WO 2001-CA1326	W 20010917
			US 2002-31812	A1 20020328

OTHER SOURCE(S): MARPAT 136:263160  
 GI




AB Title compds. (I; ring A optionally contains N, O, S; dotted lines = optional unsatn.; R1, R2, R3 = non-interfering substituents; p = 0-4; m = 0-2; L1 = linker of 1.5-10 Å; X = O, S, (substituted) C, N; Ar = aryl; n = 0-2; R = H, alkyl; Y = aryl, heteroaryl, heterocyclyl), were prepared Thus, 5-trifluoromethyl-2-chloromethylbenzimidazole (preparation given), N-(tert-butoxycarbonyl)-N-(2-pyridinylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine, and diisopropylethylamine were stirred at 80° in DMF for 16 h to yield N-(tert-butoxycarbonyl)-N-(2-pyridinylmethyl)-N'-(5-trifluoromethyl-1H-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine. Deprotection with HBr in HOAc or dioxane gave N-(2-pyridinylmethyl)-N'-(5-trifluoromethyl-1H-benzimidazol-2-ylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)-1,4-benzenedimethanamine hydrobromide. Several I inhibited HIV-1 replication in MT-4 cells with EC50<20 µg/mL.


IT 297769-64-3P 405171-56-4P 405171-84-8P  
 405171-85-9P 405171-89-3P 405171-90-6P  
 405171-91-7P 405171-92-8P 405171-95-1P  
 405174-41-6P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of azolymethylaminotetrahydroquinolines and related compds. as chemokine receptor binding agents)  
 RN 297769-64-3 CAPLUS  
 CN 1,4-Benzenedimethanamine, N-((4-phenyl-1H-imidazol-2-yl)methyl)-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)- (9CI) (CA INDEX NAME)




RN 405171-56-4 CAPLUS  
CN 1,4-Benzenedimethanamine, N-[[4-(4-phenyl-1H-imidazol-2-yl)methyl]-N-(2-pyridinylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyl)]- (9CI) (CA INDEX NAME)



RN 405171-84-8 CAPLUS  
CN 1,4-Benzenedimethanamine, N-[[4-(4-methoxyphenyl)-1H-imidazol-2-yl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)]- (9CI) (CA INDEX NAME)




RN 405171-85-9 CAPLUS  
CN 1,4-Benzenedimethanamine, N-[[4-(4-nitrophenyl)-1H-imidazol-2-yl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)]- (9CI) (CA INDEX NAME)




RN 405171-89-3 CAPLUS  
CN 1,4-Benzenedimethanamine, N-[[4-(3-methoxyphenyl)-1H-imidazol-2-yl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)]- (9CI) (CA INDEX NAME)







RN 405171-90-6 CAPLUS  
CN 1,4-Benzenedimethanamine, N-[(4-{(1,1'-biphenyl)-4-yl-1H-imidazol-2-yl)methyl}-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)]-(9CI) (CA INDEX NAME)




RN 405171-91-7 CAPLUS  
CN 1,4-Benzenedimethanamine, N'-(2-pyridinylmethyl)-N-[(4-{(5,6,7,8-tetrahydro-2-naphthalenyl)-1H-imidazol-2-yl)methyl}-N-(5,6,7,8-tetrahydro-8-quinolinyl)]-(9CI) (CA INDEX NAME)



RN 405171-92-8 CAPLUS  
CN 1,4-Benzenedimethanamine, N-[(4-{(3-bromo-2-methoxyphenyl)-1H-imidazol-2-yl)methyl}-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)]-(9CI) (CA INDEX NAME)




RN 405171-95-1 CAPLUS  
CN 1,4-Benzenedimethanamine, N-[(4-{(4-fluorophenyl)-1H-imidazol-2-yl)methyl}-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)]-, hydrobromide (10:39) (9CI) (CA INDEX NAME)




●39/10 HBr

RN 405174-41-6 CAPLUS  
CN 1,4-Benzenedimethanamine, N-[[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)- (9CI) (CA INDEX NAME)



IT 405174-06-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of azolylmethylaminotetrahydroquinolines and related compds. as chemokine receptor binding agents)  
RN 405174-06-3 CAPLUS  
CN Benzenesulfonamide, 4-nitro-N-[[4-[[[4-phenyl-1H-imidazol-2-yl]methyl] (5,6,7,8-tetrahydro-8-quinolinyl)amino]methyl]phenyl]methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN  
ACCESSION NUMBER: 2002:107321 CAPLUS  
DOCUMENT NUMBER: 136:167373  
TITLE: Preparation of imidazolyl derivatives as agonists or antagonists of somatostatin receptors  
INVENTOR(S): Thuriesau, Christophe Alain; Poltout, Lydie Francine; Galcera, Marie-Odile; Gordon, Thomas D.; Morgan, Barry A.; Moynet, Christophe Philippe; Bigg, Dennis  
PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.  
SOURCES: PCT Int. Appl., 369 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010140	A2	20020207	WO 2001-US23959	20010731
WO 2002010140	A3	20020808		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,


SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, CA 2417204 A2 20020207 CA 2001-2417204 20010731 EP 1305294 A2 20030502 EP 2001-957342 20010731 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, JP 2004518613 T2 20040624 JP 2002-516272 20010731 NZ 523774 A 20040924 NZ 2001-523774 20010731 NO 2003000473 A 20030130 NO 2003-473 20030130 PRIORITY APPLN. INFO.: US 2000-222584P P 20000801 WO 2001-US23959 W 20010731 OTHER SOURCE(S): MARPAT 136:167373 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Imidazole derivs. I [R1 = H, (CH2)mCO(CH2)mZ1, (CH2)mZ1, etc.; Z1 = (un)substituted benzo[b]thiophene, Ph, naphthyl, etc.; m = 0-6; R2 = H, alkyl; R1 and R2 taken together with the nitrogen atoms to which they are attached form II-IV; R3 = (CH2)mE(CH2)mZ2; E = O, S, CO, etc.; Z2 = H, alkyl, NH2, etc.; R4 = H, (CH2)mAl; Al = C(Y)NX1X2; C(Y)X2; C(NH)X2; X2; Y = O, S; X1 = H, alkyl, etc.; X2 = alkyl, etc.; R5 = alkyl, (un)substituted aryl, etc.; R6 = H, alkyl; R7 = alkyl, (CH2)mZ4; Z4 = (un)substituted Ph, naphthyl, indolyl, etc., which are useful as agonists or antagonists of somatostatin receptors (no data) and for inhibiting the proliferation of Helicobacter pylori, were prepared. Thus, activating 2-furancarboxylic acid with carbonyldiimidazole followed by addition of 2-((1S)-1-amino-2-(indol-3-yl)ethyl)-4-phenyl-1H-imidazole afforded 94% the title compound V. Compds. I are effective at 0.01-10.0 mg/kg/day.


IT 252292-69-6P 252302-96-8P 335244-94-5P 335246-59-8P 335246-68-8P 335246-82-7P 335247-34-2P 335247-37-5P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)  
RN 252292-69-6 CAPLUS  
CN Carbanic acid, [(1S)-2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-96-8 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335244-94-5 CAPLUS  
CN Carbamic acid, [1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-5-methylhexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335246-59-8 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335246-68-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335246-82-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)




RN 335247-34-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- $\alpha$ -(4-methylpentyl)- (9CI) (CA INDEX NAME)

252303-10-9P 252303-12-1P 252303-13-2P  
252303-14-3P 252303-15-4P 252303-16-5P  
252303-17-6P 252303-18-7P 252303-19-8P  
252303-21-2P 252303-22-3P 252303-25-6P  
252303-26-7P 252303-27-8P 252303-28-9P  
252303-29-0P 252303-30-3P 252303-32-5P  
252303-33-6P 252303-34-7P 252303-35-8P  
252303-36-9P 252303-38-1P 252303-39-2P  
252303-40-5P 252303-41-6P 252303-42-7P  
252303-44-9P 252303-46-1P 252303-47-2P  
252303-50-7P 252303-53-0P 252303-54-1P  
252303-57-4P 252304-37-3P 252304-38-4P  
252304-39-5P 252304-40-8P 252304-42-0P  
252304-43-1P 252304-45-3P 252304-46-4P  
252304-47-5P 252304-48-6P 252304-49-7P  
252304-50-0P 252304-51-1P 252304-52-2P  
252304-53-3P 252304-58-8P 252304-60-2P  
252304-62-4P 252304-64-6P 252304-66-8P  
252304-70-4P 252304-72-6P 252304-75-9P  
252304-76-0P 252304-77-1P 252304-79-3P  
252304-80-6P 252304-81-7P 252304-82-8P  
252304-83-9P 252304-85-1P 252304-87-3P  
252304-88-4P 252304-90-8P 252304-93-1P  
252304-94-2P 252304-99-7P 252305-49-0P  
252305-50-3P 252305-51-4P 252305-52-5P  
252305-53-6P 252305-54-7P 252305-55-8P  
252305-56-9P 252305-57-0P 252305-58-1P  
252305-59-2P 252305-60-5P 252305-61-6P  
252305-63-8P 252305-64-9P 252305-65-0P  
252305-66-1P 252305-67-2P 252305-68-3P  
252305-69-4P 252305-70-7P 252305-71-8P  
252305-72-9P 252305-73-0P 252305-74-1P  
252305-75-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USRS (Uses)  
(Preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)

RN 167983-80-4 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -(2-methylpropyl)-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 175531-38-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl- (9CI) (CA INDEX NAME)



RN 252279-15-5 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)




RN 335247-37-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl- (9CI) (CA INDEX NAME)




IT 167983-80-4P 175531-38-1P 252279-15-5P  
252292-70-9P 252292-72-1P 252292-74-3P  
252292-75-4P 252301-46-5P 252301-47-6P  
252301-48-7P 252301-49-8P 252301-50-1P  
252301-51-2P 252301-52-3P 252301-53-4P  
252301-54-5P 252301-56-7P 252301-57-8P  
252301-58-9P 252301-60-3P 252301-61-4P  
252301-62-5P 252301-63-6P 252301-64-7P  
252301-65-8P 252301-66-9P 252301-67-0P  
252301-70-5P 252301-71-6P 252301-72-7P  
252301-73-8P 252301-74-9P 252301-75-0P  
252301-76-1P 252301-77-2P 252301-79-4P  
252301-81-8P 252301-83-0P 252301-85-2P  
252301-86-3P 252301-87-4P 252301-88-5P  
252301-89-6P 252301-90-9P 252301-91-0P  
252301-92-1P 252301-93-2P 252301-94-3P  
252301-95-4P 252301-96-5P 252301-97-6P  
252301-98-7P 252301-99-8P 252302-00-4P  
252302-01-5P 252302-02-6P 252302-03-7P  
252302-04-8P 252302-05-9P 252302-06-0P  
252302-07-1P 252302-08-2P 252302-09-3P  
252302-10-6P 252302-11-7P 252302-12-8P  
252302-13-9P 252302-14-0P 252302-15-1P  
252302-16-2P 252302-17-3P 252302-18-4P  
252302-19-5P 252302-20-8P 252302-21-9P  
252302-22-0P 252302-23-1P 252302-24-2P  
252302-25-3P 252302-27-5P 252302-28-6P  
252302-29-7P 252302-31-1P 252302-32-2P  
252302-35-5P 252302-37-7P 252302-39-9P  
252302-41-3P 252302-43-5P 252302-44-6P  
252302-46-8P 252302-47-9P 252302-48-0P  
252302-49-1P 252302-50-4P 252302-51-5P  
252302-52-6P 252302-53-7P 252302-54-8P  
252302-55-9P 252302-56-0P 252302-58-2P  
252302-60-6P 252302-61-7P 252302-63-9P  
252302-65-1P 252302-67-3P 252302-69-5P  
252302-71-9P 252302-74-2P 252302-77-5P  
252302-79-7P 252302-80-0P 252302-81-1P  
252302-82-2P 252302-83-3P 252302-84-4P  
252302-85-5P 252302-86-6P 252302-88-8P  
252302-89-9P 252302-90-2P 252302-91-3P  
252302-92-4P 252302-93-5P 252302-95-7P  
252302-97-9P 252302-98-0P 252302-99-1P  
252303-00-7P 252303-02-9P 252303-03-0P  
252303-04-1P 252303-05-2P 252303-06-3P  
252303-07-4P 252303-08-5P 252303-09-6P

Absolute stereochemistry.




RN 252292-70-9 CAPLUS  
CN 2-Furancarboxamide, N-([(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-72-1 CAPLUS  
CN 2,5-Pyrrolidinedione, 1-[[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-74-3 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-methoxyphenyl)methyl]- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-75-4 CAPLUS  
CN 2-Thiophenecarboximidamide, N-(((1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl)-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252301-46-5 CAPLUS  
CN Carbamic acid, [5-[[[iminophenylmethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-47-6 CAPLUS  
CN Carbamic acid, [5-[[[2-chlorophenyl]iminomethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-51-2 CAPLUS  
CN Carbamic acid, [5-[[[4-(1,1-dimethylethyl)phenyl]iminomethyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-52-3 CAPLUS  
CN Carbamic acid, [5-[[[2,4-difluorophenyl]iminomethyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-53-4 CAPLUS  
CN Carbamic acid, [5-[[[imino(4-(trifluoromethoxy)phenyl)methyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-48-7 CAPLUS  
CN Carbamic acid, [5-[[[4-chlorophenyl]iminomethyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-49-8 CAPLUS  
CN Carbamic acid, [5-[[[imino(4-methoxyphenyl)methyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-50-1 CAPLUS  
CN Carbamic acid, [5-[[[imino(4-(trifluoromethyl)phenyl)methyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-54-5 CAPLUS  
CN Carbamic acid, [5-[[[2,6-dichlorophenyl]iminomethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-56-7 CAPLUS  
CN Carbamic acid, [5-[[[2-[[[1,1-dimethylethyl]sulfonyl]-1-iminoethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-57-8 CAPLUS  
CN Carbamic acid, [5-[[[imino(2-thienylmethyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)



● HI


RN 252301-58-9 CAPLUS  
CN Carbamic acid, [5-[(1-iminoethyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydride (9CI) (CA INDEX NAME)



● HI

RN 252301-60-3 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-61-4 CAPLUS  
CN Ethanimidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252301-65-8 CAPLUS  
CN Ethanimidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252301-66-9 CAPLUS  
CN 2-Thiophenecarboximidamide, N-(2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl)-, monohydride (9CI) (CA INDEX NAME)



● HI


RN 252301-67-0 CAPLUS  
CN Ethanimidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)



● HI

RN 252301-62-5 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[(1S)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-63-6 CAPLUS  
CN Ethanimidamide, N-[(1S)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-64-7 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-70-5 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(1-(phenylmethyl)-1H-imidazol-4-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-71-6 CAPLUS  
CN Ethanimidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(1-(phenylmethyl)-1H-imidazol-4-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-72-7 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• HI

RN 252301-73-8 CAPLUS

CN Ethanimidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



• HI


RN 252301-74-9 CAPLUS

CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3-pyridinylmethyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-75-0 CAPLUS

CN Carbamic acid, [5-[[[2-chloro-3-quinolinyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-76-1 CAPLUS




RN 252301-85-2 CAPLUS

CN Carbamic acid, [5-[[[1-methyl-1H-indol-3-yl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-86-3 CAPLUS

CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(phenylmethyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-87-4 CAPLUS

CN Carbamic acid, [5-[[[2-hydroxyphenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-88-5 CAPLUS

CN Carbamic acid, [5-[[[4-hydroxyphenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-[(2-quinolinylmethyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-77-2 CAPLUS

CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-[(4-pyridinylmethyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-79-4 CAPLUS

CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-[(2-pyridinylmethyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252301-81-8 CAPLUS

CN Carbamic acid, [5-[[[1H-indol-3-yl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-83-0 CAPLUS

CN 1H-Indole-6-carboxylic acid, 3-[[[5-[[[1,1-dimethylethoxy]carbonyl]amino]-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)


RN 252301-89-6 CAPLUS

CN Carbamic acid, [5-[[[4-fluorophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-90-9 CAPLUS

CN Carbamic acid, [5-[[[3-methoxyphenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-91-0 CAPLUS

CN Carbamic acid, [5-[[[4-methoxyphenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-92-1 CAPLUS

CN Carbamic acid, [5-[[[2-methoxyphenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-93-2 CAPLUS


CN Carbamic acid, [5-[[[2-nitrophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-94-3 CAPLUS  
CN Carbamic acid, [5-[[[4-nitrophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-95-4 CAPLUS  
CN Carbamic acid, [5-[[[3,4-dichlorophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-96-5 CAPLUS  
CN Carbamic acid, [5-[[[3-methoxy-2-nitrophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-97-6 CAPLUS  
CN Carbamic acid, [5-[[[4-bromophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-02-6 CAPLUS  
CN Carbamic acid, [5-[[[4-phenyl-1H-imidazol-2-yl)-5-[[2-(phenylmethoxy)ethyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252302-03-7 CAPLUS  
CN Carbamic acid, [5-[[[4-phenyl-1H-imidazol-2-yl)-5-[[2-(trifluoromethyl)phenyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-04-8 CAPLUS  
CN Carbamic acid, [5-[[[4-phenyl-1H-imidazol-2-yl)-5-[[2-(trifluoromethyl)phenyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-05-9 CAPLUS  
CN Carbamic acid, [5-[[[4-phenyl-1H-imidazol-2-yl)-5-[[2-(trifluoromethyl)phenyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-98-7 CAPLUS  
CN Carbamic acid, [5-[[[4-phenyl-1H-imidazol-2-yl)-5-[[2-(trifluoromethyl)phenyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252301-99-8 CAPLUS  
CN Carbamic acid, [5-[[[4-phenyl-1H-imidazol-2-yl)-5-[[2-(trifluoromethyl)phenyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-00-4 CAPLUS  
CN Carbamic acid, [5-[[[4-phenyl-1H-imidazol-2-yl)-5-[[2-(trifluoromethyl)phenyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-01-5 CAPLUS  
CN Carbamic acid, [5-[[[4-phenyl-1H-imidazol-2-yl)-5-[[2-(trifluoromethyl)phenyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


RN 252302-06-0 CAPLUS  
CN Carbamic acid, [5-[[[4-phenyl-1H-imidazol-2-yl)-5-[[2-(trifluoromethyl)phenyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-07-1 CAPLUS  
CN Carbamic acid, [5-[[[4-phenyl-1H-imidazol-2-yl)-5-[[2-(trifluoromethyl)phenyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-08-2 CAPLUS  
CN Carbamic acid, [5-[[[4-phenyl-1H-imidazol-2-yl)-5-[[2-(trifluoromethyl)phenyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-09-3 CAPLUS  
CN Carbamic acid, [5-[[[4-phenyl-1H-imidazol-2-yl)-5-[[2-(trifluoromethyl)phenyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-10-6 CAPLUS  
CN Carbamic acid, [5-[[[4-phenyl-1H-imidazol-2-yl)-5-[[2-(trifluoromethyl)phenyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252302-11-7 CAPLUS  
CN Carbamic acid, [5-[[[3-(3-bromophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-12-8 CAPLUS  
CN Carbamic acid, [5-[[[3-(4-methoxyphenoxy)phenyl]methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-13-9 CAPLUS  
CN 3-Quinolinemethanamine, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-14-0 CAPLUS  
CN 2-Quinolinemethanamine, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-18-4 CAPLUS  
CN 3-Quinolinemethanamine, 2-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-19-5 CAPLUS  
CN 2-Quinolinemethanamine, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-20-8 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(4-pyridinylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-15-1 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(4-pyridinylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-16-2 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(2-pyridinylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-17-3 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(3-pyridinylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-21-9 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(2-pyridinylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-22-0 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252302-23-1 CAPLUS  
CN 3-Quinolinemethanamine, 2-chloro-N-[2-(1H-indol-3-yl)-1-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)








RN 252302-24-2 CAPLUS  
CN 2-Quinolinemethanamine, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 252302-25-3 CAPLUS  
CN 1H-Indole-3-ethanamine, alpha-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252302-27-5 CAPLUS  
CN 1H-Indole-3-ethanamine, alpha-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252302-35-5 CAPLUS  
CN 1H-Indole-3-ethanamine, alpha-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252302-37-7 CAPLUS  
CN 1H-Indole-3-ethanamine, alpha-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-39-9 CAPLUS  
CN 3-Quinolinemethanamine, 2-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 252302-28-6 CAPLUS  
CN 1H-Indole-3-ethanamine, alpha-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-29-7 CAPLUS  
CN 3-Quinolinemethanamine, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-31-1 CAPLUS  
CN 2-Quinolinemethanamine, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-32-2 CAPLUS  
CN 1H-Indole-3-ethanamine, alpha-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-41-3 CAPLUS  
CN 2-Quinolinemethanamine, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-43-5 CAPLUS  
CN 1H-Indole-3-ethanamine, alpha-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-44-6 CAPLUS  
CN 1H-Indole-3-ethanamine, alpha-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-46-8 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-47-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-48-0 CAPLUS  
CN 1H-Indole-3-ethanamine, N-butyl-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-53-7 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-54-8 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(1,1-dimethylethyl)phenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-55-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-hexyl-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-49-1 CAPLUS  
CN 1H-Indole-3-ethanamine, N-pentyl-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-50-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[3-(methylthio)propyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-51-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-52-6 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[2-(phenylmethoxy)ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252302-56-0 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252302-58-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252302-60-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-butyl-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252302-61-7 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-pentyl- (9CI) (CA INDEX NAME)




RN 252302-63-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-methylthio)propyl]-α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3-methylthio)propyl] (9CI) (CA INDEX NAME)




RN 252302-65-1 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3,3-dimethylbutyl)-α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3,3-dimethylbutyl)] (9CI) (CA INDEX NAME)




RN 252302-67-3 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-phenylmethoxy)ethyl]-α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-phenylmethoxy)ethyl] (9CI) (CA INDEX NAME)




RN 252302-69-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(cyclohexylmethyl)-α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(cyclohexylmethyl)] (9CI) (CA INDEX NAME)



RN 252302-71-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(1,1-dimethylethyl)phenyl)methyl]-α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-(1,1-dimethylethyl)phenyl)methyl] (9CI) (CA INDEX NAME)




RN 252302-74-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3-fluoro-4-methoxyphenyl)methyl] (9CI) (CA INDEX NAME)




RN 252302-77-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3,3-dimethylbutyl)-α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3,3-dimethylbutyl)] (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 252302-79-7 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3-bromophenyl)methyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-80-0 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-N-pentyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-N-pentyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-82-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3,3-dimethylbutyl)-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3,3-dimethylbutyl)] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-83-3 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(cyclohexylmethyl)-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(cyclohexylmethyl)] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-84-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(1,1-dimethylethyl)phenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-(1,1-dimethylethyl)phenyl)methyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-85-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-hexyl- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-86-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-88-8 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-89-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-butyl- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-90-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-91-3 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[2-(phenylmethoxy)ethyl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-92-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-93-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(1,1-dimethylethyl)phenyl)methyl]- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-95-7 CAPLUS  
CN 1H-Indole-3-ethanamine, N-hexyl- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252302-97-9 CAPLUS  
CN Phenol, 2-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252302-98-0 CAPLUS

CN Phenol, 4-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252302-99-1 CAPLUS

CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 252303-00-7 CAPLUS

CN 1H-Indole-3-ethanamine, N-[(3-methoxyphenyl)methyl]- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-05-2 CAPLUS

CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-06-3 CAPLUS

CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-07-4 CAPLUS


CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-N-[(2-thienylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 252303-02-9 CAPLUS

CN 1H-Indole-3-ethanamine, N-[(2-methoxyphenyl)methyl]- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-03-0 CAPLUS

CN 1H-Indole-3-ethanamine, N-[(4-nitrophenyl)methyl]- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-04-1 CAPLUS

CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-08-5 CAPLUS

CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-N-[(3,4,5-trimethoxyphenyl)methyl]-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-09-6 CAPLUS

CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-10-9 CAPLUS


CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-N-[(4-(trifluoromethoxy)phenyl)methyl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 252303-12-1 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[[4-(3-(dimethylamino)propoxy)phenyl]methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-13-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[[4-(3-fluoro-4-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-18-7 CAPLUS  
CN 1H-Indole-3-ethanamine, N-hexyl-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-19-8 CAPLUS  
CN Carbamic acid, [(5S)-5-[[4-(morpholinylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-21-2 CAPLUS  
CN Carbamic acid, [(5S)-5-[[4-(phenyl-1H-imidazol-2-yl)-5-[[3-thiazolidinylcarbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 252303-14-3 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-15-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)-α-(4-phenyl-1H-imidazol-2-yl)-N-[2-(phenylmethoxy)ethyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-16-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-17-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-22-3 CAPLUS  
CN Carbamic acid, [(5S)-5-[[4-(aminocarbonyl)-1-piperidinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-25-6 CAPLUS  
CN Carbamic acid, [(5S)-5-[[4-(phenyl-1H-imidazol-2-yl)-5-[[4-phenyl-1-piperazinyl]carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-26-7 CAPLUS  
CN Carbamic acid, [(5S)-5-[[4-(phenyl-1H-imidazol-2-yl)-5-[[1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-27-8 CAPLUS  
CN Carbamic acid, [(5S)-5-[(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(phenylmethyl)-1-piperazinyl]carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-28-9 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(4-fluorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-29-0 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-34-7 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(4-chlorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-35-8 CAPLUS  
CN Carbamic acid, [(5S)-5-[(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(2-pyridinyl)-1-piperazinyl]carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-36-9 CAPLUS  
CN Carbamic acid, [(5S)-5-[(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(phenylmethyl)-1-piperidinyl]carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-30-3 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(3-chlorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-32-5 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(4-nitrophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-33-6 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-38-1 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-39-2 CAPLUS  
CN Carbamic acid, [(5S)-5-[(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(3-trifluoromethylphenyl)-1-piperazinyl]carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-40-5 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-41-6 CAPLUS  
CN Carbamic acid, [[5S]-5-[[[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-42-7 CAPLUS  
CN Carbamic acid, [[5S]-5-[[[4-(4-hydroxyphenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-44-9 CAPLUS  
CN Carbamic acid, [[5S]-5-[[[4-(2,4-dimethylphenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 252303-53-0 CAPLUS  
CN Carbamic acid, [[5S]-5-[[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-54-1 CAPLUS  
CN Carbamic acid, [[5S]-5-[[[4-(diphenylmethyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-57-4 CAPLUS  
CN Carbamic acid, [[5S]-5-[[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-46-1 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[[[[(1S)-5-[[[4-phenyl-1H-imidazol-2-yl]pentyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-47-2 CAPLUS  
CN Carbamic acid, [[5S]-5-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-50-7 CAPLUS  
CN Carbamic acid, [[5S]-5-[[[4-(2-furanylcarbonyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 252304-37-3 CAPLUS  
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, monohydride (9CI) (CA INDEX NAME)



● HI


RN 252304-38-4 CAPLUS  
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-chloro-, monohydride (9CI) (CA INDEX NAME)



● HI


RN 252304-39-5 CAPLUS  
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-chloro-, monohydride (9CI) (CA INDEX NAME)






● HI

RN 252304-40-8 CAPLUS  
CN Benzene-carboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-methoxy-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252304-42-0 CAPLUS  
CN Benzene-carboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(trifluoromethyl)-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252304-43-1 CAPLUS  
CN Benzene-carboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(1,1-dimethylethyl)-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252304-45-3 CAPLUS




● HI

RN 252304-49-7 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, monohydride (9CI) (CA INDEX NAME)



● HI


RN 252304-50-0 CAPLUS  
CN Ethanimidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252304-51-1 CAPLUS  
CN 4-Morpholinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN Benzene-carboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2,4-difluoro-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252304-46-4 CAPLUS  
CN Benzene-carboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(trifluoromethoxy)-, monohydride (9CI) (CA INDEX NAME)



● HI

RN 252304-47-5 CAPLUS  
CN Benzene-carboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2,6-dichloro-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252304-48-6 CAPLUS  
CN Ethanimidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-[(1,1-dimethylethyl)sulfonyl]-, monohydride (9CI) (CA INDEX NAME)


RN 252304-52-2 CAPLUS  
CN 3-Thiazolidinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-53-3 CAPLUS  
CN 1,4-Piperidinedicarboxamide, N1-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-58-8 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-60-2 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-62-4 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-64-6 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-66-8 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-70-4 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-72-6 CAPLUS  
CN 2(1H)-Isoquinolinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3,4-dihydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-75-9 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-76-0 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-77-1 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-79-3 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-80-6 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-81-7 CAPLUS  
CN 1,3,8-Triazaepiro[4.5]decane-8-carboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-82-8 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-83-9 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-85-1 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-87-3 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[[[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-88-4 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-90-8 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252305-49-0 CAPLUS  
CN 1H-Indole-3-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 252305-50-3 CAPLUS  
CN 1H-Indole-3-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-hydroxy- (9CI) (CA INDEX NAME)



RN 252305-51-4 CAPLUS  
CN 1H-Indole-4-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 252305-52-5 CAPLUS  
CN 1H-Indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-hydroxy- (9CI) (CA INDEX NAME)




RN 252304-93-1 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-94-2 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-99-7 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252305-53-6 CAPLUS  
CN 1H-Indole-2-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 252305-54-7 CAPLUS  
CN 1H-Indole-2-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-hydroxy- (9CI) (CA INDEX NAME)




RN 252305-55-8 CAPLUS  
CN 1H-Indole-2-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 252305-56-9 CAPLUS  
CN 1H-Indole-3-butanamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-hydroxy- (9CI) (CA INDEX NAME)




RN 252305-57-0 CAPLUS  
CN 1H-Indole-3-propanamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-hydroxy- (9CI) (CA INDEX NAME)




RN 252305-58-1 CAPLUS  
CN 1H-Indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-hydroxy- (9CI) (CA INDEX NAME)




RN 252305-59-2 CAPLUS  
CN 1H-Indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-bromo- (9CI) (CA INDEX NAME)




RN 252305-60-5 CAPLUS  
CN 1H-Indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 252305-61-6 CAPLUS  
CN Benzo[b]thiophene-2-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-63-8 CAPLUS  
CN Benzo[b]thiophene-2-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-69-4 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 252305-70-7 CAPLUS  
CN 2-Furancarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-71-8 CAPLUS  
CN 2-Pyridinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-72-9 CAPLUS  
CN Acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-(phenylthio)- (9CI) (CA INDEX NAME)




RN 252305-73-0 CAPLUS  
CN 1-Naphthalenecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-64-9 CAPLUS  
CN 2-Benzofurancarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-65-0 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3,4-dichloro- (9CI) (CA INDEX NAME)




RN 252305-66-1 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252305-67-2 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 252305-68-3 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 252305-74-1 CAPLUS  
CN 8-Quinolinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-75-2 CAPLUS  
CN 8-Quinolinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




IT 252305-76-3P 252305-78-5P 252305-79-6P  
252305-80-9P 252305-82-1P 252305-83-2P  
252305-84-3P 252305-85-4P 252305-86-5P  
252305-87-6P 252305-88-7P 252305-89-8P  
252305-90-1P 252305-91-2P 252305-92-3P  
252305-93-4P 252305-94-5P 252305-95-6P  
252305-96-7P 252305-97-8P 252305-99-0P  
252306-00-6P 252306-01-7P 252306-02-8P  
252306-03-9P 252306-05-1P 252306-06-2P  
252306-07-3P 252306-08-4P 252306-09-5P  
252306-10-6P 252306-11-9P 252306-12-0P  
252306-13-1P 252306-14-2P 252306-15-3P  
252306-16-4P 252306-17-5P 252306-19-7P

252306-20-0P 252306-21-1P 252306-22-2P  
 252306-23-3P 252306-24-4P 252306-25-5P  
 252306-26-6P 252306-27-7P 252306-29-9P  
 252306-31-3P 252306-32-4P 252306-34-6P  
 252306-35-7P 252306-36-8P 252306-37-9P  
 252306-39-1P 252306-40-4P 252306-41-5P  
 252306-42-6P 252306-65-3P 252306-66-4P  
 252306-67-5P 252306-68-6P 252306-69-7P  
 252306-70-0P 252306-71-1P 252306-72-2P  
 252306-73-3P 252306-74-4P 252306-84-6P  
 252306-85-7P 252306-86-8P 252306-87-9P  
 252306-88-0P 252306-89-1P 252306-90-4P  
 252306-91-5P 252306-92-6P 252306-93-7P  
 252306-94-8P 252306-95-9P 252306-96-0P  
 252306-97-1P 252306-98-2P 252306-99-3P  
 252307-00-9P 252307-01-0P 252307-02-1P  
 252307-04-3P 252307-05-4P 252307-06-5P  
 252307-07-6P 252307-09-8P 252307-10-1P  
 252307-11-2P 252307-12-3P 252307-13-4P  
 252307-17-8P 252307-19-0P 252307-21-4P  
 252307-22-5P 252307-23-6P 252307-24-7P  
 252307-26-9P 252307-27-0P 252307-28-1P  
 252307-29-2P 252307-30-5P 252307-31-6P  
 252307-32-7P 252307-33-8P 252307-34-9P  
 252307-36-1P 252307-37-2P 252307-38-3P  
 252307-39-4P 252307-40-7P 252307-41-8P  
 252307-42-9P 252307-43-0P 252307-45-2P  
 252307-46-3P 252307-47-4P 252307-48-5P  
 252307-49-6P 252307-50-9P 252307-51-0P  
 252307-52-1P 252307-53-2P 252307-54-3P  
 252307-55-4P 252307-56-5P 252307-57-6P  
 252307-58-7P 252307-59-8P 252307-60-1P  
 252307-61-2P 252307-62-3P 252307-63-4P  
 252307-64-5P 252307-65-6P 252307-67-8P  
 252307-68-9P 252307-69-0P 252307-70-3P  
 252307-71-4P 252307-72-5P 252307-73-6P  
 252307-75-8P 252307-76-9P 252307-77-0P  
 252307-78-1P 252307-79-2P 252307-80-5P  
 252307-81-6P 252307-82-7P 252307-83-8P  
 252307-85-0P 252307-86-1P 252307-88-3P  
 252307-89-4P 252307-90-7P 252307-91-8P  
 252307-92-9P 252307-93-0P 252307-94-1P  
 252307-95-2P 252307-96-3P 252307-97-4P  
 252307-98-5P 252307-99-6P 252308-01-3P  
 252308-02-4P 252308-03-5P 252308-04-6P  
 252308-05-7P 252308-06-8P 252308-07-9P  
 252308-08-0P 252308-10-4P 252308-11-5P  
 252308-13-7P 252308-14-8P 252308-15-9P  
 252308-16-0P 252308-17-1P 252308-18-2P  
 252308-19-3P 252308-21-7P 252308-22-8P  
 252308-23-9P 252308-24-0P 252308-25-1P  
 252308-26-2P 252308-27-3P 252308-28-4P  
 252308-30-8P 252308-31-9P 252308-32-0P  
 252308-33-1P 252308-35-3P 252308-36-4P  
 252308-37-5P 252308-38-6P 252308-39-7P  
 252308-41-1P 252308-42-2P 252308-43-3P  
 252308-44-4P 252308-45-5P 252308-46-6P  
 252308-47-7P 252308-48-8P 252308-49-9P  
 252308-52-4P 252308-53-5P 252308-54-6P  
 252308-55-7P 252308-57-9P 252308-58-0P  
 252308-59-1P 252308-60-4P 252308-62-6P  
 252308-63-7P 252308-64-8P 252308-65-9P  
 252308-66-0P 252308-67-1P 252308-79-5P  
 252308-81-9P 252308-82-0P 252308-83-1P  
 252308-84-2P 252308-85-3P 252308-86-4P


(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 252305-82-1 CAPLUS  
 CN 2-Thiophenacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-83-2 CAPLUS  
 CN Acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-(2-pyrimidinylthio)- (9CI) (CA INDEX NAME)



RN 252305-84-3 CAPLUS  
 CN 3-Pyridinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-85-4 CAPLUS  
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 252305-86-5 CAPLUS  
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-chloro- (9CI) (CA INDEX NAME)

252308-87-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(Preparation of imidazolyl deriva. as agonists or antagonists of somatostatin receptors)  
 RN 252305-76-3 CAPLUS  
 CN 3-Quinolonecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-78-5 CAPLUS  
 CN 4-Quinolonecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-79-6 CAPLUS  
 CN 1-Isoquinolinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-80-9 CAPLUS  
 CN Propanamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-




RN 252305-87-6 CAPLUS  
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 252305-88-7 CAPLUS  
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-bromo- (9CI) (CA INDEX NAME)




RN 252305-89-8 CAPLUS  
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-bromo- (9CI) (CA INDEX NAME)




RN 252305-90-1 CAPLUS  
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-bromo- (9CI) (CA INDEX NAME)




RN 252305-91-2 CAPLUS  
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 252305-92-3 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 252305-93-4 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 252305-94-5 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252305-95-6 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252305-96-7 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252305-97-8 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252305-99-0 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252306-00-6 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252306-01-7 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252306-02-8 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252306-03-9 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252306-05-1 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252306-06-2 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 252306-07-3 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-08-4 CAPLUS  
CN 1,5-Pentanediamine, N1-[(2-chloro-3-quinolinyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-09-5 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(2-quinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-10-8 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-11-9 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-12-0 CAPLUS  
CN 1H-Indole-6-carboxylic acid, 3-[[[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 252306-13-1 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-14-2 CAPLUS  
CN Phenol, 2-[[[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 252306-15-3 CAPLUS  
CN Phenol, 4-[[[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 252306-16-4 CAPLUS  
CN 1,5-Pentanediamine, N1-[(4-fluorophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-17-5 CAPLUS  
CN 1,5-Pentanediamine, N1-[(3-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-19-7 CAPLUS  
CN 1,5-Pentanediamine, N1-[(4-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-25-5 CAPLUS  
CN 1,5-Pentanediamine, N1-[(4-bromophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-26-6 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-27-7 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252306-29-9 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[(4-(phenylmethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252306-31-3 CAPLUS  
CN 1,5-Pentanediamine, N1-[(2-fluorophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-20-0 CAPLUS  
CN 1,5-Pentanediamine, N1-[(2-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-21-1 CAPLUS  
CN 1,5-Pentanediamine, N1-[(2-nitrophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-22-2 CAPLUS  
CN 1,5-Pentanediamine, N1-[(4-nitrophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-23-3 CAPLUS  
CN 1,5-Pentanediamine, N1-[(3,4-dichlorophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-24-4 CAPLUS  
CN 1,5-Pentanediamine, N1-[(3-methoxy-2-nitrophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-32-4 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[(2-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252306-34-6 CAPLUS  
CN 1,5-Pentanediamine, N1-[(1,1'-biphenyl)-4-ylmethyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-35-7 CAPLUS  
CN 1,5-Pentanediamine, N1-[(2-bromophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-36-8 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[(4-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252306-37-9 CAPLUS  
CN 1,5-Pentanediamine, N1-[(4-{3-(dimethylamino)propoxy}phenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-39-1 CAPLUS  
CN 1,5-Pentanediamine, N1-[(3-fluoro-4-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-40-4 CAPLUS  
CN 1,5-Pentanediamine, N1-[[4-(1,1-dimethylethyl)phenyl]methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 252306-41-5 CAPLUS  
CN 1,5-Pentanediamine, N1-[(3-bromophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 252306-42-6 CAPLUS  
CN 1,5-Pentanediamine, N1-[[3-(4-methoxyphenoxy)phenyl]methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-65-3 CAPLUS  
CN Propanamide, 3-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


(methylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-70-0 CAPLUS  
CN Benzamide, 4-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-71-1 CAPLUS  
CN Propanamide, 2-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-72-2 CAPLUS  
CN Pentanamide, 5-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-66-4 CAPLUS  
CN Acetamide, 2-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-67-5 CAPLUS  
CN Butanamide, 4-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-68-6 CAPLUS  
CN Hexanamide, 6-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-69-7 CAPLUS  
CN Acetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-




RN 252306-73-3 CAPLUS  
CN Benzamide, 4-(aminomethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252306-74-4 CAPLUS  
CN Benzeneacetamide, 4-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252306-84-6 CAPLUS  
CN Benzeneacetamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 252306-85-7 CAPLUS  
CN Benzeneacetamide, 3-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-86-8 CAPLUS  
CN Benzeneacetamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-87-9 CAPLUS  
CN Benzeneacetamide, 2-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-88-0 CAPLUS  
CN Benzeneacetamide, 3-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-89-1 CAPLUS  
CN Benzeneacetamide, 4-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-90-4 CAPLUS  
CN Benzeneacetamide, 2-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-91-5 CAPLUS  
CN Benzeneacetamide, 3-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-92-6 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-93-7 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-94-8 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-95-9 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-96-0 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-97-1 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-98-2 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-99-3 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-04-3 CAPLUS  
CN Benzeneacetamide, 4-(dimethylamino)-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-05-4 CAPLUS  
CN Benzeneacetamide, 3,4-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-06-5 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-05-9 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-01-0 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-02-1 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-07-6 CAPLUS  
CN Benzeneacetamide, 4-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-09-8 CAPLUS  
CN Benzeneacetamide, 4-methyl-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-10-1 CAPLUS  
CN Benzeneacetamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-11-2 CAPLUS  
CN Benzeneacetamide, 2-chloro-N-[(1S)-2-((1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-12-3 CAPLUS  
CN Benzeneacetamide, 3-chloro-N-[(1S)-2-((1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-13-4 CAPLUS  
CN Benzeneacetamide, 4-chloro-N-[(1S)-2-((1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-17-8 CAPLUS  
CN Benzeneacetamide, 2-bromo-N-[(1S)-2-((1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-19-0 CAPLUS  
CN Benzeneacetamide, 3-bromo-N-[(1S)-2-((1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-21-4 CAPLUS  
CN Benzeneacetamide, 4-bromo-N-[(1S)-2-((1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-22-5 CAPLUS  
CN Benzeneacetamide, 2-fluoro-N-[(1S)-2-((1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-23-6 CAPLUS  
CN Benzeneacetamide, 3-fluoro-N-[(1S)-2-((1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-24-7 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[(1S)-2-((1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-26-9 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-((1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-27-0 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-((1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-28-1 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-((1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-29-2 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-30-5 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252307-31-6 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-36-1 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 252307-35-0  
CMP C28 H26 N4 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMP C2 H F3 O2




RN 252307-37-2 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-32-7 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-33-8 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-34-9 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-38-3 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3,4-dichloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-39-4 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-40-7 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-41-8 CAPLUS  
CN Benzeneacetamide, 4-hydroxy-N-[(1S)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-42-9 CAPLUS  
CN Benzeneacetamide, 2,4-difluoro-N-[(1S)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252307-43-0 CAPLUS  
CN Carbamic acid, [5-[(1H-indol-5-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-49-6 CAPLUS  
CN Carbamic acid, [5-[(5-methoxy-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252307-50-9 CAPLUS  
CN Carbamic acid, [5-[(5-hydroxy-1H-indol-2-yl)carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-51-0 CAPLUS  
CN Carbamic acid, [5-[(5-methoxy-1H-indol-2-yl)carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-52-1 CAPLUS  
CN Carbamic acid, [5-[(4-(1H-indol-3-yl)-1-oxobutyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-45-2 CAPLUS  
CN Carbamic acid, [5-[(1H-indol-3-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252307-46-3 CAPLUS  
CN Carbamic acid, [5-[(1H-indol-4-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-47-4 CAPLUS  
CN Carbamic acid, [5-[(1H-indol-2-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-48-5 CAPLUS  
CN Carbamic acid, [5-[(1H-indol-3-ylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


RN 252307-53-2 CAPLUS  
CN Carbamic acid, [5-[(3-(1H-indol-3-yl)-1-oxopropyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-54-3 CAPLUS  
CN Carbamic acid, [5-[(5-hydroxy-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-55-4 CAPLUS  
CN Carbamic acid, [5-[(5-bromo-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-56-5 CAPLUS  
CN Carbamic acid, [5-[(2-methyl-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-57-6 CAPLUS  
CN Carbamic acid, [5-[(benzo[b]thien-2-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-58-7 CAPLUS  
CN Carbanic acid, [5-[(benzo[b]thien-3-ylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-59-8 CAPLUS  
CN Carbanic acid, [5-[(2-benzofuranylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-60-1 CAPLUS  
CN Carbanic acid, [5-[(3,4-dichlorophenylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-61-2 CAPLUS  
CN Carbanic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3,4,5-trimethoxyphenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-67-8 CAPLUS  
CN Carbanic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-pyridinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-68-9 CAPLUS  
CN Carbanic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(phenylthio)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-69-0 CAPLUS  
CN Carbanic acid, [5-[(1-naphthalenylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-70-3 CAPLUS  
CN Carbanic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-62-3 CAPLUS  
CN Carbanic acid, [5-[(4-methylphenylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252307-63-4 CAPLUS  
CN Carbanic acid, [5-[(4-hydroxyphenylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-64-5 CAPLUS  
CN Carbanic acid, [5-[(2,4-difluorophenylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-65-6 CAPLUS  
CN Carbanic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3,4-difluorophenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


INDEX NAME)




RN 252307-71-4 CAPLUS  
CN Carbanic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(8-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-72-5 CAPLUS  
CN Carbanic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-73-6 CAPLUS  
CN Carbanic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(4-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-75-8 CAPLUS  
CN Carbanic acid, [5-[(1-isoquinolinylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-76-9 CAPLUS  
CN Carbanic acid, [5-[(1-oxo-3-(phenylsulfonyl)propyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-77-0 CAPLUS  
CN Carbanic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-thienylacetyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-82-7 CAPLUS  
CN Carbanic acid, [5-[(4-chlorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252307-83-8 CAPLUS  
CN Carbanic acid, [5-[(2-bromophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-85-0 CAPLUS  
CN Carbanic acid, [5-[(3-bromophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-86-1 CAPLUS  
CN Carbanic acid, [5-[(4-bromophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-78-1 CAPLUS  
CN Carbanic acid, [5-[(2-pyrimidinylthio)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252307-79-2 CAPLUS  
CN Carbanic acid, [5-[(2-chlorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-80-5 CAPLUS  
CN Carbanic acid, [5-[(3-chlorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-81-6 CAPLUS  
CN Carbanic acid, [5-[(3-fluorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 252307-88-3 CAPLUS


CN Carbanic acid, [5-[(2-fluorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-89-4 CAPLUS  
CN Carbanic acid, [5-[(3-fluorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-90-7 CAPLUS  
CN Carbanic acid, [5-[(4-fluorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-91-8 CAPLUS  
CN Carbanic acid, [5-[(2-nitrophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-92-9 CAPLUS  
CN Carbanic acid, [5-[(3-nitrophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-93-0 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-nitrophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-94-1 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[2-(trifluoromethyl)phenyl]acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-95-2 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[3-(trifluoromethyl)phenyl]acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-96-3 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(trifluoromethyl)phenyl]acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-97-4 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-(4-(trifluoromethyl)phenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-98-5 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-(4-(4-methoxyphenyl)acetyl]amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-99-6 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-(4-(4-methoxyphenyl)acetyl]amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-01-3 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-(4-(4-methoxyphenyl)acetyl]amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-02-4 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-(4-(4-methoxyphenyl)acetyl]amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-03-5 CAPLUS  
CN Benzeneacetamide, 3,4-dichloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-04-6 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252308-05-7 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 252308-06-8 CAPLUS  
CN Benzeneacetamide, 2,4-difluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-07-9 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3,4-dichloro- (9CI) (CA INDEX NAME)




RN 252308-08-0 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,4-dichloro- (9CI) (CA INDEX NAME)






RN 252308-10-4 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252308-11-5 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 252308-13-7 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)


CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252308-17-1 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 252308-18-2 CAPLUS  
CN Benzeneacetamide, 4-hydroxy-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




yl)ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 252308-14-8 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 252308-15-9 CAPLUS  
CN Benzeneacetamide, 3,4-dichloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-16-0 CAPLUS


RN 252308-19-3 CAPLUS  
CN Benzeneacetamide, 3,4-difluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-21-7 CAPLUS  
CN Benzeneacetamide, 3,4-dichloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-22-8 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



RN 252308-23-9 CAPLUS  
 CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 252308-24-0 CAPLUS  
 CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 252308-25-1 CAPLUS  
 CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-30-8 CAPLUS  
 CN Benzeneacetamide, 4-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-31-9 CAPLUS  
 CN Benzeneacetamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-32-0 CAPLUS  
 CN Benzeneacetamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252308-26-2 CAPLUS  
 CN Benzeneacetamide, 3,4-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-27-3 CAPLUS  
 CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-28-4 CAPLUS

Absolute stereochemistry.




RN 252308-33-1 CAPLUS  
 CN Benzeneacetamide, 3-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-35-3 CAPLUS  
 CN Benzeneacetamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-36-4 CAPLUS  
 CN Benzeneacetamide, 2-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-37-5 CAPLUS  
CN Benzenacetamide, 3-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-38-6 CAPLUS  
CN Benzenacetamide, 4-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-39-7 CAPLUS  
CN Benzenacetamide, 2-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-44-4 CAPLUS  
CN Benzenacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-45-5 CAPLUS  
CN Benzenacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-46-6 CAPLUS  
CN Benzenacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-41-1 CAPLUS  
CN Benzenacetamide, 3-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-42-2 CAPLUS  
CN Benzenacetamide, 4-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-43-3 CAPLUS  
CN Benzenacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-47-7 CAPLUS  
CN Benzenacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-48-8 CAPLUS  
CN Benzenacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-49-9 CAPLUS  
CN Benzenacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-52-4 CAPLUS  
CN Benzeneacetamide, N-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-53-5 CAPLUS  
CN Benzeneacetamide, N-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-54-6 CAPLUS  
CN Benzeneacetamide, N-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-59-1 CAPLUS  
CN Carbamic acid, [4-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-60-4 CAPLUS  
CN Carbamic acid, [6-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)-6-oxohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-62-6 CAPLUS  
CN Carbamic acid, [2-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-55-7 CAPLUS  
CN Benzeneacetamide, 4-(dimethylamino)-N-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-57-9 CAPLUS  
CN Carbamic acid, [3-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-58-0 CAPLUS  
CN Carbamic acid, [2-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-63-7 CAPLUS  
CN Carbamic acid, [4-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)carbonyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-64-8 CAPLUS  
CN Carbamic acid, [2-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-65-9 CAPLUS  
CN Carbamic acid, [5-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-66-0 CAPLUS  
CN Carbanic acid, [4-[[[1R]-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]carbonyl]phenylmethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-67-1 CAPLUS  
CN Carbanic acid, [4-[[[1R]-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-2-oxoethyl]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252308-79-5 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-84-2 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-4-(trifluoromethyl)-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-85-3 CAPLUS  
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-86-4 CAPLUS  
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-81-9 CAPLUS  
CN Benzenecarboximidamide, 2-chloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-82-0 CAPLUS  
CN Benzenecarboximidamide, 4-chloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-83-1 CAPLUS  
CN Benzenecarboximidamide, 4-methoxy-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-87-5 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-4-(trifluoromethoxy)-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HI

IT 252308-88-6P 252308-89-7P 252308-90-0P  
252308-91-1P 252308-92-2P 252308-93-3P  
252308-94-4P 252308-95-5P 252308-96-6P  
252308-97-7P 252308-98-8P 252308-99-9P  
252309-00-5P 252309-01-6P 252309-02-7P  
252309-03-8P 252309-04-9P 252309-05-0P  
252309-06-1P 252309-07-2P 252309-08-3P  
252309-09-4P 252309-10-7P 252309-11-8P  
252309-12-9P 252309-13-0P 252309-14-1P  
252309-15-2P 252309-16-3P 252309-18-5P  
252309-19-6P 252309-20-9P 252309-21-0P  
252309-22-1P 252309-23-2P 252309-24-3P  
252309-25-4P 252309-26-5P 252309-27-6P  
252309-28-7P 252309-29-8P 252309-30-1P  
252309-42-5P 252309-43-6P 252309-44-7P  
252309-45-8P 252309-46-9P 252309-47-0P  
252309-48-1P 252309-49-2P 252309-50-5P  
252309-51-6P 252309-53-8P 252309-54-9P  
252309-55-0P 252309-56-1P 252309-57-2P  
252309-58-3P 252309-59-4P 252309-61-8P  
252309-63-0P 252309-64-1P 252309-65-2P  
252309-66-3P 252309-67-4P 252309-68-5P  
252309-69-6P 252309-70-9P 252309-71-0P  
252309-73-2P 252309-74-3P 252309-75-4P  
252309-76-5P 252309-77-6P 252309-79-8P  
252309-80-1P 252309-81-2P 252309-82-3P  
252309-84-5P 252309-85-6P 252309-86-7P  
252309-87-8P 252309-88-9P 252309-89-0P  
252309-90-3P 252309-91-4P 252309-92-5P


252309-93-6P 252309-95-8P 252309-96-9P  
 252309-97-0P 252310-00-2P 252310-01-3P  
 252310-02-4P 252310-03-5P 252310-04-6P  
 252310-05-7P 252310-06-8P 252310-08-0P  
 252310-09-1P 252310-10-4P 252310-11-5P  
 252310-12-6P 252310-13-7P 252310-14-8P  
 252310-15-9P 252310-16-0P 252310-17-1P  
 252310-18-2P 252310-19-3P 252310-21-7P  
 252310-22-8P 252310-23-9P 252310-24-0P  
 252310-25-1P 252310-26-2P 252310-27-3P  
 252310-28-4P 252310-29-5P 252310-31-9P  
 252310-32-0P 252310-33-1P 252310-34-2P  
 252310-35-3P 252310-36-4P 252310-38-6P  
 252310-39-7P 252310-40-0P 252310-41-1P  
 252310-43-3P 252310-44-4P 252310-45-5P  
 252310-46-6P 252310-47-7P 252310-48-8P  
 252310-49-9P 252310-50-2P 252310-51-3P  
 252310-52-4P 252310-53-5P 252310-55-7P  
 252310-56-8P 252310-58-0P 252310-59-1P  
 252310-60-4P 252310-62-6P 252310-63-7P  
 252310-64-8P 252310-65-9P 252310-66-0P  
 252310-68-2P 252310-71-7P 252310-72-8P  
 252310-73-9P 252310-74-0P 252310-75-1P  
 252310-76-2P 252310-77-3P 252310-80-8P  
 252310-81-9P 252310-82-0P 252310-83-1P  
 252310-84-2P 252310-85-3P 252310-86-4P  
 252310-87-5P 252310-88-6P 252310-89-7P  
 252310-93-3P 252310-94-4P 252310-97-7P  
 252310-98-8P 252311-17-0P 252311-18-1P  
 252311-19-2P 252311-20-5P 252311-22-7P  
 252311-23-8P 252311-24-9P 252311-25-0P  
 252311-26-1P 252311-27-2P 252311-28-3P  
 252311-29-4P 252311-30-7P 252311-31-8P  
 252311-33-0P 252311-34-1P 252311-35-2P  
 252311-36-3P 252311-37-4P 252311-38-5P  
 252311-39-6P 252311-40-9P 252311-41-0P  
 252311-42-1P 252311-43-2P 252311-45-4P  
 252311-46-5P 252311-47-6P 252311-48-7P  
 252311-50-1P 252311-51-2P 252311-52-3P  
 252311-53-4P 252311-54-5P 252311-55-6P  
 252311-57-8P 252311-58-9P 252311-59-0P  
 252311-60-3P 252311-61-4P 252311-62-5P  
 252311-63-6P 252311-64-7P 252311-65-8P  
 252311-66-9P 252311-67-0P 252311-68-1P  
 252311-69-2P 252311-70-5P 252311-71-6P  
 252311-72-7P 252311-73-8P 252311-74-9P  
 252311-75-0P 252311-77-2P 252311-78-3P  
 252311-79-4P 252311-80-7P 252311-81-8P  
 252311-82-9P 252311-83-0P 252311-84-1P  
 252311-86-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolyl derive. as agonists or antagonists of somatostatin receptors)

RN 252308-88-6 CAPLUS  
 CN Benzenecarboximidamide, 2,6-dichloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-92-2 CAPLUS  
 CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252308-93-3 CAPLUS  
 CN Benzenecarboximidamide, 4-methoxy-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HI


RN 252308-94-4 CAPLUS



● HI

RN 252308-89-7 CAPLUS  
 CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-90-0 CAPLUS  
 CN Benzenecarboximidamide, N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252308-91-1 CAPLUS  
 CN Benzenecarboximidamide, 2-chloro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN Benzenecarboximidamide, N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-95-5 CAPLUS  
 CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-96-6 CAPLUS  
 CN Benzenecarboximidamide, 2,4-difluoro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-97-7 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethoxy)-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-98-8 CAPLUS  
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252308-99-9 CAPLUS

RN 252309-02-7 CAPLUS  
CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-03-8 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-04-9 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-05-5 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HI

RN 252309-01-6 CAPLUS  
CN Benzenecarboximidamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI



● HI

RN 252309-05-0 CAPLUS  
CN Benzenecarboximidamide, 4-[(1,1-dimethylethyl)sulfonyl]-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-06-1 CAPLUS  
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-07-2 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-08-3 CAPLUS  
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-09-4 CAPLUS  
CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-12-9 CAPLUS  
CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-13-0 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]-4-methoxy-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-10-7 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-11-8 CAPLUS  
CN Benzenecarboximidamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-14-1 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-15-2 CAPLUS  
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HI

RN 252309-16-3 CAPLUS  
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252309-18-5 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-21-0 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-22-1 CAPLUS  
CN Benzenecarboximidamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI


RN 252309-23-2 CAPLUS  
CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 252309-19-6 CAPLUS  
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252309-20-9 CAPLUS  
CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-24-3 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-25-4 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-26-5 CAPLUS  
CN Benzenecarboximidamide, 4-[(1,1-dimethylethyl)-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-27-6 CAPLUS  
CN Benzenecarboximidamide, 2,4-difluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-28-7 CAPLUS  
CN Benzenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-29-8 CAPLUS  
CN Benzenecarboximidamide, 2,6-dichloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI


RN 252309-30-1 CAPLUS  
CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 252309-42-5 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-1-[4-(phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-43-6 CAPLUS  
CN Benzenecarboximidamide, 2-chloro-N-[(1S)-1-[4-(phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-44-7 CAPLUS  
CN Benzenecarboximidamide, 4-chloro-N-[(1S)-1-[4-(phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-45-8 CAPLUS  
CN Benzenecarboximidamide, 4-methoxy-N-[(1S)-1-[4-(phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-46-9 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-47-0 CAPLUS  
CN Benzenecarboximidamide, 4-[(1,1-dimethylethyl)-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-48-1 CAPLUS  
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-49-2 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-50-5 CAPLUS  
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-51-6 CAPLUS  
CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-53-8 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-54-9 CAPLUS  
CN Benzenecarboximidamide, 2-chloro-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-55-0 CAPLUS  
CN Benzenecarboximidamide, 4-chloro-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-56-1 CAPLUS  
CN Benzenecarboximidamide, 4-methoxy-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-57-2 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-58-3 CAPLUS  
CN Benzenecarboximidamide, 4-[(1,1-dimethylethyl)-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-59-4 CAPLUS  
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-61-8 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-63-0 CAPLUS  
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-64-1 CAPLUS  
CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252309-65-2 CAPLUS  
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-66-3 CAPLUS  
CN Phenol, 2-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-67-4 CAPLUS  
CN Phenol, 4-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-68-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]-alpha-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-69-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-methoxyphenyl)methyl]-alpha-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-70-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-71-0 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252309-73-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)


phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-77-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-79-8 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(2-thienylmethyl)-, (αS)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 252309-78-7

CMF C24 H22 N4 S

Absolute stereochemistry.




Absolute stereochemistry.




RN 252309-74-3 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-75-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-76-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 252309-80-1 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(3,4,5-trimethoxyphenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-81-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-fluorophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-82-3 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(2-trifluoromethylphenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-84-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-85-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(dimethylamino)phenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-86-7 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(4-(trifluoromethoxy)phenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252309-90-3 CAPLUS  
CN Phenol, 4-[[[2-(1H-indol-3-yl)-1-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 252309-91-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252309-92-5 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252309-87-8 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[4-[3-(dimethylamino)propoxy]phenyl]methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252309-88-9 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252309-89-0 CAPLUS  
CN Phenol, 2-[[[2-(1H-indol-3-yl)-1-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 252309-93-6 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252309-95-8 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252309-96-9 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 252309-97-0 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-00-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252310-01-3 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252310-02-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-03-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 252310-04-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-05-7 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-06-8 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-07-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 252310-08-0 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-09-1 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-10-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-11-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 252310-12-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-13-7 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)



RN 252310-14-8 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-15-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3,4-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-12-6 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-13-7 CAPLUS  
CN Phenol, 2-[[[(1R)-2-[(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-14-8 CAPLUS  
CN Phenol, 4-[[[(1R)-2-[(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 252310-18-2 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-methoxyphenyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-19-3 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-nitrophenyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-21-7 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-nitrophenyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)




RN 252310-15-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-16-0 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3-methoxyphenyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-17-1 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-methoxyphenyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-22-8 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-23-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 252310-24-0 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-25-1 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-thienylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-26-2 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3,4,5-trimethoxyphenyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-27-3 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-fluorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-28-4 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-(trifluoromethyl)phenyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-29-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-31-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(dimethylamino)phenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-32-0 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-(trifluoromethoxy)phenyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-33-1 CAPLUS


CN 1H-Indole-3-ethanamine, N-[(4-[3-(dimethylamino)propoxy]phenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-34-2 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-35-3 CAPLUS  
CN Phenol, 2-[[[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-36-4 CAPLUS  
CN Phenol, 4-[[[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-38-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-39-7 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3-methoxyphenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-40-0 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-nitrophenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)


[(4-nitrophenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-45-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-46-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


[(4-methoxyphenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-41-1 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-methoxyphenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-43-3 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-nitrophenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-44-4 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-methoxyphenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)




RN 252310-47-7 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-48-8 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-thienyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-49-9 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3,4,5-trimethoxyphenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-50-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-fluorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-51-3 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[[2-(trifluoromethyl)phenyl]methyl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-52-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)


CN 4-Morpholinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-58-0 CAPLUS  
CN 3-Thiazolidinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-59-1 CAPLUS  
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-60-4 CAPLUS  
CN 1,4-Piperidinedicarboxamide, N1-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 252310-53-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(dimethylamino)phenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-55-7 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[[4-(trifluoromethoxy)phenyl]methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-56-8 CAPLUS




RN 252310-62-6 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-63-7 CAPLUS  
CN 2H-Pyrido[3,4-b]indole-2-carboxamide, 1,3,4,9-tetrahydro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-64-8 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-65-9 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-66-0 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-68-2 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-74-0 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-75-1 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-76-2 CAPLUS  
CN 1,4-Dioxo-8-azaspiro[4.5]decane-8-carboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-71-7 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-72-8 CAPLUS  
CN 2-(1H)-Isoquinolinecarboxamide, 3,4-dihydro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-73-9 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-77-3 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-80-8 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-81-9 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-82-0 CAPLUS  
CN 1,3,8-Triazaaspiro[4.5]decane-8-carboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-83-1 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(2-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-84-2 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(4-hydroxyphenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-88-6 CAPLUS  
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-89-7 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(2-furanylcarbonyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-93-3 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-85-3 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(2,4-dimethylphenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-86-4 CAPLUS  
CN 1-Pyrrolidinecarboxamide, 3-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-87-5 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-94-4 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(diphenylmethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-97-7 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(2-fluorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-98-8 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252313-17-0 CAPLUS  
CN Benzeneacetamide, 2-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-18-1 CAPLUS  
CN Benzeneacetamide, 3-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-19-2 CAPLUS  
CN Benzeneacetamide, 4-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-24-9 CAPLUS  
CN Benzeneacetamide, 2-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-25-0 CAPLUS  
CN Benzeneacetamide, 3-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-26-1 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-20-5 CAPLUS  
CN Benzeneacetamide, 2-bromo-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-22-7 CAPLUS  
CN Benzeneacetamide, 3-bromo-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-23-8 CAPLUS  
CN Benzeneacetamide, 4-bromo-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-27-2 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252313-28-3 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-29-4 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252313-30-7 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-34-1 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252313-31-8 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-35-2 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252313-33-0 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-36-3 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252313-37-4 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-40-9 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-chloro- (9CI) (CA INDEX NAME)




RN 252313-38-5 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-41-0 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 252313-39-6 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 252313-42-1 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-43-2 CAPLUS  
CN Benzeneacetamide, 3-bromo-N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-45-4 CAPLUS  
CN Benzeneacetamide, 4-bromo-N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-46-5 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 252313-47-6 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 252313-48-7 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 252313-50-1 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252313-51-2 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-52-3 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252313-54-5 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 252313-55-6 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-53-4 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-57-8 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)







RN 252313-58-9 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252313-59-0 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252313-60-3 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-1-(4-(4-nitrophenyl)-1H-imidazol-2-yl)ethyl- (9CI) (CA INDEX NAME)




RN 252313-64-7 CAPLUS  
CN Benzeneacetamide, 4-chloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-65-8 CAPLUS  
CN Benzeneacetamide, 2-bromo-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-66-9 CAPLUS  
CN Benzeneacetamide, 3-bromo-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-61-4 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 252313-62-5 CAPLUS  
CN Benzeneacetamide, 2-chloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-63-6 CAPLUS  
CN Benzeneacetamide, 3-chloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-67-0 CAPLUS  
CN Benzeneacetamide, 4-bromo-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-68-1 CAPLUS  
CN Benzeneacetamide, 2-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-69-2 CAPLUS  
CN Benzeneacetamide, 3-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-70-5 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-71-6 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252313-72-7 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-77-2 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-78-3 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252313-79-4 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252313-73-8 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252313-74-9 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-75-0 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-80-7 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252313-81-8 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-82-9 CAPLUS  
CN Benzeneacetamide, 4-(dimethylamino)-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 252313-83-0 CAPLUS  
CN Benzeneacetamide, 2-chloro-N-[1-[4-[(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 252313-84-1 CAPLUS  
CN Benzeneacetamide, 3-chloro-N-[1-[4-[(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-86-3 CAPLUS  
CN Benzeneacetamide, 4-chloro-N-[1-[4-[(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)


335244-81-0P 335244-82-1P 335244-83-2P  
335244-84-3P 335244-85-4P 335244-86-5P  
335244-87-6P 335244-88-7P 335244-89-8P  
335244-90-1P 335244-91-2P 335244-92-3P  
335244-93-4P 335244-95-6P 335244-96-7P  
335244-97-8P 335244-98-9P 335244-99-0P  
335245-03-9P 335245-04-0P 335245-05-1P  
335245-11-9P 335245-13-1P 335245-16-4P  
335245-17-5P 335245-18-6P 335245-20-0P  
335245-21-1P 335245-27-7P 335245-36-8P  
335245-40-4P 335246-23-6P 335246-41-8P  
335246-42-9P 335246-44-1P 335246-47-4P  
335246-50-9P 335246-51-0P 335246-54-3P  
335246-55-4P 335246-56-5P 335246-58-7P  
335246-67-8P 335246-69-0P 335246-70-3P  
335246-71-4P 335246-72-5P 335246-73-6P  
335246-74-7P 335246-76-9P 335246-77-0P  
335246-78-1P 335246-79-2P 335246-80-5P  
335246-81-6P 335246-83-8P 335246-84-9P  
335246-85-0P 335246-86-1P 335246-87-2P  
335246-89-4P 335246-90-7P 335246-91-6P  
335246-92-9P 335246-93-0P 335246-97-4P  
396135-27-6P 396135-28-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses).  
(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)


RN 252313-87-4 CAPLUS  
CN Benzeneacetamide, 2-bromo-N-[1-[4-[(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-89-6 CAPLUS  
CN Benzeneacetamide, 3-bromo-N-[1-[4-[(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




IT 252313-87-4P 252313-89-6P 252313-90-9P  
252313-91-0P 252313-92-1P 252313-93-2P  
252313-94-3P 252313-96-5P 252313-97-6P  
252313-99-8P 252314-00-4P 252314-01-5P  
252314-02-6P 252314-03-7P 252314-04-8P  
252314-05-9P 252314-96-8P 252314-97-9P  
252314-98-0P 252314-99-1P 252315-01-6P  
252315-03-0P 252315-05-2P 252315-07-4P  
252315-09-6P 252315-11-0P 252315-13-6P  
252315-15-8P 252315-17-0P 252315-40-5P  
252315-42-7P 252315-44-9P 252315-47-2P  
252315-49-4P 252315-96-1P 252315-97-2P  
280775-44-2P 335242-94-9P 335242-95-0P  
335242-98-3P 335242-99-4P 335243-00-0P  
335243-01-1P 335243-03-3P 335243-04-4P  
335243-05-5P 335243-07-7P 335243-09-9P  
335243-10-2P 335243-12-4P 335243-14-6P  
335243-15-7P 335243-16-8P 335243-19-1P  
335243-20-4P 335243-21-5P 335243-22-6P  
335243-23-7P 335243-24-8P 335243-25-9P  
335243-26-0P 335243-27-1P 335243-28-2P  
335243-29-3P 335243-30-6P 335243-31-7P  
335243-32-8P 335243-33-9P 335243-34-0P  
335243-35-1P 335243-37-3P 335243-40-8P  
335243-46-4P 335243-47-5P 335243-50-0P  
335243-51-1P 335243-52-2P 335243-53-3P  
335243-56-6P 335243-57-7P 335243-59-9P  
335243-60-2P 335243-62-4P 335243-65-7P  
335243-68-0P 335243-72-6P 335243-74-8P  
335243-75-9P 335243-76-0P 335243-78-2P  
335243-79-3P 335243-81-7P 335243-83-9P  
335243-85-1P 335243-87-3P 335243-91-9P  
335243-92-0P 335243-95-3P 335244-02-5P  
335244-12-7P 335244-26-3P 335244-27-4P  
335244-29-6P 335244-31-0P 335244-35-4P  
335244-36-5P 335244-42-3P 335244-43-4P  
335244-44-5P 335244-45-6P 335244-46-7P  
335244-47-8P 335244-48-9P 335244-49-0P  
335244-50-3P 335244-51-4P 335244-52-5P  
335244-53-6P 335244-54-7P 335244-55-8P  
335244-56-9P 335244-57-0P 335244-58-1P  
335244-60-5P 335244-62-7P 335244-63-8P  
335244-64-9P 335244-67-2P 335244-68-3P  
335244-69-4P 335244-70-7P 335244-71-0P  
335244-72-9P 335244-73-0P 335244-74-1P  
335244-75-2P 335244-76-3P 335244-77-4P  
335244-78-5P 335244-79-6P 335244-80-9P




RN 252313-90-9 CAPLUS  
CN Benzeneacetamide, 4-bromo-N-[1-[4-[(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-91-0 CAPLUS  
CN Benzeneacetamide, N-[1-[4-[(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 252313-92-1 CAPLUS  
CN Benzeneacetamide, N-[1-[4-[(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 252313-93-2 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252313-94-3 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-96-5 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252313-97-6 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-99-8 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252314-00-4 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252314-01-5 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252314-02-6 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252314-03-7 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 252314-04-8 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252314-05-9 CAPLUS  
CN Thiourea, N-((1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl)-N'-phenyl- (9CI) (CA INDEX NAME)




RN 252314-96-8 CAPLUS  
CN Thiourea, N-((1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl)-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-97-9 CAPLUS  
CN Benzamide, N-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-98-0 CAPLUS  
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-99-1 CAPLUS  
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-07-4 CAPLUS  
CN Thiourea, N-hexyl-N'-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-09-6 CAPLUS  
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-11-0 CAPLUS  
CN Thiourea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-01-8 CAPLUS  
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-03-0 CAPLUS  
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-[2-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-05-2 CAPLUS  
CN Thiourea, N-(3-chlorophenyl)-N'-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-33-6 CAPLUS  
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-35-8 CAPLUS  
CN Benzamide, N-[[[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-37-0 CAPLUS  
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-40-5 CAPLUS  
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-42-7 CAPLUS  
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-44-9 CAPLUS  
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-[2-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-97-2 CAPLUS  
CN Thiophenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI


RN 280775-44-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335242-94-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl-α-(4-methylpentyl)- (9CI) (CA INDEX NAME)




RN 335242-95-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)



RN 335242-98-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


RN 252315-47-2 CAPLUS  
CN Thiourea, N-(3-chlorophenyl)-N'-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-49-4 CAPLUS  
CN Thiourea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252315-96-1 CAPLUS  
CN Thiophenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI



RN 335242-99-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-00-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,N,α-trihexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-01-1 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-2-pyrimidinyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-03-3 CAPLUS  
CN 1H-Indole-3-ethanamine, N-methyl-α-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-04-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(2-phenylethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-05-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-N,α-bis(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-07-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335243-09-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-hexyl-α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335243-16-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-butyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-19-1 CAPLUS  
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335243-20-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,α-dihexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-21-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-pentyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335243-22-6 CAPLUS




●x HCl

RN 335243-10-2 CAPLUS  
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-12-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-(2-methylpropyl)-4-phenyl-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335243-14-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-butyl-1-methyl-α-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335243-15-7 CAPLUS  
CN Carbamic acid, [1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methoxyphenyl)-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335243-23-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-[(2,6-dichlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-24-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-[(4-chlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-25-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(3-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335243-26-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-[(2-chlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-27-1 CAPLUS  
CN 1H-imidazole-2-methanamine, N-[(2-fluorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-28-2 CAPLUS  
CN 1H-imidazole-2-methanamine, N-butyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-29-3 CAPLUS  
CN 1H-imidazole-2-methanamine, α-hexyl-N-(3-methylbutyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-30-6 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)-N,α-dihexyl- (9CI) (CA INDEX NAME)




RN 335243-31-7 CAPLUS  
CN 1H-imidazole-2-methanamine, α-hexyl-N-pentyl-4-phenyl- (9CI) (CA INDEX NAME)




●x HCl

RN 335243-40-8 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclobutyl-4-(4-fluorophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335243-46-4 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-phenyl-α-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335243-47-5 CAPLUS  
CN 1H-indole-3-ethanamine, 1-methyl-α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl




RN 335243-32-8 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclohexyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-33-9 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-34-0 CAPLUS  
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)methyl]-, butyl ester (9CI) (CA INDEX NAME)




RN 335243-35-1 CAPLUS  
CN 1H-imidazole-2-methanamine, N-cyclopentyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-37-3 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(2-chlorophenyl)-N-cyclohexyl-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)


RN 335243-50-0 CAPLUS  
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-51-1 CAPLUS  
CN 1H-indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335243-52-2 CAPLUS  
CN Benzamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-53-3 CAPLUS  
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 335243-56-6 CAPLUS  
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-57-7 CAPLUS  
CN Carbamic acid, [(4-phenyl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-59-9 CAPLUS  
CN 1H-Indole-3-ethanamine, 6-fluoro- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-60-2 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-(4-nitrophenyl)-1H-imidazol-2-yl)-, hydrochloride, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● x HCl


RN 335243-74-8 CAPLUS  
CN Carbamic acid, [(1R)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-75-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -(2-methylpropyl)-4-phenyl-N-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-76-0 CAPLUS  
CN Carbamic acid, [phenyl(4-phenyl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-78-2 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ ,4-diphenyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 335243-62-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(2-phenoxyethyl)- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-65-7 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -(benzo[b]thien-3-ylmethyl)-4-phenyl-N-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-68-0 CAPLUS  
CN Carbamic acid, [2-(6-chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-72-6 CAPLUS  
CN 1H-Indole-3-ethanamine, 6-chloro- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 335243-79-3 CAPLUS  
CN Carbamic acid, [(1R)-3-phenyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-81-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl- $\alpha$ -(2-phenylethyl)-, hydrochloride, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 335243-83-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ ,4-diphenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-85-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl- $\alpha$ -(2-phenylethyl)-N-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-87-3 CAPLUS  
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-91-9 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-, hydrochloride (9CI) (CA INDEX NAME)





●x HCl

RN 335243-92-0 CAPLUS  
CN 1H-imidazole-2-methanamine, α-hexyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335243-95-3 CAPLUS  
CN 1H-imidazole-2-methanamine, α-hexyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




●x HCl

RN 335244-31-0 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(2-phenylethyl)-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335244-35-4 CAPLUS  
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-36-5 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-butyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-42-3 CAPLUS  
CN 1H-imidazole-2-methanamine, α-butyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)

RN 335244-02-5 CAPLUS  
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-12-7 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-26-3 CAPLUS  
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl] (phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-27-4 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(2-phenylethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335244-29-6 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335244-43-4 CAPLUS  
CN Carbamic acid, [1-(4-(4-methylphenyl)-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-44-5 CAPLUS  
CN Carbamic acid, [1-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-45-6 CAPLUS  
CN 1H-imidazole-2-methanamine, α-hexyl-4-(4-methylphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-46-7 CAPLUS  
CN 1H-imidazole-2-methanamine, α-hexyl-4-(2-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




•x HCl


RN 335244-47-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-butyl-4-phenyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)



RN 335244-48-9 CAPLUS  
CN Carbamic acid, [1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-49-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



•x HCl


RN 335244-50-3 CAPLUS  
CN Carbamic acid, [1-[4-(3-bromophenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-55-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-hexyl-N-(phenylmethyl)-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 335244-54-7  
CMF C23 H28 Br N3




CM 2

CRN 64-19-7  
CMF C2 H4 O2





RN 335244-56-9 CAPLUS  
CN Carbamic acid, [(1S)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335244-57-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-51-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




•x HCl

RN 335244-52-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



•x HCl


RN 335244-53-6 CAPLUS  
CN Carbamic acid, [1-[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-54-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

RN 335244-58-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-ethyl-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




•x HCl

RN 335244-60-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-ethyl-N-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-62-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methylphenyl)-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




•x HCl

RN 335244-63-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(2-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-64-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-pentyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

(9CI) (CA INDEX NAME)




RN 335244-67-2 CAPLUS  
CN Benzonitrile, 4-[2-[(1-aminoheptyl)-1H-imidazol-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-68-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[(4-bromophenyl)-α-hexyl]- (9CI) (CA INDEX NAME)




RN 335244-69-4 CAPLUS  
CN Carbamic acid, [(1R)-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-70-7 CAPLUS  
CN Carbamic acid, [(1R)-1-(4-[(1,1'-biphenyl)-4-yl]-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335244-74-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[(4-bromophenyl)-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-75-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[(1,1'-biphenyl)-4-yl-N-(phenylmethyl)-α-propyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-76-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-77-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-[(3-chlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335244-71-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[(1,1'-biphenyl)-4-yl-N-(phenylmethyl)-α-propyl]-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl


RN 335244-72-9 CAPLUS  
CN Phenol, 4-[2-[(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis[(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-73-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)-α-propyl-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335244-78-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(3-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-79-6 CAPLUS  
CN Benzonitrile, 4-[2-[(1-[(phenylmethyl)amino]heptyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 335244-80-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-81-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-methyl-4-phenyl-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335244-82-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)- $\alpha$ -hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-83-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)- $\alpha$ -hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-84-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-butyl-N-ethyl-, ( $\alpha$ S)- (9CI) (CA INDEX NAME)




RN 335244-85-4 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -methyl-4-phenyl-N-(phenylmethyl)-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)




Absolute stereochemistry.

RN 335244-86-5 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-phenyl-N-propyl- (9CI) (CA INDEX NAME)




●x HCl

RN 335244-91-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)- $\alpha$ -hexyl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-92-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-(diethylamino)phenyl)- $\alpha$ -hexyl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-93-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)- $\alpha$ -hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-95-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- $\alpha$ -(4-methylpentyl)-, hydrochloride (9CI) (CA INDEX NAME)

INDEX NAME)




RN 335244-87-6 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(3-methoxyphenyl)-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-88-7 CAPLUS  
CN Benzonitrile, 4-[2-{1-[(phenylmethyl)amino]heptyl}-1H-imidazol-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-89-8 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-N-[(4-methoxyphenyl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 335244-90-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)- $\alpha$ -hexyl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




RN 335244-96-7 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-N-(2-methylpropyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 335244-97-8 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-N-(2-methylpropyl)-4-phenyl-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 335244-96-7  
CMF C20 H31 N3




CM 2


CRN 64-19-7  
CMF C2 H4 O2




RN 335244-98-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- $\alpha$ -(4-methylpentyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-99-0 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335245-03-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- $\alpha$ -hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335245-04-0 CAPLUS  
CN Carbamic acid, ((1S)-1-(4-([1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)ethyl)-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-05-1 CAPLUS  
CN Carbamic acid, ((1R)-1-(4-([1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)ethyl)-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335245-11-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-N-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 335245-20-0 CAPLUS  
CN 1H-Indole-3-ethanamine, N-cyclobutyl-5-fluoro- $\alpha$ -(4-(4-fluorophenyl))-1H-imidazol-2-yl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-21-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- $\alpha$ -(3-methylbutyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-27-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)- $\alpha$ -hexyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-36-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl- $\alpha$ -(4-methylpentyl)-, hydrochloride (9CI) (CA INDEX NAME)




RN 335245-13-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(3,4-dichlorophenyl)- $\alpha$ -hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-16-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-([1,1'-biphenyl]-4-yl)-N-cyclohexyl- $\alpha$ -hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-17-5 CAPLUS  
CN 1H-Indole-3-ethanamine, 5-fluoro- $\alpha$ -(4-(4-fluorophenyl))-1H-imidazol-2-yl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335245-18-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl- (9CI) (CA INDEX NAME)




●x HCl

RN 335245-40-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- $\alpha$ -(1-methylethyl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-23-6 CAPLUS  
CN Phenol, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 335246-41-8 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -pentyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335246-42-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-44-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-N-cyclohexyl- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)




RN 335246-47-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-4-(4-fluorophenyl)- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)




RN 335246-50-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl- $\alpha$ -(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-51-0 CAPLUS  
CN 1H-Indole-3-ethanamine, 1-methyl- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335246-54-3 CAPLUS  
CN 1H-Indole-3-ethanamine, 6-chloro- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335246-70-3 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-71-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)



RN 335246-72-5 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-73-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)




RN 335246-74-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -ethyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-55-4 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ ,4-diphenyl- (9CI) (CA INDEX NAME)




RN 335246-56-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl- $\alpha$ -(2-phenylethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-58-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)




RN 335246-67-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -(2-phenylethyl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-69-0 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 335246-76-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-77-0 CAPLUS  
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 335246-78-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -propyl-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-79-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl- $\alpha$ -propyl-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-80-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]- $\alpha$ -hexyl-

(9CI) (CA INDEX NAME)




RN 335246-81-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, alpha-methyl-4-phenyl-, (aR)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.




RN 335246-83-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-alpha-hexyl- (9CI) (CA INDEX NAME)




RN 335246-84-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-alpha-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-85-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-alpha-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-86-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-alpha-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-93-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-alpha-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 335246-97-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)-alpha-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 396135-27-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-alpha-butyl- (9CI) (CA INDEX NAME)




RN 396135-28-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, alpha-butyl-4-phenyl- (9CI) (CA INDEX NAME)




IT 252279-08-6 252315-91-6 252315-92-7  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)  
RN 252279-08-6 CAPLUS  
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)




RN 335246-87-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-alpha-hexyl- (9CI) (CA INDEX NAME)




RN 335246-89-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(3,4-dichlorophenyl)-alpha-hexyl- (9CI) (CA INDEX NAME)



RN 335246-90-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-cyclohexyl-alpha-hexyl- (9CI) (CA INDEX NAME)




RN 335246-91-8 CAPLUS  
CN 1H-Indole-3-ethanamine, 5-fluoro-alpha-[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 335246-92-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-cyclobutyl-5-fluoro-alpha-[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-91-6 CAPLUS  
CN Carbamic acid, [(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry..




RN 252315-92-7 CAPLUS  
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




IT 252279-09-7P 335247-35-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)  
RN 252279-09-7 CAPLUS  
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 335247-35-3 CAPLUS  
CN Carbamic acid, [1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L12 ANSWER 14 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:6386 CAPLUS  
DOCUMENT NUMBER: 136:69731  
TITLE: Preparation of N-phenylthiophenecarboxamides and analogs as NO synthase and lipid peroxidation inhibitors  
INVENTOR(S): Chabrier de Lassautiere, Pierre Etienne; Auvin, Serge; Bigg, Dennis; August, Michel; Harnett, Jeremah  
PATENT ASSIGNEE(S): Societe de Conseil de Recherches et d'Applications Scientifiques (S.C.R.A.S.), Fr.  
SOURCE: U.S., 63 pp., Cont.-in-part of U. S. Ser. No. 381,749. CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 4  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6335445	B1	20020101	US 1999-456205	19991207
FR 2761066	A1	19980925	FR 1997-3528	19970324
FR 2761066	B1	20001124		
FR 2764889	A1	19981224	FR 1997-7701	19970620
FR 2764889	B1	20000901		
WO 9842696	A1	19981001	WO 1998-FR288	19980216
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, BG, BZ, CA, CH, CN, CU, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, SJ, CP, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6340700	B1	20020122	US 1999-381749	19990922
US 2002007062	A1	20020117	US 2001-882264	20010615
US 6630461	B2	20031007		
US 2002045753	A1	20020418	US 2001-945782	20010904
US 6599903	B2	20030729		
US 2002042511	A1	20020411	US 2001-953682	20010917
US 6586454	B2	20030701		
US 2003078420	A1	20030424	US 2002-191950	20020709
US 6809088	B2	20041026		


PRIORITY APPL. INFO.:

OTHER SOURCE(S): MARPAT 136:69731




• HCl

RN 384833-39-0 CAPLUS  
CN Benzamide, N-[[4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-4-[[imino-2-thienylmethyl]amino]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 384833-51-6 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[[4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]methylamino]phenyl]- (9CI) (CA INDEX NAME)



IT 218944-36-6P 218944-40-2P 218944-41-3P  
218944-66-2P 218944-68-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of N-phenylthiophenecarboxamides and analogs as NO synthase and lipid peroxidn. inhibitors)

RN 218944-36-6 CAPLUS  
CN Carbamic acid, [[4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


GI



AB R221223N:C(NH2)R1 [1; R = H, (un)substituted C6H4OR3, indolyl, etc.; R1 = alkyl or (un)substituted (hetero)ary; R3 = H, alkyl, etc.; Z = bond, CO, alkylene(carbonyl), COXH, etc.; Z1 = bond or heterocyclene; Z2 = bond, alkylene(oxy), etc.; Z3 = (un)substituted phenylene] were prepared. Thus, 4-(O2N)C6H4NH2 was amidated by 3,5-di-tert-butyl-4-hydroxybenzoic acid and the reduced product amidated by 5-methyl-2-thiophenethiocarboximide hydroiodide to give title compound II. Data for biol. activity of I were given.


IT 218944-42-4P 218944-69-5P 384833-39-0P  
384833-51-6P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of N-phenylthiophenecarboxamides and analogs as NO synthase and lipid peroxidn. inhibitors)

RN 218944-42-4 CAPLUS  
CN Benzamide, N-[[5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-4-[[imino-2-thienylmethyl]amino]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl


RN 218944-69-5 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[[4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]methylamino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 218944-40-2 CAPLUS  
CN Benzamide, N-[[4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-N-methyl-4-nitro- (9CI) (CA INDEX NAME)




RN 218944-41-3 CAPLUS  
CN Benzamide, 4-amino-N-[[4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 218944-66-2 CAPLUS  
CN Phenol, 4-[2-[[4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 218944-68-4 CAPLUS  
CN Phenol, 4-[2-[[4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:527784 CAPLUS

DOCUMENT NUMBER: 135:251427

TITLE:

AUTHOR(S):

CORPORATE SOURCE:

SOURCE:

PUBLISHER:

DOCUMENT TYPE:

LANGUAGE:

OTHER SOURCE(S):

AB Using a solution-phase parallel synthesis strategy, a series of non-peptide somatostatin analogs were prepared, and their binding affinities to the five human somatostatin receptor subtypes (sst1-5) were determined. Imidazolyl derivatives were found to bind with moderate affinity but with high selectivity to the sst3 receptor subtype. Further modifications of these structures led to a more potent class of ligands, the tetrahydro- $\beta$ -carboline derivatives. Among these, compounds BNB1644 and BNB1674 bind selectively and with high affinity to the sst3 receptor subtype ( $K_i = 0.64$  and  $0.92$  nM, resp.). Furthermore, BNB1644 and BNB1674 reverse the inhibition of cAMP accumulation induced by  $1$  nM somatostatin via sst3 receptors, with  $IC_{50} = 2.7$  and  $0.84$  nM, resp. The most potent compound BNB1674 was shown to be a competitive antagonist of human sst3 receptors by increasing the  $EC_{50}$  of SRIF-14-mediated inhibition of cAMP accumulation with a  $K_B$  of  $2.8$  nM (where  $K_B$  is the concentration of antagonist that shifts

the agonist dose-response 2-fold). These new derivatives, to the authors' knowledge, the first potent and highly selective non-peptide human sst3 antagonists known and, as such, are useful tools for investigating the physiological role of sst3 receptors.

IT 252279-08-6P 252279-09-7P 252279-24-6P  
335243-50-0P 349668-19-5P, tert-Butyl  
(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylcarbamate

361576-57-0P 361576-59-2P 361576-60-5P

361576-63-8P 361576-64-9P 361576-65-0P

361576-66-1P 361576-67-2P 361576-69-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(identification of potent non-peptide somatostatin receptor antagonists with sst3 selectivity)

RN 252279-08-6 CAPLUS

CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 361576-57-0 CAPLUS

CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)-2-[5-(phenylmethoxy)-1H-indol-3-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 361576-59-2 CAPLUS

CN Carbamic acid, [2-(5-methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361576-60-5 CAPLUS


CN Carbamic acid, [2-(5-chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361576-63-8 CAPLUS

CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252279-09-7 CAPLUS

CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252279-24-6 CAPLUS

CN Carbamic acid, [(1R)-2-benzo[b]thien-3-yl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-50-0 CAPLUS


CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 349668-19-5 CAPLUS

CN Carbamic acid, [(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




● 2 HCl

RN 361576-64-9 CAPLUS

CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 361576-65-0 CAPLUS


CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-5-(phenylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 361576-66-1 CAPLUS

CN 1H-Indole-3-ethanamine, 5-methyl- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 361576-67-2 CAPLUS  
CN 1H-Indole-3-ethanamine, 5-chloro-α-(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 361576-69-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-(benzo[b]thien-3-ylmethyl)-4-phenyl-, dihydrochloride, (nR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 16 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 2001:283789 CAPLUS






DOCUMENT NUMBER: 134:311210

TITLE: 5-Membered heterocycle derivatives useful as monoamine oxidase inhibitors, lipid peroxidation inhibitors, and sodium channel modulators, and the production thereof, and use thereof as medicaments

INVENTOR(S): Chabrier de Lassaulniers, Pierre-Etienne; Harnett, Jeremiah; Bigg, Dennis; Pommier, Jacques; Lannoy, Jacques; Liberatore, Anne-Marie; Thuriereau, Christophe

PATENT ASSIGNEE(S): Societe de Conseil de Recherches et d'Applications Scientifiques (S.C.R.A.S. Fr.

SOURCE: PCT Int. Appl., 261 pp.



II

AB The invention relates to pharmaceutical use of heterocyclic compds. of general formula Het(A)(B)-(CH<sub>2</sub>)<sub>n</sub>-CR1R2-Q (I; wherein the substituted heterocyclic ring Het(A)(B) = Q1-Q4; A = various aryl or heteroaryl systems, especially a substituted Ph or biphenyl radical, or also alkyl, cycloalkyl, or cycloalkylalkyl; B = especially H or alkyl, or also aryl or substituted alkyl; X = especially NH or S, or also substituted NH; Y = O or S;

n = 0-6; R1, R2 = especially H, alkyl, or cycloalkyl; Q = NR3R4 or OR5; R3 and R4 = especially H, alkyl, cycloalkyl, alkynyl, cyanoalkyl, alkoxyalkyl, aralkoxyalkyl, or (cycloalkyl)alkoxyalkyl; RS = H, alkyl, alkynyl, or cyanoalkyl. I and their racemates, enantiomers, and/or salts can be used for producing medicaments for inhibiting monoamine oxidases (MAO), inhibiting lipid peroxidation, and/or for acting as modulators of sodium channels. The resulting medicaments are particularly for use in treating Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, schizophrenia, depression, psychosis, pain and epilepsy. Approx. 350 synthetic examples of I and their salts are given, and numerous free bases of I are claimed. For instance, protection of sarcosinamide-HCl with BOC anhydride gave 72% BOC-N(Me)CH<sub>2</sub>CONH<sub>2</sub>, which was converted to the thioamide with (P2S5)2 in 65% yield. Cyclocondensation of the thioamide with 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (28%), followed by deprotection (73%) and selenification (92%), gave thiazole derivative II as the HCl salt. II inhibited binding of the MAO-B specific ligand [3H]-Ro-19-6327 to rat mitochondrial preps. with IC<sub>50</sub> < 10 μM. Selected I also inhibited formation of malondialdehyde by lipid peroxidation in rat cerebral cortex preps., and inhibited specific binding of [3H]-batrachotoxin to voltage-dependent sodium channels in rat cerebral cortex homogenates.

IT 252302-96-8P, (1R)-N-Benzyl-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335244-94-5P, (R,S)-tert-Butyl 1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-5-methylhexylcarbamate 335246-82-7P, (R,S)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KD, KZ, MD, RU, TJ, TM			
HW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BS, CH, CY, DE, DK, RS, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801
CA 2388505	AA	20010419	CA 2000-2388505	20001010
BR 2000014649	A	20020618	BR 2000-14649	20001010
EP 1223933	A2	20020724	EP 2000-967988	20001010
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
EP 1228760	A2	20020807	EP 2002-76763	20001010
EP 1228760	A3	20040128		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003511416	T2	20030325	JP 2001-529718	20001010
NZ 518304	A	20040730	NZ 2000-518304	20001010
NO 200201689	A	20020530	NO 2002-1689	20020410
US 2004132788	A1	20040708	US 2003-681002	20031008
PRIORITY APPL. INFO.:			FR 1999-12643	A 19991011
			FR 2000-10151	A 20000801
			FR 2000-11169	A 20000901
			EP 2000-967988	A3 20001010
			EP 2002-76763	A3 20001010
			WO 2000-FR2805	W 20001010
			JP 1989-4943	A 20010410
			JP 1990-1811	A 20020214
			US 2002-89993	A2 20020404

OTHER SOURCE(S): MARPAT 134:311210  
GI


(drug candidate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidation inhibitors, and sodium channel modulators)

RN 252302-96-8 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (nR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335244-94-5 CAPLUS  
CN Carbamic acid, [1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-5-methylhexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335246-82-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)




IT 252279-09-7, (1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335246-59-8, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)heptylamine 335246-68-9, N-Benzyl[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]methanamine  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)  
(drug candidate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidation inhibitors, and sodium channel modulators)

RN 252279-09-7 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, (nR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335246-59-8 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335246-68-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[[1,1'-biphenyl]-4-yl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)



IT 252309-65-2P, (1S)-N-Benzyl-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 280775-44-2P, N-Benzyl-4-phenyl-1H-imidazol-2-ylmethanamine 335242-80-3P, 4-[[1,1'-biphenyl]-4-yl]-N-methyl-1H-imidazol-2-ylmethanamine 335242-92-7P, N-[(S)-Cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-2-ylmethyl]cyclobutanamine 335242-94-2P, N-1-[(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl]-N-(cyclohexyl)amine 335242-95-0P, N-1-[(4-(4-fluorophenyl)-1H-imidazol-2-yl)heptyl]cyclohexanamine 335242-98-3P, N-Benzyl-N-[[4-[[1,1'-biphenyl]-4-yl]-1H-imidazol-2-yl)methyl]-1-hexanamine 335242-99-4P, N-Benzyl-4-[[1,1'-biphenyl]-4-yl]-1H-imidazol-2-yl-N-methylmethanamine 335243-00-0P, (R,S)-N-N-Dibenzyl-1-(4-phenyl-1H-imidazol-2-yl)heptanamine 335243-01-1P, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-pyrimidinamine 335243-03-3P, (1R)-N-Benzyl-2-(1H-indol-3-yl)-N-methyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335243-04-4P, (1R)-2-(1H-indol-3-yl)-N-(2-phenylethyl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335243-05-5P, (1R)-N-Benzyl-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-09-9P, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-1-hexanamine hydrochloride 335243-10-2P, (R,S)-tert-Butyl-1-(4-phenyl-1H-imidazol-2-yl)heptylcarbamate 335243-12-4P, (1S)-3-Methyl-1-(4-phenyl-1H-imidazol-2-yl)-1-butanamine hydrochloride 335243-14-6P, (R,S)-N-[[2-[(1-Methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-1-butanamine 335243-15-7P, (R,S)-4-[[2-[(1-tert-butoxycarbonyl)amino]pentyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335243-16-8P, (R,S)-N-Benzyl-1-[[4-[[1,1'-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pentanamine 335243-19-1P, (R,S)-tert-Butyl-1-[(4-phenyl-1H-imidazol-2-yl)hexyl]carbamate 335243-20-4P, (R,S)-N-Hexyl-1H-imidazol-2-yl-1-heptanamine 335243-21-5P, (R,S)-1-(4-phenyl-1H-imidazol-2-yl)hexylamine


yl)ethanamine 335243-85-1P, (1R)-N-Benzyl-3-phenyl-1-(4-phenyl-1H-imidazol-2-yl)-1-propanamine 335243-86-2P, (R,S)-N-[5,5-Trifluoro-1-(4-(4-fluorophenyl)-1H-imidazol-2-yl)pentyl]cyclohexanamine 335243-87-3P, 4-[[2-[(tert-butoxycarbonyl)amino]methyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335243-88-4P, N-[(S)-Cyclohexyl-4-(4-methylsulfonylphenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine 335243-91-9P, 4-[[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-ylmethanamine hydrochloride 335243-92-0P, (R,S)-1-(4-phenyl-1H-imidazol-2-yl)heptylamine hydrochloride 335243-94-2P, N,N-Dibenzyl-4-[[1,1'-biphenyl]-4-yl]-1H-imidazol-2-ylmethanamine 335243-95-3P, (R,S)-N-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335244-02-5P, 4-[[2-[(tert-butoxycarbonyl)amino]methyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-04-7P, 4-[[2-[(1R)-1-[(tert-butoxycarbonyl)amino]-2-cyclohexylethyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-13-6P, (1R)-1-(4-[[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl)-2-cyclohexylethylamine hydrochloride 335244-12-7P, 4-[[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl-N-methylmethanamine hydrochloride 335244-26-3P, 4-[[2-[(Benzyl)tert-butoxycarbonyl]amino]methyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-27-4P, (1R)-1-(4-[[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl)-3-phenyl-1-propanamine hydrochloride 335244-28-5P, 4-[[2-[(1R)-1-[(tert-butoxycarbonyl)amino]-3-phenylpropyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-29-6P, N-Benzyl-4-[[1,1'-biphenyl]-4-yl]-1H-imidazol-2-ylmethanamine hydrochloride 335244-30-9P, (1R)-N-Benzyl-1-[[4-[[1,1'-biphenyl]-4-yl]-1H-imidazol-2-yl]-2-cyclohexylethylamine 335244-31-0P, (1R)-N-Benzyl-1-[[4-[[1,1'-biphenyl]-4-yl]-1H-imidazol-2-yl]-3-phenyl-1-propanamine 335244-35-4P, (R,S)-tert-Butyl-1-[(4-phenyl-1H-imidazol-2-yl)pentyl]carbamate 335244-36-5P, (R,S)-1-[[4-[[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-1-pentanamine hydrochloride 335244-42-3P, (R,S)-1-(4-phenyl-1H-imidazol-2-yl)heptylamine hydrochloride 335244-43-4P, (R,S)-tert-Butyl-1-[[4-[(4-methylphenyl)-1H-imidazol-2-yl]heptyl]carbamate 335244-44-5P, (R,S)-tert-Butyl-1-[[4-[(2-methoxyphenyl)-1H-imidazol-2-yl]heptyl]carbamate 335244-45-6P, (R,S)-1-[[4-[(4-Methylphenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-46-7P, (R,S)-1-[[4-[(2-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine hydrochloride 335244-47-8P, (R,S)-N-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)-1-pentanamine 335244-48-9P, (R,S)-tert-Butyl-1-[[4-[(4-Methoxyphenyl)-1H-imidazol-2-yl]heptyl]carbamate 335244-49-0P, (R,S)-1-[[4-[[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-50-3P, (R,S)-tert-Butyl-1-[[4-[(3-bromophenyl)-1H-imidazol-2-yl]heptyl]carbamate 335244-51-4P, (R,S)-1-[[4-[(4-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine hydrochloride 335244-52-5P, (R,S)-1-[[4-[(3-Bromophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-53-6P, (R,S)-4-[[2-[(1-tert-butoxycarbonyl)amino]heptyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-55-8P, (R,S)-N-Benzyl-1-[[4-[(3-bromophenyl)-1H-imidazol-2-yl]-1-heptanamine acetate 335244-56-9P, 4-[[2-[(1S)-1-[(tert-butoxycarbonyl)amino]propyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-57-0P, (R,S)-N-Benzyl-1-[[4-[[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-1-heptanamine 335244-58-1P, (1S)-1-[[4-[[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-1-propanamine hydrochloride 335244-60-5P, (1S)-N-Benzyl-1-[[4-[[1,1'-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-propanamine 335244-62-7P, (R,S)-N-Benzyl-1-[[4-[(4-methylphenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-63-8P, (R,S)-N-Benzyl-1-[[4-[(2-methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine 335244-64-9P, (R,S)-N-Benzyl-1-[[4-phenyl-1H-imidazol-2-yl]-1-hexanamine 335244-67-2P, (R,S)-1-[[2-[(1-Aminoheptyl)-1H-imidazol-2-yl]benzonitrile hydrochloride 335244-68-3P, (R,S)-1-[[4-[(4-Bromophenyl)-1H-imidazol-2-yl]-1-heptanamine 335244-69-4P, (1R)-tert-Butyl-1-[(4-phenyl-1H-imidazol-2-yl)butyl]carbamate 335244-70-7P, 4-[[2-[(1R)-1-[(tert-butoxycarbonyl)amino]butyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-71-8P, (1R)-1-[[4-[[1,1'-

hydrochloride 335243-22-6P, (R,S)-N-Benzyl-1-[[4-[(4-methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335243-23-7P, (R,S)-N-(2,6-Dichlorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335243-24-8P, (R,S)-N-(4-Chlorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335243-25-9P, (R,S)-1-[[4-[(3-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine hydrochloride 335243-26-0P, (R,S)-N-(2-Chlorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335243-27-1P, (R,S)-N-(2-Fluorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335243-28-2P, (R,S)-N-Butyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335243-29-3P, (R,S)-N-Isopentyl-N-1-[(4-phenyl-1H-imidazol-2-yl)heptyl]amine 335243-30-6P, (R,S)-1-[[4-[(3-Bromophenyl)-1H-imidazol-2-yl]-N-hexyl]-1-heptanamine 335243-31-7P, (R,S)-N-Pentyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335243-32-8P, (R,S)-N-1-[(4-Phenyl-1H-imidazol-2-yl)heptyl]cyclohexanamine 335243-33-9P, (R,S)-N-Benzyl-1-[[4-[(3,4-dichlorophenyl)-1H-imidazol-2-yl]-1-heptanamine 335243-34-0P, Butyl-[[4-[(1,1'-biphenyl)-4-yl]-1H-imidazol-2-yl)methyl]carbamate 335243-35-1P, (R,S)-N-1-[(4-Phenyl-1H-imidazol-2-yl)heptyl]cyclopentanamine 335243-36-2P, (S)-Cyclohexyl-4-phenyl-1H-imidazol-2-ylmethanamine hydrochloride 335243-37-3P, (R,S)-N-1-[[4-[(2-Chlorophenyl)-1H-imidazol-2-yl]heptyl]cyclohexanamine hydrochloride 335243-39-5P, (S)-N-[[Cyclohexyl-4-phenyl-1H-imidazol-2-yl)methyl]cyclobutanamine hydrochloride 335243-40-8P, (R,S)-N-1-[[4-[(4-Fluorophenyl)-1H-imidazol-2-yl]heptyl]cyclobutanamine hydrochloride 335243-41-9P, N-[(S)-Cyclohexyl-4-[(3-fluoro-4-methoxyphenyl)-1H-imidazol-2-yl)methyl]cyclobutanamine 335243-42-0P, N-[(S)-Cyclohexyl-4-[(4-trifluoromethyl)phenyl]-1H-imidazol-2-yl)methyl]cyclobutanamine 335243-43-1P, N-[(S)-Cyclohexyl-4-[(3-fluorophenyl)-1H-imidazol-2-yl)methyl]cyclobutanamine 335243-44-2P, (R,S)-2-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-47-5P, (R,S)-2-(1-Methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine hydrochloride 335243-50-0P, (1R)-tert-Butyl-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylcarbamate 335243-51-1P, (1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-52-2P, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]benzamide 335243-53-3P, (1R)-Benzyl-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylcarbamate 335243-56-4P, (1R)-tert-Butyl-2-(1H-indol-3-yl)-1-(4-[(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]carbamate 335243-57-7P, tert-Butyl-[[4-phenyl-1H-imidazol-2-yl)methyl]carbamate 335243-59-9P, (R,S)-N-Benzyl-2-(6-fluoro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335243-60-2P, (1R)-2-(1H-indol-3-yl)-1-(4-[(4-nitrophenyl)-1H-imidazol-2-yl]ethanamine 335243-61-3P, (1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335243-65-7P, (1R)-2-(1-Benzothien-3-yl)-N-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335243-68-0P, (R,S)-tert-Butyl-2-(6-chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylcarbamate 335243-72-6P, (R,S)-1-(4-Chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine hydrochloride 335243-74-8P, (1R)-tert-Butyl-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butylcarbamate 335243-75-9P, (1R)-N-Benzyl-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)-1-butanamine 335243-76-0P, (R,S)-tert-Butyl-phenyl-4-phenyl-1H-imidazol-2-yl)methylcarbamate 335243-78-2P, (R,S)-Phenyl-4-phenyl-1H-imidazol-2-ylmethanamine hydrochloride 335243-79-3P, (1R)-tert-Butyl-phenyl-4-phenyl-1H-imidazol-2-ylpropylcarbamate 335243-80-6P, (1R)-tert-Butyl-2-cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethylcarbamate 335243-81-7P, (1R)-3-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)-1-propanamine hydrochloride 335243-82-0P, (1R)-2-Cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethylamine hydrochloride 335243-83-9P, (R,S)-N-Benzyl-phenyl-4-phenyl-1H-imidazol-2-ylmethanamine 335243-84-0P, (1R)-N-Benzyl-2-cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335244-2-yl)-1-butanamine hydrochloride 335244-72-9P, (R,S)-4-[[2-[(1-Aminoheptyl)-1H-imidazol-4-yl]-2,6-di-((tert-butyl)amino)ethyl]amine hydrochloride 335244-73-0P, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)-1-butanamine hydrochloride 335244-74-1P, (R,S)-N-Benzyl-1-[[4-[(4-bromophenyl)-1H-imidazol-2-yl]-1-heptanamine 335244-75-2P, (1R)-N-Benzyl-1-[[4-[[1,1'-biphenyl]-4-yl]-1H-imidazol-2-yl]-1-butanamine 335244-76-3P, (1R)-N-Benzyl-2-phenyl-1H-imidazol-2-yl)-1-butanamine 335244-77-4P, (R,S)-N-(3-Chlorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335244-78-5P, (R,S)-N-Benzyl-1-[[4-[(3-methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine 335244-79-6P, (R,S)-4-[[2-[(1-Benzylamino)heptyl]-1H-imidazol-4-yl]benzonitrile 335244-80-9P, (R,S)-4-[[2-[(1-Aminoheptyl)-1H-imidazol-4-yl]-N,N-diethylamine hydrochloride 335244-81-0P, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335244-82-1P, (R,S)-1-[[4-[(4-Fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-83-2P, (R,S)-1-[[4-[(2-Chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-84-3P, N-[(1S)-1-[[4-[[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]propyl]-1-butanamine 335244-85-4P, (1R)-N-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335244-86-5P, (R,S)-N-1-[(4-Phenyl-1H-imidazol-2-yl)heptyl]-N-propylamine 335244-87-6P, (R,S)-N-Benzyl-1-[[4-[(3-methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-88-7P, (R,S)-4-[[2-[(1-Benzylamino)heptyl]-1H-imidazol-4-yl]benzonitrile hydrochloride 335244-89-8P, (R,S)-N-(4-Methoxybenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335244-90-9P, (R,S)-N-Benzyl-1-[[4-[(4-fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-91-2P, (R,S)-N-Benzyl-1-[[4-[(2-chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-92-3P, (R,S)-N-Benzyl-N-1-[[4-[(4-diethylamino)phenyl]-1H-imidazol-2-yl]heptyl]amine hydrochloride 335244-93-4P, (R,S)-1-[[4-[(3,4-Dichlorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-95-6P, (R,S)-1-[[4-[(3-Bromophenyl)-1H-imidazol-2-yl]-5-methyl-1-hexanamine hydrochloride 335244-97-8P, (R,S)-N-Isobutyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine acetate 335244-98-9P, (R,S)-N-Benzyl-1-[[4-[(3-bromophenyl)-1H-imidazol-2-yl]-5-methyl-1-hexanamine 335244-99-0P, (R,S)-N-Benzyl-1-[[4-[(4-methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine 335245-03-9P, (R,S)-N-1-[(4-Phenyl-1H-imidazol-2-yl)heptyl]cyclobutanamine 335245-04-0P, 4-[[2-[(1S)-1-[(butoxycarbonyl)amino]ethyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335245-05-1P, 4-[[2-[(1R)-1-[(butoxycarbonyl)amino]ethyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335245-06-2P, N-[(S)-Cyclohexyl-4-phenyl-1H-imidazol-2-yl)methyl]cyclohexanamine 335245-11-9P, (R,S)-N-Isopropyl-N-1-[[4-phenyl-1H-imidazol-2-yl]heptyl]amine 335245-13-1P, (R,S)-N-1-[[4-[(3,4-Dichlorophenyl)-1H-imidazol-2-yl]heptyl]cyclohexanamine hydrochloride 335245-16-4P, (R,S)-N-1-[[4-[[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]heptyl]cyclohexanamine hydrochloride 335245-17-5P, (R,S)-2-(5-Fluoro-1H-indol-3-yl)-1-[[4-[(4-fluorophenyl)-1H-imidazol-2-yl]ethylamine hydrochloride 335245-18-6P, N-[[4-[(3-Bromophenyl)-1H-imidazol-2-yl]methyl]cyclohexanamine 335245-20-0P, (R,S)-N-2-(5-Fluoro-1H-indol-3-yl)-1-[[4-[(4-fluorophenyl)-1H-imidazol-2-yl]ethyl]cyclobutanamine hydrochloride 335245-21-1P, (R,S)-N-1-[[4-[(4-Fluorophenyl)-1H-imidazol-2-yl]-4-methylpentyl]cyclohexanamine hydrochloride 335245-22-2P, (S)-Cyclohexyl-4-[(3,4-difluorophenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-23-3P, (S)-Cyclohexyl-4-[(3-fluoro-4-methoxyphenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-24-4P, (S)-Cyclopropyl-4-[(4-fluorophenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-25-5P, N-[(S)-Cyclohexyl-4-[(4-fluorophenyl)-1H-imidazol-2-yl]fluoramine 335245-26-6P, N-[(S)-Cyclohexyl-4-[(3,4-difluorophenyl)-1H-imidazol-2-yl]methyl]cyclobutanamine 335245-27-7P, (R,S)-N-(Cyclohexylmethyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine hydrochloride 335245-28-8P, N-[(S)-Cyclohexyl-4-[(4-fluorophenyl)-


1H-imidazol-2-yl)methyl)cyclohexanamine hydrochloride 335245-29-9P  
, (S)-Cyclohexyl-N-(cyclohexylmethyl)(4-phenyl-1H-imidazol-2-yl)methanamine hydrochloride 335245-30-2P, (R,S)-N-(Cyclopropyl(4-(4-fluorophenyl)-1H-imidazol-2-yl)methyl)cyclohexanamine hydrochloride 335245-31-3P, (S)-Cyclohexyl-N-(cyclopropylmethyl)(4-phenyl-1H-imidazol-2-yl)methanamine hydrochloride 335245-34-6P, N-[(S)-Cyclohexyl(4-(4-(trifluoromethoxy)phenyl)-1H-imidazol-2-yl)methyl)cyclobutanamine 335245-36-8P, (R,S)-N-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-5-methylhexyl)cyclohexanamine hydrochloride 335245-37-9P, (S)-Cyclohexyl-N-(cyclopropylmethyl)-[4-(4-fluorophenyl)-1H-imidazol-2-yl)methanamine hydrochloride 335245-38-0P, (R,S)-N-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl)methyl)cyclobutanamine hydrochloride 335245-40-4P, N-[(1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-methylpropyl)cyclohexanamine 335245-41-5P, N-[(S)-Cyclohexyl(4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)methyl)cyclobutanamine acetate 335245-46-0P, N-[(S)-Cyclohexyl(4-(4-(methylthio)phenyl)-1H-imidazol-2-yl)methyl)cyclohexanamine 335245-47-1P, N-[(S)-Cyclohexyl(4-(4-fluorophenyl)-1H-imidazol-2-yl)methyl)cyclohexanamine 335245-48-2P, N-[(S)-4-(3,5-Bis(trifluoromethyl)phenyl)-1H-imidazol-2-yl](cyclohexyl)methyl)cyclohexanamine 335245-51-7P, N-[(S)-Cyclohexyl(4-(4-(3,4-difluorophenyl)-1H-imidazol-2-yl)methyl)cyclohexanamine 335245-53-9P, (S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-1-cyclohexyl-N-(cyclohexylmethyl)methanamine 335245-54-0P, 4-[2-[(S)-Cyclohexyl(4-(4-(3-Bromophenyl)-1H-imidazol-2-yl)methyl)cyclohexylamino]methyl]-1H-imidazol-4-yl]-N,N-diethylaniline hydrochloride 335245-55-1P, 2,6-Di-tert-butyl-4-[2-[(S)-cyclohexyl(4-(4-(3-Bromophenyl)-1H-imidazol-2-yl)methyl)cyclohexylamino]methyl]-1H-imidazol-4-yl]phenol hydrochloride 335245-56-2P, 4-[2-[(S)-Cyclohexyl(4-(4-(3-Bromophenyl)-1H-imidazol-2-yl)methyl)cyclohexylamino]methyl]-1H-imidazol-4-yl]-N,N-diethylaniline hydrochloride 335245-57-3P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl)methanamine 335245-59-5P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl)methanamine hydrochloride 335245-60-6P, N-[(S)-Cyclohexyl(4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)methyl)cyclohexanamine hydrochloride 335245-61-9P, N-[(S)-4-(3-Bromophenyl)-1H-imidazol-2-yl](cyclohexyl)methyl)cyclohexanamine hydrochloride 335245-62-0P, N-[(S)-Cyclohexyl(4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)methyl)cyclohexanamine 335245-65-3P, N-[(S)-Cyclohexyl(4-(4-fluorophenyl)-1H-imidazol-2-yl)methyl)cyclohexanamine 335245-68-6P, N-[(S)-Cyclohexyl(4-(3-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)methyl)cyclohexanamine 335245-69-7P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(3-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)methanamine 335245-70-0P, (S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-1-cyclohexyl-N-(cyclohexylmethyl)methanamine hydrochloride 335245-71-1P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(3-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)methanamine hydrochloride 335245-72-2P, (1R)-2-Cyclohexyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethanamine hydrochloride 335245-73-3P, N-[(1R)-2-Cyclohexyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethyl)cyclohexanamine 335245-74-4P, 4-[2-[(S)-Amino(cyclohexylmethyl)-1H-imidazol-4-yl]-N,N-diethylaniline hydrochloride 335245-75-5P, (S)-1-Cyclohexyl-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl)methanamine hydrochloride 335245-76-6P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl)methanamine hydrochloride 335245-78-8P, N-[(S)-Cyclohexyl(4-(3-fluorophenyl)-1H-imidazol-2-yl)methyl)cyclohexanamine hydrochloride 335245-79-9P, N-[(1R)-2-Cyclohexyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethyl)cyclohexanamine hydrochloride 335245-80-2P, 4-[2-[(S)-Amino(cyclohexylmethyl)-1H-imidazol-4-yl]-2,6-di-tert-butylphenol hydrochloride 335245-82-4P, (R)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl)methanamine

hydrochloride 335245-88-0P  
, (1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine hydrochloride 335245-91-5P, N-[(1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethyl)cyclohexanamine hydrochloride 335245-92-6P, (1R)-N-(Cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine hydrochloride 335246-24-7P, 4-[2-[(S)-Amino(cyclohexylmethyl)-1H-imidazol-4-yl]-2,6-di-tert-butylphenol 335246-43-0P, (S)-Cyclohexyl(4-phenyl-1H-imidazol-2-yl)methylamine 335246-46-3P, N-[(S)-Cyclohexyl(4-phenyl-1H-imidazol-2-yl)methyl)cyclobutanamine 335246-57-6P, (1R)-2-Cyclohexyl-1-[4-phenyl-1H-imidazol-2-yl]ethanamine 335246-94-1P, (S)-Cyclohexyl(4-(3,4-difluorophenyl)-1H-imidazol-2-yl)methanamine 335246-95-2P, (S)-Cyclohexyl(4-(3-fluoro-4-methoxyphenyl)-1H-imidazol-2-yl)methanamine 335246-96-3P, (R,S)-Cyclopropyl(4-(4-fluorophenyl)-1H-imidazol-2-yl)methanamine 335246-98-5P, (S)-Cyclohexyl-N-(cyclohexylmethyl)(4-phenyl-1H-imidazol-2-yl)methanamine 335246-99-6P, (R,S)-N-(Cyclopropyl(4-(4-fluorophenyl)-1H-imidazol-2-yl)methyl)cyclohexanamine 335247-00-2P, (S)-Cyclohexyl-N-(cyclopropylmethyl)(4-phenyl-1H-imidazol-2-yl)methanamine 335247-01-3P, (S)-Cyclohexyl-N-(cyclopropylmethyl)(4-(4-fluorophenyl)-1H-imidazol-2-yl)methanamine 335247-02-4P, N-[(S)-Cyclohexyl(4-(4-cyclohexylphenyl)-1H-imidazol-2-yl)methyl)cyclobutanamine 335247-04-6P, 4-[2-[(S)-Cyclohexyl(4-(4-cyclohexylmethyl)amino)methyl]-1H-imidazol-4-yl]-N,N-diethylaniline 335247-05-7P, 2,6-Di-tert-butyl-4-[2-[(S)-cyclohexyl(4-(4-cyclohexylmethyl)amino)methyl]-1H-imidazol-4-yl]phenol 335247-06-8P, 4-[2-[(S)-Cyclohexyl(4-(4-cyclohexylamino)methyl)-1H-imidazol-4-yl]-N,N-diethylaniline 335247-07-9P, N-[(S)-4-(3-Bromophenyl)-1H-imidazol-2-yl](cyclohexylmethyl)cyclohexanamine 335247-08-0P, (1R)-2-Cyclohexyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethanamine 335247-09-1P, 4-[2-[(S)-Amino(cyclohexylmethyl)-1H-imidazol-4-yl]-N,N-diethylaniline 335247-10-4P, (S)-1-Cyclohexyl-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl)methanamine 335247-11-5P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl)methanamine 335247-12-6P, N-[(S)-Cyclohexyl(4-(3-fluorophenyl)-1H-imidazol-2-yl)methyl)cyclohexanamine 335247-13-7P, (R)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl)methanamine 335247-14-8P, (1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine 335247-17-1P, (1R)-N-(Cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine 335247-20-6P, (1R)-1-[4-[1,1'-Biphenyl]-4-yl]-1H-imidazol-2-yl]-2-cyclohexylethanamine 335247-25-1P, N-[(R)-4-[3,5-Bis(trifluoromethyl)phenyl]-1H-imidazol-2-yl](cyclohexylmethyl)cyclohexanamine  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxid. inhibitors, and sodium channel modulators)  
RN 252309-65-2 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335242-98-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335242-99-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-00-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,N, $\alpha$ -trihexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-01-1 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-N-2-pyrimidinyl-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-03-3 CAPLUS

RN 280775-44-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335242-80-3 CAPLUS  
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[2-[(methylamino)methyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 335242-92-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- $\alpha$ -cyclohexyl-4-(4-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335242-94-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl- $\alpha$ -(4-methylpentyl)- (9CI) (CA INDEX NAME)



RN 335242-95-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)


CN 1H-Indole-3-ethanamine, N-methyl- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-04-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(2-phenylethyl)- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-05-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-N, $\alpha$ -bis(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-07-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335243-09-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-hexyl- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)




RN 335243-16-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -butyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-19-1 CAPLUS  
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335243-20-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N, $\alpha$ -dihexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-21-5 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -pentyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

Absolute stereochemistry.




●x HCl

RN 335243-10-2 CAPLUS  
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-12-4 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -(2-methylpropyl)-4-phenyl-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)




●x HCl

RN 335243-14-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-butyl-1-methyl- $\alpha$ -(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335243-15-7 CAPLUS  
CN Carbamic acid, [1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 335243-22-6 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methoxyphenyl)-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335243-23-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-[(2,6-dichlorophenyl)methyl]- $\alpha$ -hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-24-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-[(4-chlorophenyl)methyl]- $\alpha$ -hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-25-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(3-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335243-26-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-[(2-chlorophenyl)methyl]- $\alpha$ -hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-27-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-[(2-fluorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-28-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-butyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-29-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-N-(3-methylbutyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-30-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N,α-diethyl- (9CI) (CA INDEX NAME)




RN 335243-31-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-hexyl-N-pentyl-4-phenyl- (9CI) (CA INDEX NAME)



•x HCl


RN 335243-37-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-N-cyclohexyl-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



•x HCl


RN 335243-39-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-phenyl-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




•x HCl


RN 335243-40-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-4-(3-fluorophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 335243-32-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-33-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-34-0 CAPLUS  
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]-, butyl ester (9CI) (CA INDEX NAME)




RN 335243-35-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclopentyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-36-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-phenyl-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



•x HCl


RN 335243-41-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(3-fluoro-4-methoxyphenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-42-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(4-(trifluoromethyl)phenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-43-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(3-fluorophenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-46-4 CAPLUS  
CN 1H-Indazole-2-methanamine, 4-phenyl-α-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335243-47-5 CAPLUS  
CN 1H-Indole-3-ethanamine, 1-methyl-α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335243-50-0 CAPLUS  
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335243-51-1 CAPLUS



RN 335243-57-7 CAPLUS  
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-59-9 CAPLUS  
CN 1H-Indole-3-ethanamine, 6-fluoro-α-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-60-2 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-(4-nitrophenyl)-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335243-62-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(2-phenoxyethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335243-52-2 CAPLUS  
CN Benzamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-53-3 CAPLUS  
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-56-6 CAPLUS  
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-(4-nitrophenyl)-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-65-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-(benzo[b]thien-3-ylmethyl)-4-phenyl-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-68-0 CAPLUS  
CN Carbamic acid, [2-(6-chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335243-72-6 CAPLUS  
CN 1H-Indole-3-ethanamine, 6-chloro-α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335243-74-8 CAPLUS  
CN Carbamic acid, [(1R)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 335243-75-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -(2-methylpropyl)-4-phenyl-N-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-76-0 CAPLUS  
CN Carbanic acid, [phenyl(4-phenyl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335243-78-2 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ ,4-diphenyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335243-79-3 CAPLUS  
CN Carbanic acid, [(1R)-3-phenyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 335243-83-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ ,4-diphenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-84-0 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -(cyclohexylmethyl)-4-phenyl-N-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-85-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl- $\alpha$ -(2-phenylethyl)-N-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-86-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- $\alpha$ -(4,4,4-trifluorobutyl)- (9CI) (CA INDEX NAME)




RN 335243-87-3 CAPLUS  
CN Carbanic acid, [(4-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-80-6 CAPLUS  
CN Carbanic acid, [(1R)-2-cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-81-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl- $\alpha$ -(2-phenylethyl)-, hydrochloride, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




●x HCl

RN 335243-82-8 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -(cyclohexylmethyl)-4-phenyl-, hydrochloride, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl




RN 335243-88-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,  $\alpha$ -dicyclohexyl-4-[4-(methylsulfonyl)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-91-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335243-92-0 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335243-94-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-95-3 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -hexyl-4-phenyl-N-(phenylmethyl)- (9CI)  
(CA INDEX NAME)




RN 335244-02-5 CAPLUS  
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-04-7 CAPLUS  
CN Carbamic acid, [(1R)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)-2-cyclohexylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-11-6 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -(cyclohexylethyl)-, hydrochloride, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




•x HCl

RN 335244-12-7 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




•x HCl

RN 335244-26-3 CAPLUS  
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-27-4 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -(2-phenylethyl)-, hydrochloride, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




•x HCl

RN 335244-28-5 CAPLUS  
CN Carbamic acid, [(1R)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)-3-phenylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-29-6 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



•x HCl


RN 335244-30-9 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -(cyclohexylethyl)-N-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-31-0 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -(2-phenylethyl)-N-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335244-35-4 CAPLUS  
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-36-5 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -butyl-, hydrochloride (9CI) (CA INDEX NAME)




•x HCl

RN 335244-42-3 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -butyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




•x HCl


RN 335244-43-4 CAPLUS  
CN Carbamic acid, [1-(4-(4-methylphenyl)-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-44-5 CAPLUS  
CN Carbamic acid, [1-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-45-6 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methylphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-46-7 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -hexyl-4-(2-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-47-8 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -butyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-48-9 CAPLUS  
CN Carbamic acid, [1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



●x HCl


RN 335244-53-6 CAPLUS  
CN Carbamic acid, [1-[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-55-8 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)- $\alpha$ -hexyl-N-(phenylmethyl)-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 335244-54-7  
CMF C23 H28 Br N3




CM 2

CRN 64-19-7  
CMF C2 H4 O2




RN 335244-56-9 CAPLUS  
CN Carbamic acid, [(1S)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-49-0 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-50-3 CAPLUS  
CN Carbamic acid, [1-[4-(3-bromophenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-51-4 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-52-5 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)- $\alpha$ -hexyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 335244-57-0 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-58-1 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -ethyl-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




●x HCl

RN 335244-60-5 CAPLUS  
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -ethyl-N-(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-62-7 CAPLUS  
CN 1H-imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methylphenyl)-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 335244-63-8 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(2-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-64-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -pentyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-67-2 CAPLUS  
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 335244-68-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-bromophenyl)- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)




RN 335244-69-4 CAPLUS



● x HCl


RN 335244-73-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl- $\alpha$ -propyl-, hydrochloride, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl

RN 335244-74-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-bromophenyl)- $\alpha$ -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-75-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)- $\alpha$ -propyl-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-76-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)- $\alpha$ -propyl-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


CN Carbamic acid, [(1R)-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-70-7 CAPLUS  
CN Carbamic acid, [(1R)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-71-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -propyl-, hydrochloride, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● x HCl


RN 335244-72-9 CAPLUS  
CN Phenol, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)




RN 335244-77-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-[(3-chlorophenyl)methyl]- $\alpha$ -hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335244-78-5 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(3-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-79-6 CAPLUS  
CN Benzonitrile, 4-[2-[1-[(phenylmethyl)amino]heptyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 335244-80-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]- $\alpha$ -hexyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 335244-81-0 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -methyl-4-phenyl-, hydrochloride, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335244-82-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-alpha-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-83-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-alpha-hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-84-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-butyl-N-ethyl-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335244-85-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, alpha-methyl-4-phenyl-N-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)




RN 335244-90-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-alpha-hexyl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-91-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-alpha-hexyl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-92-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-alpha-hexyl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-93-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-alpha-hexyl-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335244-86-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, alpha-hexyl-4-phenyl-N-propyl-, (9CI) (CA INDEX NAME)




RN 335244-87-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, alpha-hexyl-4-(3-methoxyphenyl)-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-88-7 CAPLUS  
CN Benzonitrile, 4-[2-[(phenylmethyl)amino]heptyl]-1H-imidazol-4-yl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-89-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, alpha-hexyl-N-[(4-methoxyphenyl)methyl]-4-phenyl-, (9CI) (CA INDEX NAME)



●x HCl

RN 335244-95-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-alpha-(4-methylpentyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-97-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, alpha-hexyl-N-(2-methylpropyl)-4-phenyl-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 335244-96-7  
CMF C20 H31 N3




CM 2


CRN 64-19-7  
CMF C2 H4 O2




RN 335244-98-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-alpha-(4-methylpentyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-99-0 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335245-03-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- $\alpha$ -hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335245-04-0 CAPLUS  
CN Carbamic acid, [(1S)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-05-1 CAPLUS  
CN Carbamic acid, [(1R)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-17-5 CAPLUS  
CN 1H-Indole-3-ethanamine, 5-fluoro- $\alpha$ -(4-(4-fluorophenyl)-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-18-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl- (9CI) (CA INDEX NAME)




RN 335245-20-0 CAPLUS  
CN 1H-Indole-3-ethanamine, N-cyclobutyl-5-fluoro- $\alpha$ -(4-(4-fluorophenyl)-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-21-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- $\alpha$ -(3-methylbutyl)-, hydrochloride (9CI) (CA INDEX NAME)




RN 335245-06-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, N, $\alpha$ -dicyclohexyl-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335245-11-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-N-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 335245-13-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(3,4-dichlorophenyl)- $\alpha$ -hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335245-16-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-cyclohexyl- $\alpha$ -hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335245-22-2 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-4-(3,4-difluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-23-3 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-4-(3-fluoro-4-methoxyphenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl


RN 335245-24-4 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclopropyl-4-(4-fluorophenyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335245-25-5 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-4-(4-fluorophenyl)-N-(1-methylethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-26-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- $\alpha$ -cyclohexyl-4-(3,4-difluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-27-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)- $\alpha$ -hexyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335245-28-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, N- $\alpha$ -dicyclohexyl-4-(4-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




●x HCl

RN 335245-34-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- $\alpha$ -cyclohexyl-4-(4-(trifluoromethoxy)phenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-36-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl- $\alpha$ -(4-methylpentyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-37-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-N-(cyclopropylmethyl)-4-(4-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



●x HCl


RN 335245-29-9 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-N-(cyclohexylmethyl)-4-phenyl-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-30-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl- $\alpha$ -cyclopropyl-4-(4-fluorophenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-31-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-N-(cyclopropylmethyl)-4-phenyl-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)




●x HCl

RN 335245-38-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- $\alpha$ -cyclopentyl-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 335245-39-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- $\alpha$ -cyclohexyl-4-(4-cyclohexylphenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-40-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- $\alpha$ -(1-methylethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-41-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-[4-(trifluoromethyl)phenyl]-, (aS)-, acetate (9CI) (CA INDEX NAME)

CM 1

CRN 335243-42-0

CMF C21 H26 F3 N3

Absolute stereochemistry.



CM 2


CRN 64-19-7

CMF C2 H4 O2




RN 335245-46-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-[4-(methylthio)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-47-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-[4-(4-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)



RN 335245-54-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-[4-(diethylamino)phenyl]-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-55-1 CAPLUS  
CN Phenol, 4-[2-[(S)-cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-56-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-[4-(diethylamino)phenyl]-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

(aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335245-48-2 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-[3,5-bis(trifluoromethyl)phenyl]-N,α-dicyclohexyl-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335245-51-7 CAPLUS

CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-[3,4-difluorophenyl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335245-53-9 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-[3-bromophenyl]-N-cyclohexyl-N-(cyclohexylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-57-3 CAPLUS

CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-[4-fluorophenyl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335245-59-5 CAPLUS

CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-[4-fluorophenyl]-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-60-8 CAPLUS

CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-[4-(trifluoromethyl)phenyl]-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






●x HCl

RN 335245-61-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N,α-dicyclohexyl-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-62-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-[4-(trifluoromethyl)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-65-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cycloheptyl-α-cyclohexyl-4-(4-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-71-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-[3-(trifluoromethyl)phenyl]-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-72-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-(4-fluorophenyl)-, hydrochloride, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-73-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-α-(cyclohexylmethyl)-4-(4-fluorophenyl)-, (aR)- (9CI) (CA INDEX NAME)




RN 335245-68-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-[3-(trifluoromethyl)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-69-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-[3-(trifluoromethyl)phenyl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335245-70-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-cyclohexyl-N-(cyclohexylmethyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.



RN 335245-74-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-(4-(diethylamino)phenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-75-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-(3-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-76-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-(3-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-78-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-(3-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-79-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-α-(cyclohexylmethyl)-4-(4-fluorophenyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-80-2 CAPLUS  
CN Phenol, 4-[2-[(S)-aminocyclohexylmethyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-92-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)-4-(4-fluorophenyl)-α-(phenylmethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335246-24-7 CAPLUS  
CN Phenol, 4-[2-[(S)-aminocyclohexylmethyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335246-43-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



●x HCl

RN 335245-82-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-(4-fluorophenyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-88-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-(phenylmethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-91-5 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-α-(phenylmethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)




RN 335246-46-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-57-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-(cyclohexylmethyl)-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-94-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-(3,4-difluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-95-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-(3-fluoro-4-methoxyphenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-96-3 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclopropyl-4-(4-fluorophenyl)- (9CI)  
(CA INDEX NAME)




RN 335246-98-5 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-N-(cyclohexylmethyl)-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-99-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl- $\alpha$ -cyclopropyl-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 335247-00-2 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-N-(cyclopropylmethyl)-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-05-7 CAPLUS  
CN Phenol, 4-[2-[(S)-cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-06-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,  $\alpha$ -dicyclohexyl-4-[4-(diethylamino)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-07-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N,  $\alpha$ -dicyclohexyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-01-3 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-N-(cyclopropylmethyl)-4-(4-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-02-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- $\alpha$ -cyclohexyl-4-(4-cyclohexylphenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-04-6 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-N-(cyclohexylmethyl)-4-[4-(diethylamino)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-08-0 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -(cyclohexylmethyl)-4-(4-fluorophenyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-09-1 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-4-(4-(diethylamino)phenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-10-4 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-4-(3-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-11-5 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -cyclohexyl-N-(cyclohexylmethyl)-4-(3-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-12-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-(3-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-13-7 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-(4-fluorophenyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335247-14-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335247-17-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)-4-(4-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

yl)ethyl]benzenecarboximidamide 335243-71-5,  
N-[(1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxybenzenecarboximidamide 335244-54-7, (R,S)-N-Benzyl-1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-20-3, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-(4-aminobenzoyl)-1H-imidazole-2-methanamine 335246-23-6, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-2,6-di(tert-butyl)phenol 335246-41-8, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)hexylamine 335246-42-9, (R,S)-1-[4-(3-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine 335246-44-1, (R,S)-N-[1-[4-(2-Chlorophenyl)-1H-imidazol-2-yl]heptyl]cyclohexanamine 335246-47-4, (R,S)-N-[1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]heptyl]cyclobutanamine 335246-50-9, (R,S)-2-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335246-51-0, (R,S)-2-(1-Methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine 335246-54-3, (R,S)-2-(6-Chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine 335246-55-4, (R,S)-Phenyl(4-phenyl-1H-imidazol-2-yl)methylamine 335246-56-5, (1R)-3-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)-1-propanamine 335246-58-7, [4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]methanamine 335246-67-8, (1R)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-3-phenyl-1-propanamine 335246-69-0, (R,S)-1-[4-(4-Methylphenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-70-3, (R,S)-1-[4-(2-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine 335246-71-4, (R,S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-heptanamine 335246-72-5, (R,S)-1-[4-(4-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine 335246-73-6, (R,S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-74-7, (1S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-propanamine 335246-76-9, (R,S)-N-Benzyl-1-(4-(4-methylphenyl)-1H-imidazol-2-yl)-1-heptanamine 335246-77-0, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]benzonitrile 335246-78-1, (1R)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-butanamine 335246-79-2, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)-1-butanamine 335246-80-5, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-N,N-diethylaniline 335246-81-6, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)ethanamine 335246-83-8, (R,S)-1-[4-(2-Chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-84-9, (R,S)-N-Benzyl-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-85-0, (R,S)-N-Benzyl-1-[4-(2-chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-86-1, (R,S)-N-Benzyl-1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]heptylamine 335246-87-2, (R,S)-1-[4-(3,4-Dichlorophenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-89-4, (R,S)-N-[1-[4-(3,4-Dichlorophenyl)-1H-imidazol-2-yl]heptyl]cyclohexanamine 335246-90-7, (R,S)-N-[1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]heptyl]cyclohexanamine 335246-91-8, (R,S)-2-(5-Fluoro-1H-indol-3-yl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethylamine 335246-92-9, (R,S)-N-[2-(5-Fluoro-1H-indol-3-yl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethyl]cyclobutanamine 335246-93-0, (R,S)-N-[1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-4-methylpentyl]cyclohexanamine 335246-97-4, (R,S)-N-(Cyclohexylmethyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335247-16-0, N-[(1R)-1-(4-(4-Fluorophenyl)-1H-imidazol-2-yl)-2-phenylethyl]cyclohexanamine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USSS (Uses)


(drug candidate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)

RN 167983-80-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-(2-methylpropyl)-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


α-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-20-6 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(cyclohexylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-25-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-[3,5-bis(trifluoromethyl)phenyl]-N,α-dicyclohexyl-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 167983-80-4, (1S)-3-Methyl-1-(4-phenyl-1H-imidazol-2-yl)-1-butanamine 175531-38-1, (4-Phenyl-1H-imidazol-2-yl)methanamine 218944-40-2, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-nitrobenzoyl)-1H-imidazole-2-methanamine 218944-41-3, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-aminobenzoyl)-1H-imidazole-2-methanamine 218944-66-2, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-nitrophenyl)-1H-imidazole-2-methanamine 218944-68-4, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-aminophenyl)-1H-imidazole-2-methanamine 252279-15-5, (1R)-2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethanamine 252301-86-3, (R,S)-tert-Butyl [5-(benzylamino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]carbamate 252302-55-9, N-[(1S)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-1-hexanamine 252303-16-5, (1R)-N-(Cyclohexylmethyl)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 252306-13-1, (R,S)-N-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)-1,5-pentanediamine 335243-70-4, N-[(1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-




RN 175531-38-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-phenyl-, (9CI) (CA INDEX NAME)




RN 218944-40-2 CAPLUS  
CN Benzanide, N-[(4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl]-N-methyl-4-nitro-, (9CI) (CA INDEX NAME)



RN 218944-41-3 CAPLUS  
CN Benzanide, 4-amino-N-[(4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl]-N-methyl-, (9CI) (CA INDEX NAME)




RN 218944-66-2 CAPLUS  
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[2-[[methyl(4-nitrophenyl)amino]methyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 218944-68-4 CAPLUS


CN Phenol, 4-[2-[[[4-(aminophenyl)methylamino]methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)]- (9CI) (CA INDEX NAME)



RN 252279-15-5 CAPLUS


CN 1H-Indole-3-ethanamine, α-(4-(4-nitrophenyl)-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252301-86-3 CAPLUS


CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-(phenylmethyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252302-55-9 CAPLUS

CN 1H-Indole-3-ethanamine, N-hexyl-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-16-5 CAPLUS

CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-20-3 CAPLUS

CN Benzamide, 4-amino-N-[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 335246-23-6 CAPLUS

CN Phenol, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 335246-41-8 CAPLUS

CN 1H-Imidazole-2-methanamine, α-pentyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335246-42-9 CAPLUS

CN 1H-Imidazole-2-methanamine, α-hexyl-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-44-1 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-N-cyclohexyl-α-hexyl-



RN 252306-13-1 CAPLUS


CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-70-4 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-71-5 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335244-54-7 CAPLUS


CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-hexyl-N-

(9CI) (CA INDEX NAME)




RN 335246-47-4 CAPLUS

CN 1H-Imidazole-2-methanamine, N-cyclobutyl-4-(4-fluorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)




RN 335246-50-9 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-phenyl-α-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-51-0 CAPLUS

CN 1H-Indole-3-ethanamine, 1-methyl-α-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335246-54-3 CAPLUS

CN 1H-Indole-3-ethanamine, 6-chloro-α-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 335246-55-4 CAPLUS


CN 1H-Imidazole-2-methanamine,  $\alpha$ ,4-diphenyl- (9CI) (CA INDEX NAME)



RN 335246-56-5 CAPLUS


CN 1H-Imidazole-2-methanamine, 4-phenyl- $\alpha$ -(2-phenylethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335246-58-7 CAPLUS


CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)



RN 335246-67-8 CAPLUS


CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -(2-phenylethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-69-0 CAPLUS

CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 335246-70-3 CAPLUS

CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 335246-77-0 CAPLUS


CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 335246-78-1 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -propyl-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335246-79-2 CAPLUS


CN 1H-Imidazole-2-methanamine, 4-phenyl- $\alpha$ -propyl-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335246-80-5 CAPLUS


CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)



RN 335246-81-6 CAPLUS


CN 1H-Imidazole-2-methanamine,  $\alpha$ -methyl-4-phenyl-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-71-4 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)




RN 335246-72-5 CAPLUS

CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



RN 335246-73-6 CAPLUS


CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)



RN 335246-74-7 CAPLUS


CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- $\alpha$ -ethyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-76-9 CAPLUS

CN 1H-Imidazole-2-methanamine,  $\alpha$ -hexyl-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-83-8 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)




RN 335246-84-9 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)- $\alpha$ -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-85-0 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)- $\alpha$ -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-86-1 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]- $\alpha$ -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-87-2 CAPLUS


CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)- $\alpha$ -hexyl- (9CI) (CA INDEX NAME)




RN 335246-89-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(3,4-dichlorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)




RN 335246-90-7 CAPLUS  
CN 1H-Indole-3-ethanamine, 4-[1,1'-biphenyl]-4-yl-N-cyclohexyl-α-hexyl- (9CI) (CA INDEX NAME)




RN 335246-91-8 CAPLUS  
CN 1H-Indole-3-ethanamine, N-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 335246-92-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-cyclohexyl-4-(4-fluorophenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335246-93-0 CAPLUS




RN 335247-30-8 CAPLUS  
CN 1H-Indole-3-ethanamine, α-cyclohexyl-4-(4-fluorophenyl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335247-34-2 CAPLUS  
CN 1H-Indole-3-ethanamine, 4-(3-bromophenyl)-α-(4-methylpentyl)- (9CI) (CA INDEX NAME)




RN 335247-35-3 CAPLUS  
CN Carbanic acid, 1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]heptyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 335247-37-5, [4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-N-methylmethanamine  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(precursor; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)  
RN 335247-37-5 CAPLUS  
CN 1H-Indole-3-ethanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl- (9CI) (CA INDEX NAME)

CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-α-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 335246-97-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335247-16-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-α-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 335247-29-SP, tert-Butyl [(S)-cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]carbamate 335247-30-8P, (S)-Cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine 335247-34-2P, 1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-5-methyl-1-hexanamine 335247-35-3P, tert-Butyl [1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]heptyl]carbamate  
RL: RCT (Reactant); SPN (Synthetic preparation); PRSP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)  
RN 335247-29-5 CAPLUS  
CN Carbanic acid, 1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN  
ACCESSION NUMBER: 2001:279029 CAPLUS  
DOCUMENT NUMBER: 135:107278  
TITLE: Novel non-peptide ligands for the somatostatin set3 receptor  
AUTHOR(S): Moineau, C.; Contour-Galera, M.-O.; Poitout, L.; Morgan, B.; Gordon, T.; Roubert, P.; Thuriere, C.  
CORPORATE SOURCE: ZA de Courtaubouef, Institut Henri Beaufour, Les Ulis, F-91966, Fr.  
SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(8), 991-995  
CODEN: BWCLDS; ISSN: 0960-894X  
PUBLISHER: Elsevier Science Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB A series of imidazole derivs. has been prepared using high throughput parallel synthesis. Several compds. showed high affinity (Ki in 10-6-10-8 M range) and selectivity at recombinant human somatostatin receptor subtype 3 (hst3).  
IT 252279-09-7P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of phenylimidazolyl(indolyl)ethylamines as somatostatin receptor antagonists)  
RN 252279-09-7 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 252308-47-7P 252309-00-5P 252309-02-7P 252309-03-8P 252309-04-9P 252309-05-0P 252309-06-1P 252309-07-2P 335243-50-0P 335243-53-3P 349669-18-4P 349669-19-5P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation of phenylimidazolyl(indolyl)ethylamines as somatostatin receptor antagonists)  
RN 252308-47-7 CAPLUS  
CN Benzenecetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-00-5 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-02-7 CAPLUS  
CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-03-8 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN Benzenecarboximidamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-07-2 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HI

RN 335243-50-0 CAPLUS  
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-53-3 CAPLUS  
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



● HI

RN 252309-04-9 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-05-0 CAPLUS  
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252309-06-1 CAPLUS

Absolute stereochemistry.



RN 349668-18-4 CAPLUS  
CN Sthanimidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 349668-19-5 CAPLUS  
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 18 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:101103 CAPLUS


DOCUMENT NUMBER: 134:163050

TITLE: Preparation of hydantoin, thiohydantoin, pyrimidinone, and thioxypyrimidinone derivatives and their affinity for somatostatin receptors  
INVENTOR(S): Poitout, Lydie; Thureau, Christophe; Brault, Valerie  
SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S., Fr.  
SOURCE: PCT Int. Appl., 166 pp.




DOCUMENT TYPE: CODEN: PIXXD2  
LANGUAGE: Patent  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009090	A2	20010208	WO 2000-FR2164	20000728
WO 2001009090	A3	20020808		
W:	AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG			
FR 2796945	A1	20010202	FR 1999-9886	19990730
FR 2796945	B1	20020628		
CA 2380070	AA	20010208	CA 2000-2380070	20000728
AU 2000070091	A5	20010219	AU 2000-70091	20000728
BR 2000012852	A	20020430	BR 2000-12852	20000728
EP 1246807	A2	20010209	EP 2000-958634	20000728
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
NZ 516718	A	20030429	NZ 2000-516718	20000728
JP 200318011	T2	20030603	JP 2001-514294	20000728
US 6759415	B1	20040706	US 2002-48144	20020123
NO 200200463	A	20020213	NO 2002-463	20020129
US 200429908	A1	20041021	US 2004-813139	20040330
PRIORITY APPL. INFO.:			FR 1999-9886	A 19990730
OTHER SOURCE(S):	MARPAT 134:163050		WO 2000-FR2164	W 20000728
GI			US 2002-48144	A3 20020123



AB The title compds. I [R1 = carbocyclic or heterocyclic aryl radical optionally substituted or a nonarom. heterocyclic radical optionally substituted; R2 = H, alkyl, aryl; R3 = H, (CH2)pZ3, Z3 = alkyl, cycloalkyl, bisaryalkyl, diaryalkyl, Y1(CH2)p-phenyl-(X)n, carbocyclic or heterocyclic aryl, nonarom. heterocyclic radical, X1 = H, Cl, F, Br, I, CF3, NO2, CH, NH2, CN, N3, OCF3, alkyl, alkoxy, S-alkyl, (CH2)pNH2, (CH2)pNH-alkyl, (CH2)pN-dialkyl; Y1 = O, S, NH, -; R4 = (CH2)pZ4, Z4 = amino, alkylamino, N,N-dialkylamino; R5 = H, alkyl; X = O, S; p = 0-6; q = 1-5; n = 0, 1; provided that when n represents 0, m represents 1, 2 or 3, and when n represents 1, m represents 0 or 1, useful for treating pathol. conditions or diseases wherein somatostatin receptors are involved, were prepared E.g., benzyl (2S)-2-amino-3-(4-phenyl-1H-imidazol-2-yl)propanoate


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056729	A1	20000928	WO 2000-CA321	20000324
W:	AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2368047	AA	20000928	CA 2000-2368047	20000324
EP 1163238	A1	20011219	EP 2000-913979	20000324
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 2000010655	A	20020213	BR 2000-10655	20000324
TR 200102799	T2	20020722	TR 2001-200102799	20000324
NZ 514709	A	20030328	NZ 2000-514709	20000324
JP 2003524620	T2	20030819	JP 2000-606590	20000324
US 6750348	B1	20040615	US 2000-535314	20000324
AU 775123	B2	20040715	AU 2000-35460	20000324
NO 2001004593	A	20011029	NO 2001-4593	20010921
US 2004235823	A1	20041125	US 2004-837467	20040430
PRIORITY APPL. INFO.:			US 1999-125833P	P 19990324
OTHER SOURCE(S):	MARPAT 133:266589		US 2000-535314	A3 20000324
GI			WO 2000-CA321	W 20000324



AB Title compds. [Y(X)(Z)(CR1R2)nArCR3R4n(R5)(CR6R7)qR8, W = N, Y is void; WY = CH; R1 to R7 may be the same or different and are independently selected from H, straight, branched or cyclic C1-6 alkyl; R8 = substituted heterocyclic group or a substituted aromatic group; Ar = aromatic or heteroarom. ring each optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups; n and q are independently = 0-2; X = O, Q1; A = optionally substituted, saturated or


was prepared  
IT 325139-07-9  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of hydantoin, thiohydantoin, pyrimidinone, and thioxopyrimidinone derivs. and their affinity for somatostatin receptors)  
RN 325139-07-9 CAPIUS  
CN 1H-imidazole-2-propanoic acid,  $\beta$ -[[[(1,1-dimethylethoxy)carbonyl]amino]-4-phenyl-, phenylmethyl ester, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 325139-12-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of hydantoin, thiohydantoin, pyrimidinone, and thioxopyrimidinone derivs. and their affinity for somatostatin receptors)  
RN 325139-12-6 CAPIUS  
CN 1H-imidazole-2-propanoic acid,  $\beta$ -amino-4-phenyl-, phenylmethyl ester, dihydrochloride, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


L12 ANSWER 19 OF 36 CAPIUS COPYRIGHT 2005 ACS ON STN  
ACCESSION NUMBER: 2000:688234 CAPIUS  
DOCUMENT NUMBER: 133:266589  
TITLE: Preparation of heterocyclic derivatives as chemokine receptor antagonists effective against HIV, tumor, and allergy  
INVENTOR(S): Bridger, Gary; Skerl, Renato; Kaller, Al; Harwig, Curtis; Bogucki, David; Wilson, Trevor R.; Crawford, Jason; McEachern, Ernest J.; Atama, Ben; Nan, Siglao; Zhou, Yuanxi; Schols, Dominique  
PATENT ASSIGNEE(S): Anormed Inc., Can.  
SOURCE: PCT Int. Appl., 274 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

unsatd. 5 or 6-membered ring; P = optionally substituted carbon atom, optionally substituted nitrogen atom, sulfur or oxygen atom; B = optionally substituted 5 to 7-membered ring; Ring A and Ring B in the above formula can be connected to the group W from any position via the group V; V = bond, (CH2)m, CO, m = 0-2; Z = H, optionally substituted C1-6 alkyl group, CO-6 alkyl group substituted with an optionally substituted aromatic or heterocyclic group, optionally substituted CO-6 alkylamino, C3-7 cycloalkylamino group, optionally substituted carbonyl group or sulfonyl, pharmaceutically acceptable acid addition, salts, metal complexes, stereoisomers, isomer mixts., and pharmaceutical composition are prepared

Title compds. are having protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5 and inhibiting the subsequent binding of their natural ligands. Thus, the title compound I was prepared and tested for inhibition of HIV-1 NL4.3 or IIB replication in MT-4 cells and exhibited EC50's of less than 20 $\mu$ g/mL.

IT 297769-64-3P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of heterocyclic derivs. as chemokine receptor antagonists effective against HIV, tumor, and allergy)

RN 297769-64-3 CAPIUS  
CN 1,4-Benzenedimethanamine, N-[(4-phenyl-1H-imidazol-2-yl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RS FORMAT

L12 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 2000:457071 CAPLUS

DOCUMENT NUMBER: 133:89553

TITLE:

Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors. Gordon, Thomas B.; Morgan, Barry A.

PATENT ASSIGNEE(S): Societe de Conseil de Recherches et d'Applications

SCIENTIFIQUES S.A., Pr.

SOURCE: PCT Int. Appl., 95 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039130	A2	20000706	WO 1999-US31302	19991230
WO 2000039130	A3	20001102		
W: AS, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KE, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NS, SN, TD, TG				
CA 2356756	AA	20000706	CA 1999-2356756	19991230
EP 1140942	A2	20011010	EP 1999-968984	19991230
EP 1140942	B1	20040310		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO				
EP 1382607	A2	20040121	EP 2003-78315	19991230
EP 1382607	A3	20040630		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, FI, CY				
AT 261447	S	20040315	AT 1999-968984	19991230
ES 2215420	T3	20041001	ES 1999-968984	19991230
RU 2241712	C2	20041210	RU 2001-121317	19991230
NO 2001003281	A	20010829	NO 2001-3281	20010629
PRIORITY APPL. INFO.:				
			US 1998-114301P	P 19981231
			US 1998-224428	A1 19981231
			EP 1999-968984	A3 19991230
			WO 1999-US31302	W 19991230

OTHER SOURCE(S):

GI

MARPAT 133:89553






L12 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN  
 ACCESSION NUMBER: 1999:811276 CAPLUS  
 DOCUMENT NUMBER: 132:50255  
 TITLE: Preparation of cyclic somatostatin analogs  
 INVENTOR(S): Gordon, Thomas D.  
 PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques S.A., Pr.  
 SOURCES: PCT Int. Appl., 73 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965942	A1	19991223	WO 1999-US13304	19990611
W: AS, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GM, GR, HR, HU, ID, IL, IN, IS, JP, KS, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TW, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KD, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MM, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NS, SN, TD, TO				
CA 2335184	AA	19991223	CA 1999-2335184	19990611
AU 9948223	A1	20000105	AU 1999-48223	19990611
AU 745493	B2	20020321		
EP 1086131	A1	20010328	EP 1999-931793	19990611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IS, FI				
JP 2003518409	T2	20020625	JP 2000-554767	19990611
RU 2242481	C2	20041220	RU 2001-101530	19990611
TW 527361	B	20030411	TW 1999-88110016	19990615
NO 2000006320	A	20010212	NO 2000-6320	20001212
US 6602849	B1	20030805	US 2001-719784	20010214
PRIORITY APPL. INFO.:				
OTHER SOURCE(S): MARPAT 132:50255				
GI				


RN 252753-75-6 CAPLUS  
 CN Carbamic acid, [(1S)-1-[4-(3-methoxyphenyl)-1H-imidazol-2-yl]-2-phenylethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252753-98-3 CAPLUS  
 CN L-Tyrosinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-tryptophyl-D-tryptophyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N-[(1S)-1-[4-(3-methoxyphenyl)-1H-imidazol-2-yl]-2-phenylethyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A



AB Imidazole-containing somatostatin cyclic deriva. I [Y, Z = D- or L-natural or unnatural α-amino acid; n = 0-50, provided that both n cannot be zero at the same time; m = 1-10; a = H or R1; b = OH, OR1, or (un)substituted amino or a and b form an amide bond; R1 = H, alkyl, arylalkyl; R2 = H or (un)substituted alkyl, Ph, phenylalkyl, or heterocyclyl alkyl; R3, R4 = H or (un)substituted alkyl, cycloalkyl, aryl, or arylalkyl or R3 and R4 together with carbons to which they are attached are (un)substituted aryl; R5 = H or (un)substituted alkyl or arylalkyl; R6 = H, alkyl, alkoxy, arylalkyl, or arylalkoxy] were prepared which selectively bind to somatostatin receptor subtypes. Thus, cyclo[Tyr-D-Trp-Lys-Val-Phe(4-(3-methoxyphenyl)imidazole)-Gly] was prepared by a multistep procedure starting with cyclocondensation of benzyloxycarbonyl-L-phenylalanine with 2-bromo-3'-methoxyacetophenone to form 2-[(1S)-amino-2-phenylethyl]-4-(3-methoxyphenyl)imidazole, followed by protection, peptide coupling, and deprotection steps.


IT 252753-48-3P 252753-50-7P 252753-75-6P  
 252753-98-3P 252754-02-2P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of cyclic somatostatin analogs)  
 RN 252753-48-3 CAPLUS  
 CN 1H-imidazole-2-methanamine, 4-(3-methoxyphenyl)-α-(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252753-50-7 CAPLUS  
 CN Carbamic acid, [(1S)-1-[4-(3-methoxyphenyl)-1H-imidazol-2-yl]-2-phenylethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-B




RN 252754-02-2 CAPLUS  
 CN L-Valinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-D-tryptophyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-N-[(1S)-1-[4-(3-methoxyphenyl)-1H-imidazol-2-yl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L12 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 1999:795813 CAPLUS

DOCUMENT NUMBER: 132:35702

TITLE: Preparation of imidazolyl- $\beta$ -carbolines and related compounds as somatostatin receptor mediators and sodium channel blockers.  
INVENTOR(S): Thureau, Christophe Alain; Poitout, Lydie Francine; Galcera, Marie-odile; Moinet, Christophe Philippe; Gordon, Thomas D.; Morgan, Barry A.; Bigg, Dennis C. H.; Pomier, Jacques

PATENT ASSIGNEE(S): Societe De Conseil De Recherches Et D'applications Scientifiques S. A., Fr.

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXX02

LANGUAGE: Patent


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964420	A1	19991216	WO 1999-US12874	19990608
W: AR, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, ES, FI, GB, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2335339	AA	19991216	CA 1999-2335339	19990608
AU 9945536	A1	19991230	AU 1999-45536	19990608
AU 761020	B2	20030529		
EP 1086101	A1	20010328	EP 1999-928479	19990608
EP 1086101	B1	20021218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IS, FI				
JP 200317500	T2	20020618	JP 2000-553429	19990608
AT 229954	E	20030115	AT 1999-928479	19990608
ES 2188184	T3	20030616	ES 1999-928479	19990608


RN 252279-09-7 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252279-12-2 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252279-13-3 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-14-4 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-(4-nitrophenyl)-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252279-15-5 CAPLUS

NZ 508765	A	20031031	NZ 1999-508765	19990608
RU 2233841	C2	20040810	RU 2001-101433	19990608
NO 2000006268	A	20010129	NO 2000-6268	20001211
HK 1032049	A1	20030417	HK 2001-102432	20010404
US 6586445	B1	20030701	US 2001-719455	20010613
US 2004038970	A1	20040226	US 2003-383949	20030307
PRIORITY APPL. INFO.:			US 1998-89180P	P 19980612
			US 1998-97297	A1 19980612
			WO 1999-US12874	W 19990608
			US 2001-719455	A3 20010613


OTHER SOURCE(S): MARPAT 132:35702  
GI



AB Title compds. [I; dotted lines = optional double bonds; X = N, NR4; R1 = H, (CH2)mCO(CH2)nZ1, (CH2)mZ1, etc.; Z1 = (substituted) alkyl, benzothienyl, Ph, naphthyl, benzofuryl, thienyl, indolyl, etc.; R2 = alkyl, ACO2Z5, (substituted) Ph, etc.; Z5 = H, alkyl, aryl, aralkyl; R3 = H; R4 = CYNX1X2, COX2, X2; Y = O, S; X2 = (CH2)mY1X3; X3 = H, (substituted) alkyl, cycloalkyl, alkoxy, aryloxy, alkylamino, Ph, etc.; Y1 = O, S, NH, bond; R5 = alkyl, cycloalkyl, (substituted) Ph, furyl, thienyl, pyrrolyl, pyridinyl, etc.; R6 = H, PhSO2; R7 = H, alkyl, alkoxyalkyl, dialkylaminoalkyl; X1 = H, Cl, F, Br, Iodo, NO2, OH, CF3, alkyl, etc.; m = 0-6; n = 1-5], were prepared as drugs (no data). Thus, 2-[(1S)-amino-2-(3-indolyl)ethyl]-4-phenyl-1H-imidazole in CHCl3 was treated with p-anisaldehyde and CP3CO2H followed by 2 days stirring to give a residue which was stirred overnight with aminomethylpolystyrene resin in THF to give 78% 1,2,3,4-tetrahydro-1(RS)-(4-methoxyphenyl)-3(S)-(4-phenyl-1H-imidazol-2-yl)-9H-pyrido[3,4-b]indole.


IT 252279-08-6 252279-09-7 252279-12-2  
252279-13-3 252279-14-4 252279-15-5  
252279-34-8  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of imidazolyl- $\beta$ -carbolines and related compds. as somatostatin receptor mediators and sodium channel blockers)  
RN 252279-08-6 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-(4-nitrophenyl)-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252279-34-8 CAPLUS  
CN 1H-Indazole-2-methanamine,  $\alpha$ -(benzo[b]thien-3-ylmethyl)-4-phenyl-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 252279-23-5P 252279-24-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of imidazolyl- $\beta$ -carbolines and related compds. as somatostatin receptor mediators and sodium channel blockers)  
RN 252279-23-5 CAPLUS  
CN 1H-Indazole-2-methanamine,  $\alpha$ -(benzo[b]thien-3-ylmethyl)-4-phenyl-, monohydrochloride, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 252279-24-6 CAPLUS  
CN Carbamic acid, [(1R)-2-benzo[b]thien-3-yl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 1999:795794 CAPLUS

DOCUMENT NUMBER:

TITLE: Preparation of imidazolyl derivatives as agonists or antagonists of somatostatin receptors

INVENTOR(S): Thureau, Christophe Alain; Poitout, Lydie Francine; Galtiera, Marie-Odile; Gordon, Thomas D.; Morgan, Barry; Moine, Christophe Philippe

PATENT ASSIGNEE(S): Societe de Conseil de Recherches et d'Applications Scientifiques, S.A., Fr.

SOURCE: PCT Int. Appl., 342 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964401	A2	19991216	WO 1999-US12760	19990608
WO 9964401	A3	20030417		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RN: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BG, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2334945	AA	19991216	CA 1999-2334945	19990608
AU 9944257	A1	19991216	AU 1999-44257	19990608
AU 746963	B2	20020509		
EP 1086086	A1	20010328	EP 1999-927323	19990608
EP 1086086	B1	20041013		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 200321921	T2	20030812	JP 2000-553410	19990608
AT 279396	E	20041015	AT 1999-927323	19990608
NO 200006267	A	20010207	NO 2000-6267	20001211
US 2004176379	A1	20040909	US 2004-771725	20040204
PRIORITY APPLN. INFO.:			US 1998-89087P	P 19980612
			US 1998-96431	A1 19980612
			WO 1999-US12760	W 19990608
			US 2001-719457	A3 20010613

OTHER SOURCE(S): MARPAT 132:35701  
GI

252302-29-7P 252302-31-1P 252302-32-2P  
252302-35-5P 252302-37-7P 252302-39-9P  
252302-41-3P 252302-43-5P 252302-44-6P  
252302-46-8P 252302-47-9P 252302-48-0P  
252302-49-1P 252302-50-4P 252302-51-5P  
252302-52-6P 252302-53-7P 252302-54-8P  
252302-55-9P 252302-56-0P 252302-58-2P  
252302-60-6P 252302-61-7P 252302-63-9P  
252302-65-1P 252302-67-3P 252302-69-5P  
252302-71-9P 252302-74-2P 252302-77-5P  
252302-79-7P 252302-80-0P 252302-81-1P  
252302-82-2P 252302-83-3P 252302-84-4P  
252302-85-5P 252302-86-6P 252302-88-8P  
252302-89-9P 252302-90-2P 252302-91-3P  
252302-92-4P 252302-93-5P 252302-95-7P  
252302-96-8P 252302-97-9P 252302-98-0P  
252302-99-1P 252303-00-7P 252303-02-9P  
252303-03-0P 252303-04-1P 252303-05-2P  
252303-06-3P 252303-07-4P 252303-08-5P  
252303-09-6P 252303-10-9P 252303-12-1P  
252303-13-2P 252303-14-3P 252303-15-4P  
252303-16-5P 252303-17-6P 252303-18-7P  
252303-19-8P 252303-21-2P 252303-22-3P  
252303-25-6P 252303-26-7P 252303-27-8P  
252303-28-9P 252303-29-0P 252303-30-3P  
252303-32-5P 252303-33-6P 252303-34-7P  
252303-35-8P 252303-36-9P 252303-38-1P  
252303-39-2P 252303-40-5P 252303-41-6P  
252303-42-7P 252303-44-9P 252303-46-1P  
252303-47-2P 252303-50-7P 252303-53-0P  
252303-54-1P 252303-57-4P 252304-37-3P  
252304-38-4P 252304-39-5P 252304-40-6P  
252304-42-0P 252304-43-1P 252304-45-3P  
252304-46-4P 252304-47-5P 252304-48-6P  
252304-49-7P 252304-50-0P 252304-51-1P  
252304-52-2P 252304-53-3P 252304-58-8P  
252304-60-2P 252304-62-4P 252304-64-6P  
252304-66-8P 252304-70-4P 252304-72-6P  
252304-75-9P 252304-76-0P 252304-77-1P  
252304-79-3P 252304-80-6P 252304-81-7P  
252304-82-8P 252304-83-9P 252304-85-1P  
252304-87-3P 252304-88-4P 252304-90-8P  
252304-93-1P 252304-94-2P 252304-99-7P  
252305-49-0P 252305-50-3P 252305-51-4P  
252305-52-5P 252305-53-6P 252305-54-7P  
252305-55-8P 252305-56-9P 252305-57-0P  
252305-58-1P 252305-59-2P 252305-60-5P  
252305-61-6P 252305-63-8P 252305-64-9P  
252305-65-0P 252305-66-1P 252305-67-2P  
252305-68-3P 252305-69-4P 252305-70-7P  
252305-71-8P 252305-72-9P 252305-73-0P  
252305-74-1P 252305-75-2P 252305-76-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Preparation of imidazolyl deriva. as agonists or antagonists of somatostatin receptors)

RN 252292-70-9 CAPLUS  
CN 2-Furancarboxamide, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. [1; R1 = H, (CH2)mCO(CH2)m21, (CH2)m21, etc.; Z1 = (un)substituted benzo[b]thiophene, Ph, naphthyl, etc.; R2 = H, alkyl; R1 and R2 taken together with the nitrogen atoms to which they are attached form 11-IV; R3 = (CH2)mS(CH2)m22; S = O, S, CO, etc.; Z2 = H, alkyl, NH2, etc.; R4 = H, (CH2)mAl; Al = C(Y)N(X)X2; C(Y)X2; C(NH)X2, X2; Y = O, S; X1 = H, alkyl, etc.; X2 = alkyl, etc.; R5 = alkyl, (un)substituted aryl, etc.; R6 = H, alkyl; R7 = alkyl, (CH2)m24; Z4 = (un)substituted Ph, naphthyl, indolyl, etc.; m = 0-6] which are useful as agonists or antagonists of somatostatin receptors (no data), and for inhibiting the proliferation of Helicobacter pylori, were prepared. Thus, activating 2-furancarboxylic acid with carbonyldiimidazole followed by addition of 2-[(1S)-1-amino-2-(indol-3-yl)ethyl]-4-phenyl-1H-imidazole afforded 94% the title compound V. Compds. I are effective at 0.01-10.0 mg/kg/day.


IT 252292-69-6P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(Preparation of imidazolyl deriva. as agonists or antagonists of somatostatin receptors)

RN 252292-69-6 CAPLUS  
CN Carbamic acid, 1-[(1S)-2-(1H-indol-3-yl)-1-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 252292-70-9P 252292-72-1P 252292-74-3P  
252292-75-4P 252301-46-5P 252301-47-6P  
252301-48-7P 252301-49-8P 252301-50-1P  
252301-51-2P 252301-52-3P 252301-53-4P  
252301-54-5P 252301-56-7P 252301-57-8P  
252301-58-9P 252301-60-3P 252301-61-4P  
252301-62-5P 252301-63-6P 252301-64-7P  
252301-65-8P 252301-66-9P 252301-67-0P  
252301-70-5P 252301-71-6P 252301-72-7P  
252301-73-8P 252301-74-9P 252301-75-0P  
252301-76-1P 252301-77-2P 252301-79-4P  
252301-81-8P 252301-83-0P 252301-85-2P  
252301-86-3P 252301-87-4P 252301-88-5P  
252301-89-6P 252301-90-9P 252301-91-0P  
252301-92-1P 252301-93-2P 252301-94-3P  
252301-95-4P 252301-96-5P 252301-97-6P  
252301-98-7P 252301-99-8P 252302-00-4P  
252302-01-5P 252302-02-6P 252302-03-7P  
252302-04-8P 252302-05-9P 252302-06-0P  
252302-07-1P 252302-08-2P 252302-09-3P  
252302-10-6P 252302-11-7P 252302-12-8P  
252302-13-9P 252302-14-0P 252302-15-1P  
252302-16-2P 252302-17-3P 252302-18-4P  
252302-19-5P 252302-20-6P 252302-21-9P  
252302-22-0P 252302-23-1P 252302-24-2P  
252302-25-3P 252302-27-5P 252302-28-6P




RN 252292-72-1 CAPLUS  
CN 2,5-Pyrrolidinedione, 1-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]carbonyloxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-74-3 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-75-4 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252301-46-5 CAPLUS  
CN Carbamic acid, [5-[[[iminophenylmethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-47-6 CAPLUS  
CN Carbamic acid, [5-[[[2-chlorophenyl]iminomethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-48-7 CAPLUS  
CN Carbamic acid, [5-[[[4-chlorophenyl]iminomethyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-52-3 CAPLUS  
CN Carbamic acid, [5-[[[2,4-difluorophenyl]iminomethyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-53-4 CAPLUS  
CN Carbamic acid, [5-[[[imino[4-(trifluoromethoxy)phenyl]methyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-54-5 CAPLUS  
CN Carbamic acid, [5-[[[2,6-dichlorophenyl]iminomethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-49-8 CAPLUS  
CN Carbamic acid, [5-[[[imino[4-(methoxyphenyl)methyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-50-1 CAPLUS  
CN Carbamic acid, [5-[[[imino[4-(trifluoromethyl)phenyl]methyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-51-2 CAPLUS  
CN Carbamic acid, [5-[[[4-(1,1-dimethylethyl)phenyl]iminomethyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-56-7 CAPLUS  
CN Carbamic acid, [5-[[[2-[[[1,1-dimethylethyl]sulfonyl]-1-iminoethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-57-8 CAPLUS  
CN Carbamic acid, [5-[[[imino-2-thienylmethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)



● HI


RN 252301-58-9 CAPLUS  
CN Carbamic acid, [5-[[[1-iminoethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 252301-60-3 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-61-4 CAPLUS  
CN Ethanimidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252301-62-5 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[(1S)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




● HI

RN 252301-66-9 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)



● HI


RN 252301-67-0 CAPLUS  
CN Ethanimidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)



● HI

RN 252301-70-5 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-63-6 CAPLUS  
CN Ethanimidamide, N-[(1S)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252301-64-7 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HI


RN 252301-65-8 CAPLUS  
CN Ethanimidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)



● HI

RN 252301-71-6 CAPLUS  
CN Ethanimidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-72-7 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252301-73-8 CAPLUS  
CN Ethanimidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




• HI


RN 252301-74-9 CAPLUS  
CN Carbamic acid, [5-((4-phenyl-1H-imidazol-2-yl)-5-((2-pyridinylmethyl)amino)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-75-0 CAPLUS  
CN Carbamic acid, [5-(((2-chloro-3-quinolinyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-76-1 CAPLUS  
CN Carbamic acid, [5-((4-phenyl-1H-imidazol-2-yl)-5-(((2-quinolinylmethyl)amino)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-77-2 CAPLUS  
CN Carbamic acid, [5-((4-phenyl-1H-imidazol-2-yl)-5-(((4-pyridinylmethyl)amino)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-86-3 CAPLUS  
CN Carbamic acid, [5-((4-phenyl-1H-imidazol-2-yl)-5-((phenylmethyl)amino)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252301-87-4 CAPLUS  
CN Carbamic acid, [5-(((2-hydroxyphenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-88-5 CAPLUS  
CN Carbamic acid, [5-(((4-hydroxyphenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-89-6 CAPLUS  
CN Carbamic acid, [5-(((4-fluorophenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-79-4 CAPLUS  
CN Carbamic acid, [5-((4-phenyl-1H-imidazol-2-yl)-5-((2-pyridinylmethyl)amino)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252301-81-8 CAPLUS  
CN Carbamic acid, [5-(((1H-indol-3-yl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-83-0 CAPLUS  
CN 1H-Indole-6-carboxylic acid, 3-[[[5-(((1,1-dimethylethoxy)carbonyl)amino)-1-(4-phenyl-1H-imidazol-2-yl)pentyl)amino)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 252301-85-2 CAPLUS  
CN Carbamic acid, [5-(((1-methyl-1H-indol-3-yl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


RN 252301-90-9 CAPLUS  
CN Carbamic acid, [5-(((3-methoxyphenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-91-0 CAPLUS  
CN Carbamic acid, [5-(((4-methoxyphenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252301-92-1 CAPLUS  
CN Carbamic acid, [5-(((2-methoxyphenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-93-2 CAPLUS  
CN Carbamic acid, [5-(((2-nitrophenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-94-3 CAPLUS  
CN Carbamic acid, [5-(((4-nitrophenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)







RN 252301-95-4 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-dichlorophenyl)methylamino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-96-5 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-methoxy-2-nitrophenyl)methylamino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-97-6 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-bromophenyl)methylamino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-98-7 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[2-thienyl)methylamino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-03-7 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[2-(trifluoromethyl)phenyl)methylamino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252302-04-8 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[2-(trifluoromethyl)phenyl)methylamino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-05-9 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-bromophenyl)methylamino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-06-0 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-dimethylethylamino)phenyl)methylamino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-99-8 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[4,5-trimethoxyphenyl)methylamino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252302-00-4 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(phenylmethoxy)phenyl)methylamino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-01-5 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(phenylmethoxy)phenyl)methylamino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-02-6 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(phenylmethoxy)phenyl)methylamino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


RN 252302-07-1 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(trifluoromethoxy)phenyl)methylamino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-08-2 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(trifluoromethoxy)phenyl)methylamino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-09-3 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(trifluoromethoxy)phenyl)methylamino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-10-6 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(trifluoromethoxy)phenyl)methylamino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252302-11-7 CAPLUS  
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(trifluoromethoxy)phenyl)methylamino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-12-8 CAPLUS  
CN Carbamic acid, 5-[[[3-(4-methoxyphenoxy)phenyl]methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-13-9 CAPLUS  
CN 3-Quinolinemethanamine, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-14-0 CAPLUS  
CN 2-Quinolinemethanamine, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-15-1 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(4-

Absolute stereochemistry.




RN 252302-19-5 CAPLUS  
CN 2-Quinolinemethanamine, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252302-20-8 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(4-pyridinylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-21-9 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(2-pyridinylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


pyridinylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-16-2 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(2-pyridinylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-17-3 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(3-pyridinylmethyl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252302-18-4 CAPLUS  
CN 3-Quinolinemethanamine, 2-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252302-22-0 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252302-23-1 CAPLUS  
CN 3-Quinolinemethanamine, 2-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252302-24-2 CAPLUS  
CN 2-Quinolinemethanamine, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 252302-25-3 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252302-27-5 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252302-28-6 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(3-pyridinylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-35-5 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-pyridinylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-37-7 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(3-pyridinylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-39-9 CAPLUS  
CN 3-Quinolinemethanamine, 2-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-39-7 CAPLUS  
CN 3-Quinolinemethanamine, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-31-1 CAPLUS  
CN 2-Quinolinemethanamine, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-32-2 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(4-pyridinylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-41-3 CAPLUS  
CN 2-Quinolinemethanamine, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-43-5 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(4-pyridinylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-44-6 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-pyridinylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-46-8 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-47-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-48-0 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-53-7 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-54-8 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(1,1-dimethylethyl)phenylmethyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-55-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(2-methoxyphenyl)-α-(4-phenyl-1H-imidazol-2-yl)-N-[2-(phenylmethoxy)ethyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-49-1 CAPLUS  
CN 1H-Indole-3-ethanamine, N-pentyl-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-50-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[3-(methylthio)propyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-51-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-52-6 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[2-(phenylmethoxy)ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252302-56-0 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)




RN 252302-58-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)




RN 252302-60-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-butyl-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)




RN 252302-61-7 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-pentyl-, (αS)- (9CI) (CA INDEX NAME)




RN 252302-63-9 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[3-(methylthio)propyl]- (9CI) (CA INDEX NAME)




RN 252302-65-1 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)- $\alpha$ -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 252302-67-3 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-(phenylmethoxy)ethyl)- (9CI) (CA INDEX NAME)




RN 252302-69-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)- $\alpha$ -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)





RN 252302-79-7 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-80-0 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-pentyl-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252302-71-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]- $\alpha$ -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 252302-74-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-hexyl- $\alpha$ -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252302-77-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 252302-81-1 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-82-2 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[2-(phenylmethoxy)ethyl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-83-3 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-84-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-85-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-hexyl- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-86-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-88-8 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-89-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-butyl- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-90-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-91-3 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[2-(phenylmethoxy)ethyl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-92-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-93-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(1,1-dimethylethyl)phenylmethyl]- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-95-7 CAPLUS  
CN 1H-Indole-3-ethanamine, N-hexyl- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-96-8 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(phenylmethyl)-, ( $\alpha$ R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-97-9 CAPLUS  
CN Phenol, 2-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-98-0 CAPLUS  
CN Phenol, 4-[[[(1R)-2-[(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-99-1 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-00-7 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-05-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-06-3 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-07-4 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(4-thienyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 252303-02-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-03-0 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-04-1 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)


RN 252303-08-5 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(3,4,5-trimethoxyphenyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-09-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-10-9 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(4-(trifluoromethoxy)phenyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 252303-12-1 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-13-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[[3-fluoro-4-methoxyphenyl]methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-18-7 CAPLUS  
CN 1H-Indole-3-ethanamine, N-hexyl-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-19-8 CAPLUS  
CN Carbamic acid, [(5S)-5-[(4-morpholinylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-21-2 CAPLUS  
CN Carbamic acid, [(5S)-5-(4-phenyl-1H-imidazol-2-yl)-5-[(3-thiazolidinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 252303-14-3 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-15-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)-α-(4-phenyl-1H-imidazol-2-yl)-N-[2-(phenylmethoxy)ethyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-16-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-17-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-22-3 CAPLUS  
CN Carbamic acid, [(5S)-5-[[4-(aminocarbonyl)-1-piperidinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-25-6 CAPLUS  
CN Carbamic acid, [(5S)-5-(4-phenyl-1H-imidazol-2-yl)-5-[[4-(phenyl-1-piperazinyl)carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-26-7 CAPLUS  
CN Carbamic acid, [(5S)-5-(4-phenyl-1H-imidazol-2-yl)-5-[[1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 252303-27-8 CAPLUS  
CN Carbamic acid, [(5S)-5-[[4-(phenyl-1H-imidazol-2-yl)-5-[[[4-(phenylmethyl)-1-piperazinyl]carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-28-9 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(4-fluorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-29-0 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-34-7 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(4-chlorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-35-8 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(2-pyridinyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-36-9 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(phenylmethyl)-1-piperidinyl]carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-30-3 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(3-chlorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-32-5 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(4-nitrophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-33-6 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-38-1 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(1,2-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-39-2 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-(3-(trifluoromethyl)phenyl)-1-piperazinyl]carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-40-5 CAPLUS  
CN Carbamic acid, [(5S)-5-[[[4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-41-6 CAPLUS  
CN Carbanic acid, [(5S)-5-[[[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-42-7 CAPLUS  
CN Carbanic acid, [(5S)-5-[[[4-(4-hydroxyphenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-44-9 CAPLUS  
CN Carbanic acid, [(5S)-5-[[[4-(2,4-dimethylphenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 252303-53-0 CAPLUS  
CN Carbanic acid, [(5S)-5-[[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-54-1 CAPLUS  
CN Carbanic acid, [(5S)-5-[[[4-(diphenylmethyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-57-4 CAPLUS  
CN Carbanic acid, [(5S)-5-[[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-46-1 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[[[(1S)-5-[[[1,1-dimethylethoxycarbonyl]amino]-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-47-2 CAPLUS  
CN Carbanic acid, [(5S)-5-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-50-7 CAPLUS  
CN Carbanic acid, [(5S)-5-[[[4-(2-furanylcarbonyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 252304-37-3 CAPLUS  
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252304-38-4 CAPLUS  
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-chloro-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252304-39-5 CAPLUS  
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-chloro-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252304-40-8 CAPLAUS  
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-methoxy-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252304-42-0 CAPLAUS  
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(trifluoromethyl)-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252304-43-1 CAPLAUS  
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(1,1-dimethylethyl)-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252304-45-3 CAPLAUS




● HI

RN 252304-49-7 CAPLAUS  
CN 2-Thiophenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, monohydride (9CI) (CA INDEX NAME)



● HI


RN 252304-50-0 CAPLAUS  
CN Ethanimidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252304-51-1 CAPLAUS  
CN 4-Morpholinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2,4-difluoro-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252304-46-4 CAPLAUS  
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(trifluoromethoxy)-, monohydride (9CI) (CA INDEX NAME)



● HI

RN 252304-47-5 CAPLAUS  
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2,6-dichloro-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252304-48-6 CAPLAUS  
CN Ethanimidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-((1,1-dimethylethyl)sulfonyl)-, monohydride (9CI) (CA INDEX NAME)


RN 252304-52-2 CAPLAUS  
CN 3-Thiazolidinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-53-3 CAPLAUS  
CN 1,4-Piperidinedicarboxamide, N1-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-58-8 CAPLAUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-60-2 CAPLAUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-62-4 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-64-6 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-66-8 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-70-4 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-77-1 CAPLUS  
CN 1-Piperidinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 252304-79-3 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-80-6 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(3-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-72-6 CAPLUS  
CN 2-[1H]-[aquinolinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3,4-dihydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252304-75-9 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-76-0 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-81-7 CAPLUS  
CN 1,3,5-Triaza[4.5]decane-8-carboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-82-8 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-83-9 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-85-1 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-87-3 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[[[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-88-4 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-90-8 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252305-49-0 CAPLUS  
CN 1H-Indole-5-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-50-3 CAPLUS  
CN 1H-Indole-3-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)



RN 252305-51-4 CAPLUS  
CN 1H-Indole-4-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-52-5 CAPLUS  
CN 1H-Indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252304-93-1 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-94-2 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-99-7 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252305-53-6 CAPLUS  
CN 1H-Indole-2-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 252305-54-7 CAPLUS  
CN 1H-Indole-2-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-hydroxy- (9CI) (CA INDEX NAME)




RN 252305-55-8 CAPLUS  
CN 1H-Indole-2-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 252305-56-9 CAPLUS  
CN 1H-Indole-3-butamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-57-0 CAPLUS  
CN 1H-Indole-3-propanamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-58-1 CAPLUS  
CN 1H-indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-hydroxy- (9CI) (CA INDEX NAME)




RN 252305-59-2 CAPLUS  
CN 1H-indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-bromo- (9CI) (CA INDEX NAME)




RN 252305-60-5 CAPLUS  
CN 1H-indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 252305-61-6 CAPLUS  
CN Benzo[b]thiophene-2-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-63-8 CAPLUS  
CN Benzo[b]thiophene-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-69-4 CAPLUS  
CN 2-Quinolincarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 252305-70-7 CAPLUS  
CN 2-Quinolincarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-71-8 CAPLUS  
CN 2-Pyridinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-72-9 CAPLUS  
CN Acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-(phenylthio)- (9CI) (CA INDEX NAME)




RN 252305-73-0 CAPLUS  
CN 1-Naphthalenecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-64-9 CAPLUS  
CN 2-Benzofuranecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-65-0 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3,4-dichloro- (9CI) (CA INDEX NAME)




RN 252305-66-1 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252305-67-2 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 252305-68-3 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 252305-74-1 CAPLUS  
CN 8-Quinolincarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)



RN 252305-75-2 CAPLUS  
CN 3-Quinolincarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)



RN 252305-76-3 CAPLUS  
CN 3-Quinolincarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




IT 252305-78-5P 252305-79-6P 252305-80-9P

252305-82-1P 252305-83-2P 252305-84-3P  
 252305-85-4P 252305-86-5P 252305-87-6P  
 252305-88-7P 252305-89-8P 252305-90-1P  
 252305-91-2P 252305-92-3P 252305-93-4P  
 252305-94-5P 252305-95-6P 252305-96-7P  
 252305-97-8P 252306-00-6P  
 252306-01-7P 252306-02-8P 252306-03-9P  
 252306-05-1P 252306-06-2P 252306-07-3P  
 252306-08-4P 252306-09-5P 252306-10-6P  
 252306-11-9P 252306-12-0P 252306-13-1P  
 252306-14-2P 252306-15-3P 252306-16-4P  
 252306-17-5P 252306-19-7P 252306-20-0P  
 252306-21-1P 252306-22-2P 252306-23-3P  
 252306-24-4P 252306-25-5P 252306-26-6P  
 252306-27-7P 252306-29-9P 252306-31-3P  
 252306-32-4P 252306-34-6P 252306-35-7P  
 252306-36-8P 252306-37-9P 252306-39-1P  
 252306-40-4P 252306-41-5P 252306-42-6P  
 252306-65-3P 252306-66-4P 252306-67-5P  
 252306-68-6P 252306-69-7P 252306-70-0P  
 252306-71-1P 252306-72-2P 252306-73-3P  
 252306-74-4P 252306-84-6P 252306-85-7P  
 252306-86-8P 252306-87-9P 252306-88-0P  
 252306-89-1P 252306-90-4P 252306-91-5P  
 252306-92-6P 252306-93-7P 252306-94-8P  
 252306-95-9P 252306-96-0P 252306-97-1P  
 252306-98-2P 252306-99-3P 252307-00-9P  
 252307-01-0P 252307-02-1P 252307-04-3P  
 252307-05-4P 252307-06-5P 252307-07-6P  
 252307-09-8P 252307-10-1P 252307-11-2P  
 252307-12-3P 252307-13-4P 252307-17-8P  
 252307-19-0P 252307-21-4P 252307-22-5P  
 252307-23-6P 252307-24-7P 252307-26-9P  
 252307-27-0P 252307-28-1P 252307-29-2P  
 252307-30-5P 252307-31-6P 252307-32-7P  
 252307-33-8P 252307-34-9P 252307-36-1P  
 252307-37-2P 252307-38-3P 252307-39-4P  
 252307-40-7P 252307-41-8P 252307-42-9P  
 252307-43-0P 252307-45-2P 252307-46-3P  
 252307-47-4P 252307-48-5P 252307-49-6P  
 252307-50-9P 252307-51-0P 252307-52-1P  
 252307-53-2P 252307-54-3P 252307-55-4P  
 252307-56-5P 252307-57-6P 252307-58-7P  
 252307-59-8P 252307-60-1P 252307-61-2P  
 252307-62-3P 252307-63-4P 252307-64-5P  
 252307-65-6P 252307-67-8P 252307-68-9P  
 252307-69-0P 252307-70-3P 252307-71-4P  
 252307-72-5P 252307-73-6P 252307-75-8P  
 252307-76-9P 252307-77-0P 252307-78-1P  
 252307-79-2P 252307-80-5P 252307-81-6P  
 252307-82-7P 252307-83-8P 252307-85-0P  
 252307-86-1P 252307-88-3P 252307-89-4P  
 252307-90-7P 252307-91-8P 252307-92-9P  
 252307-93-0P 252307-94-1P 252307-95-2P  
 252307-96-3P 252307-97-4P 252307-98-5P  
 252307-99-6P 252308-01-3P 252308-02-4P  
 252308-03-5P 252308-04-6P 252308-05-7P  
 252308-06-8P 252308-07-9P 252308-08-0P  
 252308-10-4P 252308-11-5P 252308-13-7P  
 252308-14-8P 252308-15-9P 252308-16-0P  
 252308-17-1P 252308-18-2P 252308-19-3P  
 252308-21-7P 252308-22-8P 252308-23-9P  
 252308-24-0P 252308-25-1P 252308-26-2P  
 252308-27-3P 252308-28-4P 252308-30-8P  
 252308-31-9P 252308-32-0P 252308-33-1P


252308-35-3P 252308-36-4P 252308-37-5P  
 252308-38-6P 252308-39-7P 252308-41-1P  
 252308-42-2P 252308-43-3P 252308-44-4P  
 252308-45-5P 252308-46-6P 252308-47-7P  
 252308-48-8P 252308-49-9P 252308-52-4P  
 252308-53-5P 252308-54-6P 252308-55-7P  
 252308-57-9P 252308-58-0P 252308-59-1P  
 252308-60-4P 252308-62-6P 252308-63-7P  
 252308-64-8P 252308-65-9P 252308-66-0P  
 252308-67-1P 252308-79-5P 252308-81-9P  
 252308-82-0P 252308-83-1P 252308-84-2P  
 252308-85-3P 252308-86-4P 252308-87-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of imidazolyl deriva. as as agonists or antagonists of histaminergic receptors)


RN 252305-78-5 CAPLUS  
 CN 4-Quinolincarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-79-6 CAPLUS  
 CN 1-Isoquinolinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-80-9 CAPLUS  
 CN Propanamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 252305-82-1 CAPLUS  
 CN 2-Thiopheneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-83-2 CAPLUS  
 CN Acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-(2-pyrimidinylthio)- (9CI) (CA INDEX NAME)




RN 252305-84-3 CAPLUS  
 CN 3-Pyridinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-85-4 CAPLUS  
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 252305-86-5 CAPLUS  
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-chloro- (9CI) (CA INDEX NAME)




RN 252305-87-6 CAPLUS  
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 252305-88-7 CAPLUS  
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-bromo- (9CI) (CA INDEX NAME)




RN 252305-89-8 CAPLUS  
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-bromo- (9CI) (CA INDEX NAME)




RN 252305-90-1 CAPLUS  
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-bromo- (9CI) (CA INDEX NAME)




RN 252305-91-2 CAPLUS  
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 252305-92-3 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 252305-93-4 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 252305-94-5 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252305-95-6 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252305-96-7 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252305-97-8 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252305-99-0 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252306-00-6 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252306-01-7 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252306-02-8 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252306-03-9 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252306-05-1 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252306-06-2 CAPLUS  
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 252306-07-3 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-08-4 CAPLUS  
CN 1,5-Pentanediamine, N1-[(2-chloro-3-quinolinyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-09-5 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(2-quinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-10-8 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 252306-11-9 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-12-0 CAPLUS  
CN 1H-Indole-6-carboxylic acid, 3-[[[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 252306-13-1 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(phenylmethyl)- (9CI) (CA INDEX NAME)







RN 252306-14-2 CAPLUS  
CN Phenol, 2-[[[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 252306-15-3 CAPLUS  
CN Phenol, 4-[[[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 252306-16-4 CAPLUS  
CN 1,5-Pentanediamine, N1-[(4-fluorophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-17-5 CAPLUS  
CN 1,5-Pentanediamine, N1-[(3-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-19-7 CAPLUS  
CN 1,5-Pentanediamine, N1-[(4-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-25-5 CAPLUS  
CN 1,5-Pentanediamine, N1-[(4-bromophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-26-6 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-27-7 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252306-29-9 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[(4-phenylmethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252306-31-3 CAPLUS  
CN 1,5-Pentanediamine, N1-[(2-fluorophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-20-0 CAPLUS  
CN 1,5-Pentanediamine, N1-[(2-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-21-1 CAPLUS  
CN 1,5-Pentanediamine, N1-[(2-nitrophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-22-2 CAPLUS  
CN 1,5-Pentanediamine, N1-[(4-nitrophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-23-3 CAPLUS  
CN 1,5-Pentanediamine, N1-[(3,4-dichlorophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-24-4 CAPLUS  
CN 1,5-Pentanediamine, N1-[(3-methoxy-2-nitrophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-32-4 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[(2-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252306-34-6 CAPLUS  
CN 1,5-Pentanediamine, N1-[(1,1'-biphenyl)-4-ylmethyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-35-7 CAPLUS  
CN 1,5-Pentanediamine, N1-[(2-bromophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-36-8 CAPLUS  
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[(4-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252306-37-9 CAPLUS  
CN 1,5-Pentanediamine, N1-[(4-{3-(dimethylamino)propoxy}phenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-39-1 CAPLUS  
CN 1,5-Pentanediamine, N1-[(3-fluoro-4-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-40-4 CAPLUS  
CN 1,5-Pentanediamine, N1-[(4-(1,1-dimethylethyl)phenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 252306-41-5 CAPLUS  
CN 1,5-Pentanediamine, N1-[(3-bromophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 252306-42-6 CAPLUS  
CN 1,5-Pentanediamine, N1-[(3-(4-methoxyphenoxy)phenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-65-3 CAPLUS  
CN Propanamide, 3-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


(methylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-70-0 CAPLUS  
CN Benzanide, 4-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-71-1 CAPLUS  
CN Propanamide, 2-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-72-2 CAPLUS  
CN Pentanamide, 5-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-66-4 CAPLUS  
CN Acetamide, 2-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-67-5 CAPLUS  
CN Butanamide, 4-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-68-6 CAPLUS  
CN Hexanamide, 6-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-69-7 CAPLUS  
CN Acetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-




RN 252306-73-3 CAPLUS  
CN Benzanide, 4-(aminomethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-74-4 CAPLUS  
CN Benzeneacetamide, 4-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-84-6 CAPLUS  
CN Benzeneacetamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-85-7 CAPLUS  
CN Benzeneacetamide, 3-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-86-8 CAPLUS  
CN Benzeneacetamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-87-9 CAPLUS  
CN Benzeneacetamide, 2-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-91-5 CAPLUS  
CN Benzeneacetamide, 3-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-92-6 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-93-7 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-88-0 CAPLUS  
CN Benzeneacetamide, 3-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-89-1 CAPLUS  
CN Benzeneacetamide, 4-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-90-4 CAPLUS  
CN Benzeneacetamide, 2-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-94-8 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-95-9 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-96-0 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-97-1 CAPLUS  
CN Benzenesacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-98-2 CAPLUS  
CN Benzenesacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-99-3 CAPLUS  
CN Benzenesacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-04-3 CAPLUS  
CN Benzenesacetamide, 4-(dimethylamino)-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-05-4 CAPLUS  
CN Benzenesacetamide, 3,4-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-06-5 CAPLUS  
CN Benzenesacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-00-9 CAPLUS  
CN Benzenesacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-01-0 CAPLUS  
CN Benzenesacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-02-1 CAPLUS  
CN Benzenesacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-07-6 CAPLUS  
CN Benzenesacetamide, 4-methyl-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-09-8 CAPLUS  
CN Benzenesacetamide, 4-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-10-1 CAPLUS  
CN Benzenesacetamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-11-2 CAPLUS  
CN Benzenacetamide, 2-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-12-3 CAPLUS  
CN Benzenacetamide, 3-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-13-4 CAPLUS  
CN Benzenacetamide, 4-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-17-8 CAPLUS  
CN Benzenacetamide, 2-bromo-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-19-0 CAPLUS  
CN Benzenacetamide, 3-bromo-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-21-4 CAPLUS  
CN Benzenacetamide, 4-bromo-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-22-5 CAPLUS  
CN Benzenacetamide, 2-fluoro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-23-6 CAPLUS  
CN Benzenacetamide, 3-fluoro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-24-7 CAPLUS  
CN Benzenacetamide, 4-fluoro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-26-9 CAPLUS  
CN Benzenacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-27-0 CAPLUS  
CN Benzenacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-28-1 CAPLUS  
CN Benzenacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-29-2 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-30-5 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252307-31-6 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-36-1 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 252307-35-0  
CMF C28 H26 N4 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 252307-37-2 CAPLUS  
CN Benzeneacetamide, 4-(dimethylamino)-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-32-7 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-33-8 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-34-9 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-38-3 CAPLUS  
CN Benzeneacetamide, 3,4-dichloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-39-4 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-40-7 CAPLUS  
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-41-8 CAPLUS  
CN Benzeneacetamide, 4-hydroxy-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-42-9 CAPLUS  
CN Benzeneacetamide, 2,4-difluoro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252307-43-0 CAPLUS  
CN Carbanic acid, [5-[(1H-indol-5-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-49-6 CAPLUS  
CN Carbanic acid, [5-[(5-methoxy-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252307-50-9 CAPLUS  
CN Carbanic acid, [5-[(5-hydroxy-1H-indol-2-yl)carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-51-0 CAPLUS  
CN Carbanic acid, [5-[(5-methoxy-1H-indol-2-yl)carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-52-1 CAPLUS  
CN Carbanic acid, [5-[(4-(1H-indol-3-yl)-1-oxobutyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-45-2 CAPLUS  
CN Carbanic acid, [5-[(1H-indol-3-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252307-46-3 CAPLUS  
CN Carbanic acid, [5-[(1H-indol-4-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-47-4 CAPLUS  
CN Carbanic acid, [5-[(1H-indol-2-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-48-5 CAPLUS  
CN Carbanic acid, [5-[(1H-indol-3-ylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


RN 252307-53-2 CAPLUS  
CN Carbanic acid, [5-[(3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-54-3 CAPLUS  
CN Carbanic acid, [5-[(5-hydroxy-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-55-4 CAPLUS  
CN Carbanic acid, [5-[(5-bromo-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-56-5 CAPLUS  
CN Carbanic acid, [5-[(2-methyl-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-57-6 CAPLUS  
CN Carbanic acid, [5-[(benzo[b]thian-2-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-58-7 CAPLAUS  
CN Carbamic acid, 5-[(benzo[h]thien-3-ylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-59-8 CAPLAUS  
CN Carbamic acid, 5-[(2-benzofuranylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-60-1 CAPLAUS  
CN Carbamic acid, 5-[(3,4-dichlorophenylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-61-2 CAPLAUS  
CN Carbamic acid, 5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3,4,5-trimethoxyphenylacetyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-67-8 CAPLAUS  
CN Carbamic acid, 5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-pyridinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-68-9 CAPLAUS  
CN Carbamic acid, 5-[(4-phenyl-1H-imidazol-2-yl)-5-[(phenylthio)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-69-0 CAPLAUS  
CN Carbamic acid, 5-[(1-naphthalenylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-70-3 CAPLAUS  
CN Carbamic acid, 5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-62-3 CAPLAUS  
CN Carbamic acid, 5-[(4-methylphenylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252307-63-4 CAPLAUS  
CN Carbamic acid, 5-[(4-hydroxyphenylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-64-5 CAPLAUS  
CN Carbamic acid, 5-[(2,4-difluorophenylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-65-6 CAPLAUS  
CN Carbamic acid, 5-[(2-furanylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


INDEX NAME)



RN 252307-71-4 CAPLAUS  
CN Carbamic acid, 5-[(4-phenyl-1H-imidazol-2-yl)-5-[(8-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-72-5 CAPLAUS  
CN Carbamic acid, 5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-73-6 CAPLAUS  
CN Carbamic acid, 5-[(4-phenyl-1H-imidazol-2-yl)-5-[(4-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)







RN 252307-75-8 CAPLUS  
CN Carbamic acid, [5-[(1-isoquinolinylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-76-9 CAPLUS  
CN Carbamic acid, [5-[(1-oxo-3-(phenylsulfonyl)propyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-77-0 CAPLUS  
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-chienylacetyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-82-7 CAPLUS  
CN Carbamic acid, [5-[(4-chlorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252307-83-8 CAPLUS  
CN Carbamic acid, [5-[(2-bromophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-85-0 CAPLUS  
CN Carbamic acid, [5-[(3-bromophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-86-1 CAPLUS  
CN Carbamic acid, [5-[(4-bromophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-78-1 CAPLUS  
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-pyrimidinylthio)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252307-79-2 CAPLUS  
CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-[(3-pyridinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-80-5 CAPLUS  
CN Carbamic acid, [5-[(2-chlorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-81-6 CAPLUS  
CN Carbamic acid, [5-[(3-chlorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 252307-88-3 CAPLUS


CN Carbamic acid, [5-[(2-fluorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-89-4 CAPLUS  
CN Carbamic acid, [5-[(3-fluorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-90-7 CAPLUS  
CN Carbamic acid, [5-[(4-fluorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-91-8 CAPLUS  
CN Carbamic acid, [5-[(2-nitrophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-92-9 CAPLUS  
CN Carbamic acid, [5-[(3-nitrophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-93-0 CAPLUS  
CN Carbamic acid, 5-[[[4-nitrophenyl]acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-94-1 CAPLUS  
CN Carbamic acid, 5-[[[4-phenyl-1H-imidazol-2-yl]-5-[[[3-(trifluoromethyl)phenyl]acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-95-2 CAPLUS  
CN Carbamic acid, 5-[[[4-phenyl-1H-imidazol-2-yl]-5-[[[3-(trifluoromethyl)phenyl]acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-96-3 CAPLUS  
CN Carbamic acid, 5-[[[4-phenyl-1H-imidazol-2-yl]-5-[[[3-(trifluoromethyl)phenyl]acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-97-4 CAPLUS  
CN Carbamic acid, 5-[[[2-methoxyphenyl]acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-98-5 CAPLUS  
CN Carbamic acid, 5-[[[3-methoxyphenyl]acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-99-6 CAPLUS  
CN Carbamic acid, 5-[[[4-methoxyphenyl]acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-01-3 CAPLUS  
CN Carbamic acid, 5-[[[phenylacetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-02-4 CAPLUS  
CN Carbamic acid, 5-[[[4-(dimethylamino)phenyl]acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-03-5 CAPLUS  
CN Benzeneacetamide, 3,4-dichloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-04-6 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252308-05-7 CAPLUS  
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 252308-06-8 CAPLUS  
CN Benzeneacetamide, 4-hydroxy-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-07-9 CAPLUS  
CN Benzeneacetamide, 2,4-difluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-08-0 CAPLUS  
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,4-dichloro- (9CI) (CA INDEX NAME)



RN 252308-10-4 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252308-11-5 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 252308-13-7 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)


CN Benzenesacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252308-17-1 CAPLUS  
CN Benzenesacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 252308-18-2 CAPLUS  
CN Benzenesacetamide, 4-hydroxy-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




yl)ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 252308-14-8 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 252308-15-9 CAPLUS  
CN Benzenesacetamide, 3,4-dichloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-16-0 CAPLUS


RN 252308-19-3 CAPLUS  
CN Benzenesacetamide, 2,4-difluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-21-7 CAPLUS  
CN Benzenesacetamide, 3,4-dichloro-N-[1-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252308-22-8 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252308-23-9 CAPLUS  
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 252308-24-0 CAPLUS  
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 252308-25-1 CAPLUS  
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-30-8 CAPLUS  
CN Benzeneacetamide, 4-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-31-9 CAPLUS  
CN Benzeneacetamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-32-0 CAPLUS  
CN Benzeneacetamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252308-26-2 CAPLUS  
CN Benzeneacetamide, 3,4-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-27-3 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-28-4 CAPLUS

Absolute stereochemistry.




RN 252308-33-1 CAPLUS  
CN Benzeneacetamide, 3-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-35-3 CAPLUS  
CN Benzeneacetamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-36-4 CAPLUS  
CN Benzeneacetamide, 2-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-37-5 CAPLUS  
CN Benzeneacetamide, 3-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-38-6 CAPLUS  
CN Benzeneacetamide, 4-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-39-7 CAPLUS  
CN Benzeneacetamide, 2-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-41-1 CAPLUS  
CN Benzeneacetamide, 3-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-42-2 CAPLUS  
CN Benzeneacetamide, 4-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-43-3 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-44-4 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-45-5 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-46-6 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-47-7 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-48-8 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-49-9 CAPLUS  
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-52-4 CAPLUS  
CN Benzeneacetamide, N-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-53-5 CAPLUS  
CN Benzeneacetamide, N-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-54-6 CAPLUS  
CN Benzeneacetamide, N-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-59-1 CAPLUS  
CN Carbamic acid, (4-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)-4-oxobutyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-60-4 CAPLUS  
CN Carbamic acid, [6-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)-6-oxohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-62-6 CAPLUS  
CN Carbamic acid, [2-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-55-7 CAPLUS  
CN Benzeneacetamide, 4-(dimethylamino)-N-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-57-9 CAPLUS  
CN Carbamic acid, [3-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-58-0 CAPLUS  
CN Carbamic acid, [2-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-63-7 CAPLUS  
CN Carbamic acid, [4-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)carbonyl]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-64-8 CAPLUS  
CN Carbamic acid, [2-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-65-9 CAPLUS  
CN Carbamic acid, [5-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-66-0 CAPLUS  
CN Carbamic acid, [[4-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]carbonyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-67-1 CAPLUS  
CN Carbamic acid, [4-[2-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-2-oxoethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252308-79-5 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-84-2 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-4-(trifluoromethyl)-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-85-3 CAPLUS  
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-86-4 CAPLUS  
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-81-9 CAPLUS  
CN Benzenecarboximidamide, 2-chloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-82-0 CAPLUS  
CN Benzenecarboximidamide, 4-chloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-83-1 CAPLUS  
CN Benzenecarboximidamide, 4-methoxy-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-87-5 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-4-(trifluoromethoxy)-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HI

IT 252308-88-6P 252308-89-7P 252308-90-0P  
252308-91-1P 252308-92-2P 252308-93-3P  
252308-94-4P 252308-95-5P 252308-96-6P  
252308-97-7P 252308-98-8P 252308-99-9P  
252309-00-0P 252309-01-6P 252309-02-7P  
252309-03-8P 252309-04-9P 252309-05-0P  
252309-06-1P 252309-07-2P 252309-08-3P  
252309-09-4P 252309-10-7P 252309-11-8P  
252309-12-9P 252309-13-0P 252309-14-1P  
252309-15-2P 252309-16-3P 252309-18-5P  
252309-19-6P 252309-20-9P 252309-21-0P  
252309-22-1P 252309-23-2P 252309-24-3P  
252309-25-4P 252309-26-5P 252309-27-6P  
252309-28-7P 252309-29-8P 252309-30-1P  
252309-42-5P 252309-43-6P 252309-44-7P  
252309-45-8P 252309-46-9P 252309-47-0P  
252309-48-1P 252309-49-2P 252309-50-5P  
252309-51-6P 252309-53-8P 252309-54-9P  
252309-55-0P 252309-56-1P 252309-57-2P  
252309-58-3P 252309-59-4P 252309-61-8P  
252309-63-0P 252309-64-1P 252309-65-2P  
252309-66-3P 252309-67-4P 252309-68-5P  
252309-69-6P 252309-70-9P 252309-71-0P  
252309-73-2P 252309-74-3P 252309-75-4P  
252309-76-5P 252309-77-6P 252309-78-8P  
252309-80-1P 252309-81-2P 252309-82-3P  
252309-84-5P 252309-85-6P 252309-86-7P  
252309-87-8P 252309-88-9P 252309-89-0P  
252309-90-3P 252309-91-4P 252309-92-5P


252309-93-6P 252309-95-8P 252309-96-9P  
 252309-97-0P 252310-00-2P 252310-01-3P  
 252310-02-4P 252310-03-5P 252310-04-6P  
 252310-05-7P 252310-06-8P 252310-08-0P  
 252310-09-1P 252310-10-4P 252310-11-5P  
 252310-12-6P 252310-13-7P 252310-14-8P  
 252310-15-9P 252310-16-0P 252310-17-1P  
 252310-18-2P 252310-19-3P 252310-21-7P  
 252310-22-8P 252310-23-9P 252310-24-0P  
 252310-25-1P 252310-26-2P 252310-27-3P  
 252310-28-4P 252310-29-5P 252310-31-9P  
 252310-32-0P 252310-33-1P 252310-34-2P  
 252310-35-3P 252310-36-4P 252310-38-6P  
 252310-39-7P 252310-40-0P 252310-41-1P  
 252310-43-3P 252310-44-4P 252310-45-5P  
 252310-46-6P 252310-47-7P 252310-48-8P  
 252310-49-9P 252310-50-2P 252310-51-3P  
 252310-52-4P 252310-53-5P 252310-55-7P  
 252310-56-8P 252310-58-0P 252310-59-1P  
 252310-60-4P 252310-62-6P 252310-63-7P  
 252310-64-8P 252310-65-9P 252310-66-0P  
 252310-68-2P 252310-71-7P 252310-72-8P  
 252310-73-9P 252310-74-0P 252310-75-1P  
 252310-76-2P 252310-77-3P 252310-80-8P  
 252310-81-9P 252310-82-0P 252310-83-1P  
 252310-84-2P 252310-85-3P 252310-86-4P  
 252310-87-5P 252310-88-6P 252310-89-7P  
 252310-93-1P 252310-94-4P 252310-97-7P  
 252310-98-8P 252311-17-0P 252311-18-1P  
 252311-19-2P 252311-20-5P 252311-22-7P  
 252311-23-8P 252311-24-9P 252311-25-0P  
 252311-26-1P 252311-27-2P 252311-28-3P  
 252311-29-4P 252311-30-7P 252311-31-8P  
 252311-33-0P 252311-34-1P 252311-35-2P  
 252311-36-1P 252311-37-4P 252311-38-5P  
 252311-39-6P 252311-40-9P 252311-41-0P  
 252311-42-1P 252311-43-2P 252311-45-4P  
 252311-46-5P 252311-47-6P 252311-48-7P  
 252311-50-1P 252311-51-2P 252311-52-3P  
 252311-53-4P 252311-54-5P 252311-55-6P  
 252311-57-8P 252311-58-9P 252311-59-0P  
 252311-60-3P 252311-61-4P 252311-62-5P  
 252311-63-6P 252311-64-7P 252311-65-8P  
 252311-66-9P 252311-67-0P 252311-68-1P  
 252311-69-2P 252311-70-5P 252311-71-6P  
 252311-72-7P 252311-73-8P 252311-74-9P  
 252311-75-0P 252311-77-2P 252311-78-3P  
 252311-79-4P 252311-80-7P 252311-81-8P  
 252311-82-9P 252311-83-0P 252311-84-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)

RN 252308-88-6 CAPLUS

CN Benzenethanimidamide, 2,6-dichloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252308-89-7 CAPLUS

CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252308-90-0 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252308-91-1 CAPLUS

CN Benzenecarboximidamide, 2-chloro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252308-92-2 CAPLUS

CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252308-93-3 CAPLUS

CN Benzenecarboximidamide, 4-methoxy-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252308-94-4 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252308-95-5 CAPLUS

CN Benzenecarboximidamide, 4-[(1,1-dimethylethyl)-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252308-96-6 CAPLUS

CN Benzenecarboximidamide, 2,4-difluoro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.






● HI

RN 252308-97-7 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethoxy)-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-98-8 CAPLUS  
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252308-99-9 CAPLUS

RN 252309-02-7 CAPLUS  
CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-03-8 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-04-9 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-00-5 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HI

RN 252309-01-6 CAPLUS  
CN Benzenecarboximidamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI



● HI

RN 252309-05-0 CAPLUS  
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-06-1 CAPLUS  
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-07-2 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethoxy)-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-08-3 CAPLUS

CN Benzenecarboximidamide, 2,6-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-09-4 CAPLUS

CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-12-9 CAPLUS

CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-13-0 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]-4-methoxy-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-10-7 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-11-8 CAPLUS

CN Benzenecarboximidamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-14-1 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-15-2 CAPLUS

CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-16-3 CAPLUS  
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-18-5 CAPLUS  
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-19-6 CAPLUS  
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252309-20-9 CAPLUS  
CN Benzenecarboximidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-21-0 CAPLUS  
CN Benzenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-22-1 CAPLUS  
CN Benzenecarboximidamide, 2-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-23-2 CAPLUS  
CN Benzenecarboximidamide, 4-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-24-3 CAPLUS  
CN Benzenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-25-4 CAPLUS  
CN Benzenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-26-5 CAPLUS  
CN Benzenecarboximidamide, 4-((1,1-dimethylethyl)-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-28-7 CAPLUS  
CN Benzenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-27-6 CAPLUS  
CN Benzenecarboximidamide, 2,4-difluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-29-8 CAPLUS  
CN Benzenecarboximidamide, 2,6-dichloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI


RN 252309-30-1 CAPLUS  
CN Benzenecarboximidamide, 2-[[[1,1-dimethylethyl)sulfonyl]-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 252309-42-5 CAPLUS  
CN Benzenecarboximidamide, N-[[[15]-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-43-6 CAPLUS  
CN Benzenecarboximidamide, 2-chloro-N-[[[15]-1-(4-phenyl-1H-imidazol-2-yl)-2-

[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-44-7 CAPLUS  
CN Benzenecarboximidamide, 4-chloro-N-[[[15]-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-45-8 CAPLUS  
CN Benzenecarboximidamide, 4-methoxy-N-[[[15]-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-46-9 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-4-(trifluoromethyl)-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-47-0 CAPLUS  
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-48-1 CAPLUS  
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-49-2 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-4-(trifluoromethoxy)-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-50-5 CAPLUS  
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-51-6 CAPLUS  
CN Benzenecarboximidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-53-8 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-54-9 CAPLUS  
CN Benzenecarboximidamide, 2-chloro-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-55-0 CAPLUS  
CN Benzenecarboximidamide, 4-chloro-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-56-1 CAPLUS  
CN Benzenecarboximidamide, 4-methoxy-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-57-2 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-58-3 CAPLUS  
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-59-4 CAPLUS  
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-61-8 CAPLUS  
CN Benzenecarboximidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethoxy)-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-63-0 CAPLUS  
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-64-1 CAPLUS  
CN Ethanimidamide, 2-([(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]sulfonyl)-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252309-65-2 CAPLUS  
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-phenylmethyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-66-3 CAPLUS  
CN Phenol, 2-([(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-67-4 CAPLUS  
CN Phenol, 4-([(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-68-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]-alpha-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-69-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-methoxyphenyl)methyl]-alpha-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-70-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-71-0 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252309-73-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)


phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-77-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-78-8 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(2-thienylmethyl)-, (aS)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 252309-78-7  
CMF C24 H22 N4 S

Absolute stereochemistry.




Absolute stereochemistry.




RN 252309-74-3 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-75-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-76-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)


CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 252309-80-1 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(3,4,5-trimethoxyphenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-81-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-fluorophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-82-3 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(2-trifluoromethylphenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-84-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-85-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(dimethylamino)phenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-86-7 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(4-(trifluoromethoxy)phenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252309-90-3 CAPLUS  
CN Phenol, 4-[[[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 252309-91-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252309-92-5 CAPLUS  
CN 1H-Indole-3-ethanamine, α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252309-87-8 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252309-88-9 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252309-89-0 CAPLUS  
CN Phenol, 2-[[[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 252309-93-6 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[[4-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 252309-95-8 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[[2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 252309-96-9 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[[2-nitrophenyl]methyl]- (9CI) (CA INDEX NAME)







RN 252309-97-0 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-00-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]-α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-01-3 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]-α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-02-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]-α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-03-5 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 252310-04-6 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-05-7 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-fluorophenyl)methyl]-α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-06-8 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-08-0 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]-α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-09-1 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-(dimethylamino)phenyl)methyl]-α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 252310-10-4 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-11-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-[3-(dimethylamino)propoxy]phenyl)methyl]-α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-12-6 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**



RN 252310-13-7 CAPIUS  
CN Phenol, 2-[[[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethylamino)methyl]- (9CI) (CA INDEX NAME)


**Absolute stereochemistry.**



RN 252310-14-8 CAPIUS  
CN Phenol, 4-[[[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]-(9CI) (CA INDEX NAME)


**Absolute stereochemistry.**

**Absolute stereochemistry.**




RN 252310-18-2 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-N-  
[(2-methoxyphenyl)methyl]-, (aR)- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**




RN 252310-19-3 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-  
[(2-nitrophenyl)methyl]-, (aR)- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**




RN 252310-21-7 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -{4-(4-methoxyphenyl)-1H-imidazol-2-yl}-N-  
[(4-nitrophenyl)methyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)




RN 252310-15-9 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

### Absolute stereochemistry.




RN 252310-16-0 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-  
[(3-methoxyphenyl)methyl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

### Absolute stereochemistry.




RN 252310-17-1 CAPLUS  
CN 1H-Indole-3-ethanamine,  $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-  
[[4-(4-methoxyphenyl)methyl]-, (aR)- (9CI) (CA INDEX NAME)

### Absolute stereochemistry.




RN 252310-22-8 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]- $\alpha$ -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, ( $\alpha$ R)- (9CI) (CA INDEX NAME)

### Absolute stereochemistry.




RN 252310-23-9 CAPIUS  
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]- $\alpha$ -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**




RN 252310-24-0 CAPLUS  
 CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-25-1 CAPLUS  
 CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-thienylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-26-2 CAPLUS  
 CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3,4,5-trimethoxyphenyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-27-3 CAPLUS  
 CN 1H-Indole-3-ethanamine, N-[(2-fluorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-28-4 CAPLUS  
 CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-(trifluoromethyl)phenyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-29-5 CAPLUS  
 CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-31-9 CAPLUS  
 CN 1H-Indole-3-ethanamine, N-[[4-(dimethylamino)phenyl]methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-32-0 CAPLUS  
 CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[[4-(trifluoromethoxy)phenyl]methyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-33-1 CAPLUS


CN 1H-Indole-3-ethanamine, N-[[4-(3-(dimethylamino)propoxy)phenyl]methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-34-2 CAPLUS  
 CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-35-3 CAPLUS  
 CN Phenol, 2-[[[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-36-4 CAPLUS  
 CN Phenol, 4-[[[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-38-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-39-7 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3-methoxyphenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-40-0 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-nitrophenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)


[(4-nitrophenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-45-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-46-6 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


[(4-methoxyphenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-41-1 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-methoxyphenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-43-3 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-nitrophenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-44-4 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-bromophenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)




RN 252310-47-7 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-48-8 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-thienyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-49-9 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3,4,5-trimethoxyphenyl)methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-50-2 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-fluorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-51-3 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[[2-(trifluoromethyl)phenyl]methyl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-52-4 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)


CN 4-Morpholinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-58-0 CAPLUS  
CN 3-Thiazolidinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-59-1 CAPLUS  
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-60-4 CAPLUS  
CN 1,4-Piperidinedicarboxamide, N1-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 252310-53-5 CAPLUS  
CN 1H-Indole-3-ethanamine, N-[[4-(dimethylamino)phenyl]methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-55-7 CAPLUS  
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[[4-(trifluoromethoxy)phenyl]methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-56-8 CAPLUS




RN 252310-62-6 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-63-7 CAPLUS  
CN 2H-Pyrido[3,4-b]indole-2-carboxamide, 1,3,4,9-tetrahydro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-64-8 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-65-9 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(4-fluorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-66-0 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(2-methoxyphenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-68-2 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(3-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-74-0 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(4-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-75-1 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(4-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-76-2 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(4-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-71-7 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(4-nitrophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-72-8 CAPLUS  
CN 2-(1H)-Isoquinolinecarboxamide, 3,4-dihydro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-73-9 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(4-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-77-3 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(4-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-80-8 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(4-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-81-9 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(4-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-82-0 CAPLUS  
CN 1,3,8-TriazaSpiro[4.5]decane-8-carboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-83-1 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(2-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-84-2 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(4-hydroxyphenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-88-6 CAPLUS  
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-89-7 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(2-furanylcarbonyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-93-3 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-85-3 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(2,4-dimethylphenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-86-4 CAPLUS  
CN 1-Pyrrolidinecarboxamide, 3-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-87-5 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-94-4 CAPLUS  
CN 1-Piperazinecarboxamide, 4-[(diphenylmethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-97-7 CAPLUS  
CN 1-Piperazinecarboxamide, 4-(2-fluorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-98-8 CAPLUS  
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252313-17-0 CAPLAUS  
CN Benzenesacetamide, 2-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-18-1 CAPLAUS  
CN Benzenesacetamide, 3-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-19-2 CAPLAUS  
CN Benzenesacetamide, 4-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-24-9 CAPLAUS  
CN Benzenesacetamide, 2-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-25-0 CAPLAUS  
CN Benzenesacetamide, 3-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-26-1 CAPLAUS  
CN Benzenesacetamide, 4-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-20-5 CAPLAUS  
CN Benzenesacetamide, 2-bromo-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-22-7 CAPLAUS  
CN Benzenesacetamide, 3-bromo-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-23-8 CAPLAUS  
CN Benzenesacetamide, 4-bromo-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 252313-27-2 CAPLAUS  
CN Benzenesacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252313-28-3 CAPLAUS  
CN Benzenesacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-29-4 CAPLAUS  
CN Benzenesacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)







RN 252313-30-7 CAPLUS  
CN Benzenacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-34-1 CAPLUS  
CN Benzenacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252313-31-8 CAPLUS  
CN Benzenacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-35-2 CAPLUS  
CN Benzenacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252313-33-0 CAPLUS  
CN Benzenacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-36-3 CAPLUS  
CN Benzenacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252313-37-4 CAPLUS  
CN Benzenacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-40-9 CAPLUS  
CN Benzenacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-chloro- (9CI) (CA INDEX NAME)




RN 252313-38-5 CAPLUS  
CN Benzenacetamide, 4-(dimethylamino)-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-41-0 CAPLUS  
CN Benzenacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 252313-39-6 CAPLUS  
CN Benzenacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 252313-42-1 CAPLUS  
CN Benzenacetamide, 2-bromo-N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-43-2 CAPLUS  
CN Benzenesacetamide, 3-bromo-N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-47-6 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 252313-45-4 CAPLUS  
CN Benzenesacetamide, 4-bromo-N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-48-7 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 252313-46-5 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 252313-50-1 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252313-51-2 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-54-5 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-52-3 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252313-55-6 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-53-4 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-57-8 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252313-58-9 CAPLAUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252313-59-0 CAPLAUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252313-60-3 CAPLAUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-1-methoxy- (9CI) (CA INDEX NAME)




RN 252313-64-7 CAPLAUS  
CN Benzenesacetamide, 4-chloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-65-8 CAPLAUS  
CN Benzenesacetamide, 2-bromo-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-66-9 CAPLAUS  
CN Benzenesacetamide, 3-bromo-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-61-4 CAPLAUS  
CN Benzenesacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 252313-62-5 CAPLAUS  
CN Benzenesacetamide, 2-chloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-63-6 CAPLAUS  
CN Benzenesacetamide, 3-chloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-67-0 CAPLAUS  
CN Benzenesacetamide, 4-bromo-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-68-1 CAPLAUS  
CN Benzenesacetamide, 2-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-69-2 CAPLAUS  
CN Benzenesacetamide, 3-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-70-5 CAPLUS  
CN Benzenesacetamide, 4-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-73-8 CAPLUS  
CN Benzenesacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252313-71-6 CAPLUS  
CN Benzenesacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252313-74-9 CAPLUS  
CN Benzenesacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-72-7 CAPLUS  
CN Benzenesacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-75-0 CAPLUS  
CN Benzenesacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-77-2 CAPLUS  
CN Benzenesacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-80-7 CAPLUS  
CN Benzenesacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252313-78-3 CAPLUS  
CN Benzenesacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252313-81-8 CAPLUS  
CN Benzenesacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-1- (9CI) (CA INDEX NAME)




RN 252313-79-4 CAPLUS  
CN Benzenesacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252313-82-9 CAPLUS  
CN Benzenesacetamide, 4-(dimethylamino)-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-83-0 CAPLUS  
CN Benzeneacetamide, 2-chloro-N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-84-1 CAPLUS  
CN Benzeneacetamide, 3-chloro-N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




IT 252313-86-3P 252313-87-4P 252313-89-6P  
252313-90-9P 252313-91-0P 252313-92-1P  
252313-93-2P 252313-94-3P 252313-96-5P  
252313-97-6P 252313-99-8P 252314-00-4P  
252314-01-5P 252314-02-6P 252314-03-7P  
252314-04-8P 252314-05-9P 252314-96-8P



RN 252313-90-9 CAPLUS  
CN Benzeneacetamide, 4-bromo-N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 252313-91-0 CAPLUS  
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 252313-92-1 CAPLUS  
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)


252314-97-9P 252314-98-0P 252314-99-1P  
252315-01-8P 252315-03-0P 252315-05-2P  
252315-07-4P 252315-09-6P 252315-11-0P  
252315-33-6P 252315-35-8P 252315-37-0P  
252315-40-5P 252315-42-7P 252315-44-9P  
252315-47-2P 252315-49-4P 252315-96-1P  
252315-97-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of imidazolyl deriva. as agonists or antagonists of acetylcholinesterase)


RN 252313-86-3 CAPLUS  
CN Benzeneacetamide, 4-chloro-N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-87-4 CAPLUS  
CN Benzeneacetamide, 2-bromo-N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-89-6 CAPLUS  
CN Benzeneacetamide, 3-bromo-N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-93-2 CAPLUS  
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252313-94-3 CAPLUS  
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-96-5 CAPLUS  
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252313-97-6 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-99-8 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252314-00-4 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 252314-04-8 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(methoxy)- (9CI) (CA INDEX NAME)




RN 252314-05-9 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 252314-96-8 CAPLUS  
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252314-01-5 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 252314-02-6 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252314-03-7 CAPLUS  
CN Benzenesacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252314-97-9 CAPLUS  
CN Benzanide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]thioxamethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-98-0 CAPLUS  
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-99-1 CAPLUS  
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-01-8 CAPLUS  
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-(4-(phenylmethoxy)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-03-0 CAPLUS  
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-(2-(1-methylethyl)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-05-2 CAPLUS  
CN Thiourea, N-(3-chlorophenyl)-N'-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-33-6 CAPLUS  
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 252315-35-8 CAPLUS  
CN Benzamide, N-[[[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-37-0 CAPLUS  
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-07-4 CAPLUS  
CN Thiourea, N-hexyl-N'-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-09-6 CAPLUS  
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-(2-(4-morpholinyl)ethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-11-0 CAPLUS  
CN Thiourea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-40-5 CAPLUS  
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-42-7 CAPLUS  
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-(4-(phenylmethoxy)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-44-9 CAPLUS  
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-(2-(1-methylethyl)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-47-2 CAPLUS  
CN Thiourea, N-(3-chlorophenyl)-N'-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-49-4 CAPLUS  
CN Thiourea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252315-96-1 CAPLUS  
CN Thiophenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydride (9CI) (CA INDEX NAME)



● HI



RN 252315-92-7 CAPLUS  
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L12 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 1999:27832 CAPLUS

DOCUMENT NUMBER: 130:81398

TITLE: Novel 2-(iminomethyl)aminophenyl derivatives as NO synthase inhibitors and traps for radical oxygen species

INVENTOR(S): Auvin, Serge; Harnett, Jeremiah; Bigg, Dennis; Chabrier De Lessaunerie, Pierre-Stienne

PATENT ASSIGNEE(S): Societe De Conseil de Recherches et D'Applications Scientifiques (S.C.R.A.S. Fr.

SOURCE: PCT Int. Appl., 134 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: French

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9858934	A1	19981230	WO 1998-FR1250	19980615
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KD, KZ, MD, RU, TJ, TM, RM, GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CP, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2764889	A1	19981224	FR 1997-7701	19970620
FR 2764889	B1	20000901		
TW 422842	B	20010221	TW 1998-87109245	19980610
AU 9882189	A1	19990104	AU 1998-82189	19980615
AU 737964	B2	20010906		
EP 991654	A1	20000412	EP 1998-932205	19980615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
TR 9903175	T2	20000421	TR 1999-9903175	19980615
BR 9810197	A	20000808	BR 1998-10197	19980615

RN 252315-97-2 CAPLUS  
CN Thiophenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)



● HI

IT 252279-08-6 252279-09-7 252315-91-6


252315-92-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors

RN 252279-08-6 CAPLUS

CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252279-09-7 CAPLUS

CN 1H-Indole-3-ethanamine,  $\alpha$ -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252315-91-6 CAPLUS


CN Carbamic acid, [(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

NZ 501656	A	20011221	NZ 1998-501656	19980615
JP 2002507965	T2	20020312	JP 1999-503871	19980615
RU 2202543	C2	20030420	RU 2000-101328	19980615
ZA 9805392	A	19990120	ZA 1998-5392	19980619
NO 9906208	A	20000215	NO 1999-6208	19991215
MX 9911971	A	20000430	MX 1999-11971	19991217
US 2002007062	A1	20020117	US 2001-882264	20010615
US 6630461	B2	20031007		
US 2002045753	A1	20020418	US 2001-945782	20010904
US 6599903	B2	20030729	US 2001-953682	20010917
US 2002042511	A1	20020411	US 2002-191950	20020709
US 6586454	B2	20030701		
US 2003078420	A1	20030424		
US 6809088	B2	20041026		

PRIORITY APPLN. INFO.:

OTHER SOURCES(S): MARPAT 130:81398  
GI



AB Amidines AXHETC6H4N:CBH2 [A = H, (un)substituted HOC6H4, 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl; B = (un)substituted alkyl, Ph, pyridyl, thienyl, furyl, pyrrolyl, thiazolyl; X = (un)substituted CONHX1, NHCOX1, CH1, CO, bond; X1 = (CH2)n; n = 0-6; Y = Y1, COHY1, NHCOY1, COY1, Y1CO, (un)substituted NHY1, Y1NH, Y1CH2NHCO, OY1, SY1, Y1S, Y1OY1, Y1NHY1; Y1 = (CH2)n; Het = (un)substituted heterocyclic] were prepared for use as NO synthase inhibitors and reactive oxygen species traps. Thus, 4-FC6H4NO2 was treated with imidazole and the 1-p-nitrophenylimidazole reduced to the amine and treated with the thiophene fragment to give the amidine 1. I had an NO synthase-inhibiting IC50 < 3.5  $\mu$ M.


IT 218944-36-6P 218944-40-2P 218944-41-3P

218944-66-2P 218944-68-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

preparation of novel 2-(iminomethyl)aminophenyl derivs. as NO synthase inhibitors and traps for radical oxygen species

RN 218944-36-6 CAPLUS

CN Carbamic acid, [(4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 218944-40-2 CAPLUS


CN Benzamide, N-[(4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-




2-yl)methyl]-N-methyl-4-nitro- (9CI) (CA INDEX NAME)




RN 218944-41-3 CAPLUS  
CN Benzamide, 4-amino-N-[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 218944-66-2 CAPLUS  
CN Phenol, 2,6-bis[[4-(1,1-dimethylethyl)-4-[2-[[methyl(4-nitrophenyl)amino]methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 218944-68-4 CAPLUS  
CN Phenol, 4-[2-[[4-(aminophenyl)methylamino]methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



IT 218944-42-4P 218944-69-5P  
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRSP (Preparation); USES (Uses)  
(preparation of novel 2-(iminomethyl)aminophenyl deriva. as NO synthase inhibitors and traps for radical oxygen species)  
RN 218944-42-4 CAPLUS  
CN Benzamide, N-[[5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-

AU 9749680 A1 19980715 AU 1997-49680 19971120  
EP 946587 A2 19991006 EP 1997-912529 19971120  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IS, FI  
JP 2001505585 T2 20010424 JP 1998-527528 19971120  
ZA 9710603 A 19980625 ZA 1997-10603 19971125  
A 1996-4219 A 19961216  
AU 1997-5929 A 19970401  
AU 1997-9030 A 19970909  
WO 1997-JP4243 W 19971120  
PRIORITY APPLN. INFO.:  
OTHER SOURCE(S): MARPAT 129:95714  
GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I (X = S, NR9; Y = CHR3, (un)substituted phenylene; R1 = (un)substituted indolyl, (un)substituted benzofuranyl; R2 = H, phenyl-lower alkyl; R3 = H, (CH2)nR6; R4 = H, (un)substituted Ph, (un)substituted pyridyl; R5 = H, imidazolyl, Ph, nitrophenyl, phenyl-lower alkyl, optionally esterified carboxy, CONRR8; R4R5 = CH:CHCH:CH; R6 = optionally protected OH, acyl, carboxy, acylamino, lower alkoxy, phenyl-lower alkoxy, lower alkylthio, (un)substituted Ph; R7, R8 = independently H, Ph, phenyl-lower alkyl, lower alkyl, lower alkoxy; R9 = H, lower alkyl, lower cycloalkyl, (un)substituted benzyl; m = 0, 1; n = 0-3 and pharmaceutically acceptable salts thereof are described as strong inhibitors of the production of nitric oxide. Compds. I are useful for prevention and treatment of nitric oxide-mediated diseases such as adult respiratory distress syndrome, cardiovascular ischemia, myocarditis, heart failure, synovitis, shock, diabetes, diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, glomerulonephritis, peptic ulcer, inflammatory bowel disease, cerebral infarction, cerebral ischemia, cerebral hemorrhage, migraine, rheumatoid arthritis, gout, neuritis, post-herpetic neuralgia, osteoarthritis, osteoporosis, systemic lupus erythematosus, rejection by organ transplantation, asthma, metastasis, Alzheimer's disease, arthritis, CNS disorders, dermatitis, hepatitis, liver cirrhosis, multiple sclerosis, pancreatitis, atherosclerosis, and the like in humans and animals. Thus, 2-step cyclocondensation of amino ketone III (preparation given) with protected 3-(2-pyridyl)-L-alanine and methylamine gave protected imidazole III (Boc = Me3CO2C). Deprotection of III followed by acylation with indole-3-carboxylic acid gave desired compound IV. IV inhibited nitric oxide production 100% in murine macrophage cell line RAW264.7 at 10<sup>-5</sup> M.

IT 209525-11-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRSP (Preparation); USES (Uses)  
(preparation of new heterocyclic amides as nitric oxide production inhibitors)  
RN 209525-11-1 CAPLUS  
CN 1H-Indole-2-carboxamide, N-[[1S]-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

2-yl)methyl]-4-[(imino-2-thienylmethyl)amino]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 218944-69-5 CAPLUS  
CN 2-Thiophenecarboximidamide, N-[[4-[[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl]methylamino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

REFERENCES COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1998:424263 CAPLUS  
DOCUMENT NUMBER: 129:95714  
TITLE: Preparation of new heterocyclic amides as nitric oxide production inhibitors  
Yatabe, Takumi; Inoue, Takayuki; Hamashima, Hitoshi; Shima, Ichiro; Ohne, Kazuhiko; Yoshihara, Kousei; Oku, Teruo  
PATENT ASSIGNER(S): Fujisawa Pharmaceutical Co., Ltd., Japan; Itoh, Yoshikuni  
SOURCE: PCT Int. Appl., 533 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9827108	A2	19980625	WO 1997-JP4243	19971120
WO 9827108	A3	19980730		
W: AU, CA, CN, HU, IL, JP, KR, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RM: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				




IT 209528-41-6P 209528-42-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of new heterocyclic amides as nitric oxide production inhibitors)  
RN 209528-41-6 CAPLUS  
CN Carbanic acid, [(1S)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-2-(2-pyridinyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209528-42-7 CAPLUS  
CN 2-Pyridinethanamine, α-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, trihydrobromide, (±S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 3 HBr

L12 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1998:424117 CAPLUS  
DOCUMENT NUMBER: 129:113523  
TITLE: Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing  
INVENTOR(S): Bocan, Thomas Michael Andrew; Boxer, Peter Alan; Peterson, Joseph Thomas, Jr.; Schrier, Denis; White, Andrew David  
PATENT ASSIGNER(S): Werner-Lambert Co., USA; Bocan, Thomas Michael Andrew;

SOURCE: Boxer, Peter Alan; Peterson, Joseph Thomas, Jr.; Schrier, Denis; White, Andrew David  
PCT Int. Appl., 163 pp.  
CODEN: PIXX22  
Patent  
English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WD 9826773	A1	19980625	WD 1997-US21532	19971121
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, SE, GB, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MW, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RU: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BS, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CO, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2264692	AA	19980625	CA 1997-2264692	19971121
AU 9877353	A1	19980715	AU 1998-77353	19971121
AU 737117	B2	20010809		
EP 946166	A1	19991006	EP 1997-949584	19971121
EP 946166	B1	20040218		
R: AT, BS, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO				
BR 9714142	A	20000229	BR 1997-14142	19971121
JP 2001507342	T2	20010605	JP 1998-527715	19971121
NZ 334925	A	20010629	NZ 1997-334925	19971121
EP 1366765	A1	20031203	EP 2003-18081	19971121
R: AT, BS, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IS, SI, LT, LV, FI, RO, MK, AL				
AT 259640	E	20040315	AT 1997-949584	19971121
PT 946166	T	20040630	PT 1997-949584	19971121
ES 2212142	T3	20040716	ES 1997-949584	19971121
ZA 9711279	A	19980623	ZA 1997-11279	19971215
EP 6340709	B1	20020122	US 1999-269123	19990319
			US 1996-32753P	P 19961217
			EP 1997-949584	A3 19971121
			WD 1997-US21532	W 19971121


PRIORITY APPL. INFO.:  
MARPAT 129:113521

OTHER SOURCE(S):  
AB Matrix metalloproteinase inhibitors 4-RC6H4SO2NHCH(R1)COR2 [R = (un)substituted Ph; R1 = alkyl, phenylalkyl, phenyl; R2 = OH, alkoxy, NHCH] and 4-RC6H4C(=NR3)CR4R5CR6R7COR8 [R3 = (un)substituted OH, NH2; R4-R7 = H, F, (un)substituted alkyl; R8 = OH, SH] are useful for preventing and treating neural disorders, especially Alzheimer's, Huntington's, and Parkinson's disease and amyotrophic lateral sclerosis, and in promoting wound healing. IC50 for matrix metalloproteinase inhibition are reported for a number of compds. Formulations containing (R)-4-(4-MCC6H4)C6H4SO2NHCH(CO2H)CH2Ph, (S)-4-(4-H2NCC6H4)C6H4SO2NHCH(CO2H)CH2CH2C6H4OEt, and 4-(4-BrC6H4)C6H4SO2NHCH(CO2H)CH2Me are reported.

IT 181361-72-8 209199-38-2  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(Use of matrix metalloproteinase inhibitors for treating neural disorders and promoting wound healing)


RN 181361-72-8 CAPLUS  
CN Butanediamide, N4-hydroxy-N1-[(1S)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209199-38-2 CAPLUS  
CN Cyclohexanecarboxamide, N-hydroxy-1-[[[(1S)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN  
ACCESSION NUMBER: 1998:207292 CAPLUS  
DOCUMENT NUMBER: 128:270871  
TITLE: Preparation of azolyl dipeptide analogs as retroviral protease inhibitors  
INVENTOR(S): Carr, Thomas Joseph; Demarah, Peter Lawrence; Dreyer, Geoffrey Bainbridge; Fenwick, Ashley Edward  
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA  
SOURCE: U.S., 42 pp., Cont. of U.S. Ser. No. 193,026, abandoned.  
CODEN: USXXAM  
Patent  
English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5733882	A	19980331	US 1995-396356	19950228
PRIORITY APPL. INFO.: OTHER SOURCE(S): GI			US 1994-193026	B1 19940117

MARPAT 128:270871




AB The present invention provides compds., more particularly dipeptide analogs I [R1, R3 = independently (un)substituted O, Q-C1-6 alkyl, Q-C2-6 alkenyl, Q-C2-6 alkynyl, C1-6 alkyl substituted by 1-5 F atoms; Q = H, C3-6 cycloalkyl, C5-6 cycloalkenyl, aryl, heterocyclyl; R2 = H, OH; R4 = R6NR11, CONR12CH2R7; R5 = R6NR11, R10NR11; X = NR11, O, S; R7 = O, Q-C1-6 alkyl, Q-C2-6 alkenyl; R8, R9 = independently H, OH, halo, NO2, acyl, CF3, aryl, etc.; R8R9 = fused C2-4 alkylene, aryl, heterocyclyl; R10 = A-(B)n; R11 = H, C1-4 alkyl; B = amino acid; A = H, (un)substituted aryl, heterocyclyl, aryl-W, heterocyclyl-W, phthaloyl, etc.; W = CO, O2C, NR11CO, SCO, NR11CO, SO2, NR11SO2, P(O) (OR)2]; R22 = H, C1-6 alkyl, Ph, phenyl-C1-4 alkyl; with proviso(s), or a pharmaceutically acceptable salt thereof, which bind to retroviral proteases. These compds. are inhibitors of retroviral proteases and are useful for treating diseases related to infection by retroviruses. Thus, cyclocondensation of protected valinal 2-Val-H (Z = PhCH2O2C) with ammonia and glyoxal gave imidazole II. Deprotection of II, followed by coupling with dipeptide isostere III, and final desilylation gave desired title compound IV as its HCl salt. The prepared compds., including IV, showed inhibition of HIV-1 protease with Ki = 1 nM to 5 μM, and inhibited infection of cells with the HIV virus with IC50 = 0.1 to 10 μM.

IT 149379-11-3P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Preparation of azolyl dipeptide analogs as retroviral protease inhibitors)

RN 149379-11-3 CAPLUS  
CN Carbanic acid, [2-hydroxy-5-[[2-methyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]amino]-5-oxo-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester, [1S-[1R\*,2R\*,4S\*,5(R\*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 149356-97-8P 149379-10-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(Preparation of azolyl dipeptide analogs as retroviral protease inhibitors)


RN 149356-97-8 CAPLUS  
CN Carbanic acid, [2-methyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149379-10-2 CAPLUS  
CN Carbanic acid, [2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-[[2-methyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]amino]-5-oxo-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester, [1S-[1R\*,2R\*,4S\*,5(R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN  
ACCESSION NUMBER: 1997:568118 CAPLUS  
DOCUMENT NUMBER: 127:248417  
TITLE: Preparation of amino acid heterobicyclic amide


STOP. 1/7/03

STOPPED HERE --- 102(a), 102(e)

derivatives as farnesyl transferase inhibitors  
Gordon, Thomas D.; Morgan, Barry A.  
Biomassure Incorporated, USA  
PCT Int. Appl., 79 pp.  
CODEN: PIXXD2  
Patent  
DOCUMENT TYPE:  
LANGUAGE:  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730053	A1	19970821	WO 1997-US2651	19970214
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GN, ML, MR, NS, SN, TD, TG				
US 2002013319	A1	20020131	US 1996-752546	19961120
US 6673927	B2	20040106		
CA 2245823	AA	19970821	CA 1997-2245823	19970214
AU 9719645	A1	19970902	AU 1997-19645	19970214
US 716636	B2	20000302		
ZA 9701254	A	19980714	ZA 1997-1254	19970214
EP 904274	A1	19990331	EP 1997-907717	19970214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1216545	A	19990512	CN 1997-193864	19970214
JP 2001500838	T2	20010123	JP 1997-529596	19970214
TW 432066	B	20010501	TW 1997-86101769	19970214
RU 2201931	C2	20030410	RU 1998-117378	19970214
US 2003119864	A1	20030626	US 2002-273735	20021018
PRIORITY APPL. INFO.:			US 1996-49997P	P 19960216
			US 1996-602438	A 19960216
			US 1996-752546	A 19961120
			WO 1997-US2651	W 19970214


OTHER SOURCES(S): MARPAT 127:248417  
GI




AB Title compds. I and II [R1 = H, lower alkyl, lower alkylthio; R1R2 = CH2, CO, CMe2; R2, R3 = independently H, lower alkyl, cycloalkyl; R4 = H2, O; R5 = H, (un)substituted lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkyl lower alkyl, cycloalkenyl, cycloalkenyl lower

CN Propanamide, 3,3'-dithiobis[2-amino-N-[(1S)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]pentyl]-N-methyl-, (2R,2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




PAGE 1-A



PAGE 1-B


IT 195450-20-3P 195450-42-1P 195450-43-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of amino acid bicyclic amide deriva. as farnesyl transferase inhibitors)  
RN 195450-28-3 CAPLUS  
CN Carboxylic acid, 1-[4-phenyl-1H-imidazol-2-yl]pentyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195450-42-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, n-butyl-N-methyl-4-phenyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195450-43-2 CAPLUS

alkyl, aryl, aryl lower alkyl, heterocyclyl, heterocyclyl lower alkyl; R6, R7 = independently H, CONHCH2R13CO2R14, (un)substituted lower alkyl, cycloalkyl, cycloalkyl lower alkyl, cycloalkenyl, cycloalkenyl lower alkyl, aryl, aryl lower alkyl, heterocyclyl, heterocyclyl lower alkyl; R6R7 = fused aryl or heterocyclyl; R8, R9 = independently H, (un)substituted lower alkyl, cycloalkyl, cycloalkyl lower alkyl, cycloalkenyl, cycloalkenyl lower alkyl, aryl, aryl lower alkyl, heterocyclyl, heterocyclyl lower alkyl; R8, R9 = fused aryl or heterocyclyl; X = NR9, S, O; R13 = (un)substituted lower alkyl; R14 = H, lower alkyl, and pharmaceutically acceptable salts thereof are capable of inhibiting the activity of farnesyl transferase. Thus, tetrahydroimidazo[1,2-a]pyrazine III, prepared in 6 steps from Chz-L-Nle-OH (Chz = PhCH2O2C), BrCH2CO2CH2OMe-2, BrCH2CO2Et, and Boc-L-Cys(CPh3)-OH (Boc = Me3CO2C), displayed antiproliferative activities of 6.25-12.5  $\mu$ M, 12.5  $\mu$ M, 10-30  $\mu$ M, and 12.5-25  $\mu$ M against A-427 lung carcinomas, HT-29 colon adenocarcinomas, Calu-1 lung carcinomas, and MIA PaCa pancreatic cancer cells, resp.


IT 195449-70-8P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of amino acid bicyclic amide deriva. as farnesyl transferase inhibitors)  
RN 195449-70-8 CAPLUS  
CN Propanamide, 2-amino-3-mercapto-N-[1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]pentyl]-N-methyl-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 195449-56-0P 195449-72-0P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of amino acid bicyclic amide deriva. as farnesyl transferase inhibitors)  
RN 195449-56-0 CAPLUS  
CN Propanamide, 2-amino-3-mercapto-N-methyl-N-[1-[4-phenyl-1H-imidazol-2-yl]pentyl]-, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195449-72-0 CAPLUS

CN Carboxylic acid, [2-[methyl[1-[4-phenyl-1H-imidazol-2-yl]pentyl]amino]-2-oxo-1-[[[(triphenylmethyl)thio]methyl]ethyl]-, 1,1-dimethylethyl ester, [S-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN

ACCESSION NUMBER: 1996:467020 CAPLUS

DOCUMENT NUMBER: 125:114630

TITLE: Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands

INVENTOR(S): Thurkauf, Andrew; Horvath, Raymond F.; Yuan, Jun; Peterson, John M.

PATENT ASSIGNER(S): Neurogen Corporation, USA

SOURCE: PCT Int. Appl., 94 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9616040	A1	19960830	WO 1995-US15262	19951122
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GN, ML, MR, NE, SN, TD, TG				
US 5681956	A	19971028	US 1995-401201	19950309
US 5633777	A	19970527	US 1995-462833	19950605
US 5646281	A	19970708	US 1995-461135	19950605
US 5655762	A	19970812	US 1995-461858	19950605
US 5712392	A	19980127	US 1995-464548	19950605
AU 9643689	A1	19960617	AU 1996-43689	19951122
ZA 9509910	A	19970822	ZA 1995-9910	19951122
US 9509911	A	19970822	ZA 1995-9911	19951122
EP 793653	A1	19970910	EP 1995-942473	19951122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 9707500	A	19980223	ZA 1997-7500	19951122
JP 10502670	T2	19980310	JP 1995-517074	19951122
JP 2941950	B2	19990830		
BR 9509760	A	19980630	BR 1995-9760	19951122
US 6069251	A	20000530	US 1997-859861	19970521
US 6358955	B1	20020319	US 2000-497988	20000204
US 2002143044	A1	20021003	US 2002-100691	20020318
US 6797824	B2	20040928		
PRIORITY APPL. INFO.:			US 1994-344154	A2 19941123
			US 1994-344552	A2 19941123

US 1995-401201 A2 19950309  
US 1990-635256 A2 19901228  
US 1993-81317 A2 19931108  
US 1994-313435 A2 19940927  
US 1995-462833 A1 19950605  
WO 1995-US15262 W 19951122  
US 1997-859861 A1 19970521  
US 2000-497988 A1 20000204

OTHER SOURCE(S): MARPAT 125:114630  
GI




AB Disclosed are compds. (I), wherein R1 represents optionally substituted aryl, heteroaryl, alkyl, or cycloalkyl groups; X, Z, and Y are optionally substituted nitrogen or carbon atoms; R3 and R4 are organic or inorg. substituents which may together form ring structures; m is zero, one or two; and R5 and R6 are organic or inorg. substituents; and the pharmaceutically acceptable addition salts thereof, which compds. are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Specifically, 2-phenyl-4(5)-[(4-(2-pyrimidinyl)piperazin-1-yl)methyl]imidazole dihydrochloride was prepared and was shown to bind to the dopamine D4 receptor site (K<sub>i</sub> = 1033, 8200, 2.7 for D2, D3, D4 binding sites, resp.).  
IT 179332-49-1P 179333-51-8P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Uses) (preparation of imidazole derivs. as dopamine receptor partial agonists or antagonists for memory enhancement and treatment of schizophrenia and depression and Parkinsonism)  
RN 179332-49-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-methyl-4-phenyl-N-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 179333-51-8 CAPLUS  
CN 1H-Imidazole-2-methanamine, N-methyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 181361-76-2 CAPLUS  
CN Butanediamide, 2-cyclohexyl-N4-hydroxy-N1-[3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, [S-(R\*,R\*)] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 167983-28-ODP, derivs.  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation, activity, and structure of matrix metalloproteinase inhibitors containing a heterocyclic P2'-P3' amide bond isostere)  
RN 167983-28-0 CAPLUS  
CN Carbamic acid, [3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN  
ACCESSION NUMBER: 1996:239751 CAPLUS  
DOCUMENT NUMBER: 124:289584

TITLE: Preparation of 7-[(benzimidazolymethyl)aminocarbonyl]-1,4-benzodiazepine-2-acetates and analogs as vitronectin receptor antagonists  
INVENTOR(S): Ali, Padia; Bondinelli, William; Ruffman, William; Francis, Lego, M. Amparo; Keenan, Richard McCulloch; Kwon, Chet; Miller, William Henry; Nguyen, Thomas; Takata, Dennis T.  
PATENT ASSIGNEE(S): SmithKline Beecham Corp., USA  
SOURCE: PCT Int. Appl., 193 pp.




L12 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN  
ACCESSION NUMBER: 1996:466542 CAPLUS  
DOCUMENT NUMBER: 125:21708  
TITLE: Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2'-P3' amide bond isostere  
AUTHOR(S): Chen, Jian Jeffrey; Zhang, Yiping; Hammond, Scott; Dewdney, Nolan; Ho, Teresa; Lin, Xiaohong; Browner, Michel F.; Castelano, Arlindo L.  
CORPORATE SOURCE: Roche Bioscience, Inflammatory Disease Business Unit, Palo Alto, CA, 94304, USA  
SOURCE: Bioorganic & Medicinal Chemistry Letters (1996), 6(13), 1601-1606  
CODEN: BMCLE8; ISSN: 0960-894X  
PUBLISHER: Elsevier  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB A novel series of hydroxamate-based inhibitors of matrix metalloproteinases containing benzimidazole and imidazole heterocycles as amide bond isosteres have been prepared. Potent inhibition (in the low nanomolar range) and selectivity (> 100-fold) can be attained with inhibitors containing only one amide bond. X-ray crystal structures of matrilysin (MMP-7) with two different inhibitors bound confirm that imidazole is an excellent amide bond isostere.  
IT 167983-80-4DP, derivs.  
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 167983-80-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, α-(2-methylpropyl)-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 181361-72-8P 181361-76-2P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation, activity, and structure of matrix metalloproteinase inhibitors containing a heterocyclic P2'-P3' amide bond isostere)  
RN 181361-72-8 CAPLUS  
CN Butanediamide, N4-hydroxy-N1-[(1S)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

DOCUMENT TYPE: CODEN: PIXXD2  
Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9600730	A1	19960111	WO 1995-US8306	19950629
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, DE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SG, SI, SK, TJ, TT, UA, US, US, UZ, VN				
RN: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CF, CG, CI, CH, GA, GN, GM, MR, NE, SN, TD, TG				
AU 9530010	A1	19960125	AU 1995-30010	19950629
AU 702661	B2	19950225		
EP 767792	A1	19970416	EP 1995-926152	19950629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1156995	A	19970813	CN 1995-194853	19950629
HU 76344	A2	19970828	HU 1996-3525	19950629
BR 9508178	A	19971118	BR 1995-8178	19950629
JP 10504808	T2	19980512	JP 1995-503462	19950629
US 5977101	A	19991102	US 1996-505171	19961220
NO 9605608	A	19970227	NO 1996-5608	19961227
NZ 329656	A	20000128	NZ 1998-329656	19980128
NZ 329822	A	20000228	NZ 1998-329822	19980223
PRIORITY APPLN. INFO.:			US 1994-267695	A 19940629
			US 1995-428933	A 19950425
			WO 1995-US8306	W 19950629


OTHER SOURCE(S): MARPAT 124:289584  
GI




AB Title compds. (e.g., I; A = fibrinogen receptor antagonist template (sic); G = NH, O, S, etc.; R2,R3 = H, halo, alkyl, etc.; R2R3 = atoms to form a ring; W = CH2CH2CH2, VZ; R1 = H, (un)substituted alkyl; U,V = bond, CO, O, CH2CH, etc.; Z = N-attached pyrrolidine- or piperidine-di-yl) were prepared. Thus, Me 7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate was amidated by 2-aminomethylbenzimidazole to give, after saponification, title compound II. Title compds. inhibit vitronectin binding to SK&F 107260 in the concentration range of about 0.001 to 50μM (sic).  
IT 175529-80-3P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Uses) (preparation of

7-[(benzimidazolymethyl)aminocarbonyl]-1,4-benzodiazepine-2-acetates and analogs as vitronectin receptor antagonists)  
RN 175529-80-3 CAPLUS  
CN 1H-1,4-Benzodiazepine-2-acetic acid, 2,3,4,5-tetrahydro-4-methyl-3-oxo-7-[[[(4-phenyl-1H-imidazol-2-yl)methyl]amino]carbonyl]- (9CI) (CA INDEX NAME)


NAME)



IT 175531-38-1  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of  
 7-[(benzimidazolylmethyl)aminocarbonyl]-1,4-benzodiazepine-2-  
 acetates and analogs as vitronectin receptor antagonists)  
 RN 175531-38-1 CAPLUS  
 CN 1H-imidazole-2-methanamine, 4-phenyl- (9CI) (CA INDEX NAME)



IT 175531-07-4P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of  
 7-[(benzimidazolylmethyl)aminocarbonyl]-1,4-benzodiazepine-2-  
 acetates and analogs as vitronectin receptor antagonists)  
 RN 175531-07-4 CAPLUS  
 CN 1H-1,4-Benzodiazepine-2-acetic acid, 2,3,4,5-tetrahydro-4-methyl-3-oxo-7-  
 [[[(4-phenyl-1H-imidazol-2-yl)methyl]amino]carbonyl]-, methyl ester (9CI)  
 (CA INDEX NAME)





L12 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN  
 ACCESSION NUMBER: 1995:804314 CAPLUS  
 DOCUMENT NUMBER: 123:228900  
 TITLE: Preparation of azole-fused peptides as substance P  
 antagonists and analgesics.  
 INVENTOR(S): Morgan, Barry A.; Gordon, Thomas D.; Hansen, Philip  
 S.; Singh, Jasbir  
 PATENT ASSIGNEE(S): Sterling Winthrop Inc., USA  
 SOURCE: U.S., 34 pp. Cont. of U.S. Ser. No. 131,706,  
 abandoned.  
 COCEN: USXXAM  
 DOCUMENT TYPE: Patent

LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5378803	A	19950103	US 1992-912949	19920710
PRIORITY APPLN. INFO.:			US 1992-912949	B1 19920710
			US 1987-131706	19871211

OTHER SOURCE(S): MARPAT 123:228900  
 GI



AB Title compds. (I; Q1 = Pro, bond; Q2 = Pro, D-Trp, bond; Q3 = Pro, D-Trp,  
 Phe, (R)-(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2-yl-3-carbonyl, bond;  
 Q4 = Pro, D-Trp, Phe, bond; Q5 = D-Trp, Phe, bond; Q6 = Leu, Met, bond; Q7  
 = Phe, N-MePhe, Met, bond; R1 = H, Z, BOC; R2 = H; R3 = Me2CH, Me2CHCH2,  
 H2N(CH2)4, PhCH2, 4-HOC6H4CH2, pyridylmethyl, (1H-indol-3-yl)methyl; R2R3  
 = atoms to form 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2,3-diyl; R5 = H,  
 OH or alkali metal salt thereof, MeO, EtO, amino, etc.; X = oxa thia,  
 imido; Y = oxo, H2; n = 0,1; starred center is L or D; with a proviso),  
 were prepared. Thus, title compound (II; starred center has D-configuration),  
 prepared via thionation of 2-D-Trp-NH2 with P2S5 and cyclocondensation of  
 the product with Et 3-chloro-2-oxo-3-phenylpropionate, antagonized  
 substance P in the guinea pig ileum test with pA2 = 7.3, and in the mouse  
 acetylcholine-induced writhing test showed intrathecal ED50 = 0.78  
 µg/mouse.


IT 167982-33-4P 168110-21-2P  
 RL: SAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
 BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of azole-fused peptides as substance P antagonists and  
 analgesics)  
 RN 167982-33-4 CAPLUS  
 CN D-Tryptophanamide, L-prolyl-D-tryptophyl-L-phenylalanyl-N-[3-methyl-1-(4-  
 phenyl-1H-imidazol-2-yl)butyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of azole-fused peptides as substance P antagonists and  
 analgesics)


RN 167983-28-0 CAPLUS  
 CN Carbamic acid, [3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-,  
 phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167983-29-1 CAPLUS  
 CN 1H-Imidazole-2-methanamine, α-(2-methylpropyl)-4-phenyl-  
 dihydrochloride, (S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



● 2 HCl

RN 167982-30-4 CAPLUS  
 CN D-Tryptophanamide, 1-[(1,1-dimethylethoxy)carbonyl]-L-prolyl-D-tryptophyl-  
 L-phenylalanyl-N-[3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, (S)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 168110-21-2 CAPLUS  
 CN D-Tryptophanamide, L-prolyl-D-tryptophyl-L-phenylalanyl-N-[3-methyl-1-(4-  
 phenyl-1H-imidazol-2-yl)butyl]-, (S)-, trimethanesulfonate (9CI) (CA  
 INDEX NAME)

CH 1

CRN 167982-33-4  
 CMF C50 H55 N9 O4

Absolute stereochemistry.



CH 2


CRN 75-75-2  
 CMF C H4 O3 S



IT 167983-28-0P 167983-29-1P 167983-30-4P  
 167983-80-4P

RN 167983-80-4 CAPLUS  
CN 1H-Imidazole-2-methanamine,  $\alpha$ -(2-methylpropyl)-4-phenyl-,  
(aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1993:517245 CAPLUS  
DOCUMENT NUMBER: 119:117245  
TITLE: Preparation of N-imidazolylalkyl-5-amino-4-hydroxyhexanamides and analogs as retroviral protease inhibitors  
INVENTOR(S): Carr, Thomas Joseph; DeMarsh, Peter Lawrence; Penwick, Ashley Edward  
PATENT ASSIGNEE(S): Smithkline Beecham Corp., USA  
SOURCE: PCT Int. Appl., 146 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9302057	A1	19930204	WO 1992-US6047	19920717
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KR, LU, NL, NO, PL, RO, RU, SE, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LJ, NL, SE				
AU 9224129	A1	19930223	AU 1992-24129	19920717
CN 1071434	A	19930428	CN 1992-109761	19920717
CA 9205360	A	19930614	CA 1992-5360	19920717
EP 602069	A1	19940622	EP 1992-917238	19920717
R: BE, CH, DE, FR, GB, IT, LJ, NL				
JP 07500577	T2	19950119	JP 1992-503016	19920717
ES 2068739	B1	19951101	ES 1993-107	19930121
ES 2068739	A1	19950416		


PRIORITY APPL. INFO.:  
US 1991-731563 A 19910717  
US 1992-870975 A 19920420  
WO 1992-US6047 A 19920717

OTHER SOURCE(S): MARPAT 119:117245  
AB R5CH(R1CH(OH)CH2CH(R3)R4 [I; R1, R3 = fluoroalkyl, cycloalk(en)yl(alkyl), aryl(alkyl), heterocyclyl(alkyl), etc.; R2 = H, OH; R4 = azolylamino, H-(azolylalkyl)carbamoyl; R5 = substituted amino] were prepared. Thus, Me2CHCH(RH2) (R = imidazol-2-yl) (preparation given) was condensed with (2R, 4S, 5S)-PhCH2CH(NHCO2Me)CH(OR6)CH2CH(CH2Ph)COR7 (II; R6 = SiMe2OMe, R7 = OH) to give, after deprotection, II (R6 = H, R7 = NHCH(RH)Me2, R = imidazol-2-yl). I had Ki of 1 nM to 5  $\mu$ M for inhibition of HIV-1 protease.  
IT 149356-97-SP 149379-10-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PRSP (Preparation); RACT (Reactant or reagent)  
(preparation and reaction of, in preparation of retroviral protease inhibitors)  
RN 149356-97-8 CAPLUS  
CN Carbamic acid, [2-methyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)


AUTHOR(S): 4-phenylimidazoles  
Morgenstern, R.; Bechmann, K.  
CORPORATE SOURCE: Inst. Pharmakol. Toxikol., Humboldt-Univ., Berlin, Ger. Dem. Rep.  
SOURCE: Pharmazie (1975), 30(2), 103-5  
CODEN: PHARAT; ISSN: 0031-7144  
DOCUMENT TYPE: Journal  
LANGUAGE: German  
GI For diagram(s), see printed CA Issue.  
AB All 40 4-phenylimidazoles (I) tested for antihistaminic activity on guinea pig ileum were effective and inhibited histamine-induced contractions competitively and noncompetitively dependent on the dose. Some compds. at comens. below antagonistic values induced contractions themselves. The influence of substituents at C-4, C-2, N-1, or C-5 on antihistaminic activity was discussed.  
IT 48167-31-3 54887-81-9 54887-82-0  
RL: BIOL (Biological study)  
(antihistaminic)  
RN 48167-31-3 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,N-diethyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 54887-81-9 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,N-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 54887-82-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-methoxyphenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



L12 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1973:136289 CAPLUS  
DOCUMENT NUMBER: 78:136289  
TITLE: Imidazole derivatives  
INVENTOR(S): Bornowski, Heinz; Herzig, Guenter  
SOURCE: Fr. Demande, 14 pp.  
CODEN: FRXXBL  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Absolute stereochemistry.




RN 149379-10-2 CAPLUS  
CN Carbamic acid, [2-[[[1,1-dimethylethyl]dimethylallyl]oxy]-5-[[2-methyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]amino]-5-oxo-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester, [1S-[1R\*,2R\*,4S\*,5(R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 149379-11-3P  
RL: SPN (Synthetic preparation); PRSP (Preparation)  
(preparation of, as retroviral protease inhibitor)  
RN 149379-11-3 CAPLUS  
CN Carbamic acid, [2-hydroxy-5-[[2-methyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]amino]-5-oxo-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester, [1S-[1R\*,2R\*,4S\*,5(R\*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1975:557696 CAPLUS  
DOCUMENT NUMBER: 83:157696  
TITLE: Antihistaminic activities of certain

FR 2132632 A1 19721124 FR 1972-4864 19720214  
FR 2132632 B1 19770415  
CH 572041 A 19760130 CH 1972-4956 19720405  
SU 450805 T 19741125 SU 1972-1768897 19720406  
PRIORITY APPL. INFO.: DD 1971-154266 A1 19710407  
AB The imidazoles I (R = morpholino, piperidino, Me2N, Et2N; R1 = H, 3,4-(MeO)2, p-MeO, p-NO2, p-Br; R2 = H, Me, Pr; R3 = H, Me) and their acid salts were prepared by Mannich reaction of the corresponding phenylimidazoles. Thus, 4-(3,4-dimethoxyphenyl)-5-propylimidazole was heated at 100° with HCHO and morpholine in HOAc to give 69% I (R = morpholino, R1 = 3,4-(MeO)2, R2 = Pr, R3 = H), isolated as the di-HCl salt.  
IT 41053-81-0P 41053-82-1P 41053-83-2P  
41053-93-4P 54887-82-0P  
RL: SPN (Synthetic preparation); PRSP (Preparation)  
(preparation of)  
RN 41053-81-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,N-dimethyl-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 41053-82-1 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,N-diethyl-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 41053-83-2 CAPLUS  
CN 1H-Imidazole-2-methanamine, N,N-diethyl-4-phenyl-, compd. with 2,4,6-trinitrophenol (1:2) (9CI) (CA INDEX NAME)


CN 1

CN 48167-31-3  
CN 414 H19 H3




CN 2

CRN 88-89-1  
CMF C6 H3 N3 O7




RN 41053-93-4 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-methoxyphenyl)-N,N-dimethyl-,  
dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 54887-82-0 CAPLUS  
CN 1H-Imidazole-2-methanamine, 4-(4-methoxyphenyl)-N,N-dimethyl- (9CI) (CA  
INDEX NAME)



=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	185.04	533.54

	SINCE FILE	TOTAL
	ENTRY	SESSION
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	-26.28	-28.47

STN INTERNATIONAL LOGOFF AT 13:20:34 ON 06 JAN 2005